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1. Summary 
Endotoxin tolerance of human monocytes contributes to sepsis-induced immunosuppression, a 
leading cause of sepsis-related deaths worldwide. Although several studies already demonstrated 
distinct alterations of cytokine expression, phagocytotic capability and expression changes of 
particular receptor- and glycoproteins to be linked with the tolerant state in human monocytes, no 
study investigated changes of the whole glycoproteome on a global level. Due to the fact that most 
membrane-bound receptors are glycosylated, the characterization of the tolerant monocyte cell 
state by glycoproteomics using tandem mass spectrometry (LC-MS/MS) might reveal new and 
useful markers to distinguish tolerant from naϊve cells and can provide possible new targets for 
improving immune-modulatory therapies.                                                                    
In this doctoral thesis, (a) PAMPs binding to cell surface-expressed pattern recognition receptors 
(PRRs) (TLR4 agonist LPS, TLR2/1 agonist Pam3CSK and TLR2/6 agonist MALP2),             (b) 
PAMPs binding to intracellular PRR (NOD-like receptor (NLR) ligands 1 and 2; iE-DAP and 
MDP) and (c) the alarmin S100A12, signaling via the receptor for advanced glycation endproducts 
(RAGE) and TLR4, were examined for their capability to induce the monocyte tolerant state. 
Qualitative and quantitative analysis of glycoprotein expression changes in purified monocytes of 
three different peripheral blood donors were assessed with and without LPS-, Pam3CSK- and 
MALP2-stimulation and analyzed in the naϊve and tolerant state.                                                                                         
Tolerance was measured by restimulation with LPS of monocytes that were prestimulated with 
adjusted concentrations of either LPS, Pam3CSK or MALP2. Prestimulation with all three PRR 
agonists led to highly decreased expression of the pro-inflammatory cytokines TNF-α and IL-6, 
which is consistent with the cells entering a tolerant state. NLR ligands iE-DAP and MDP induced 
only weak pro-inflammatory responses in human monocytes and none of the NLR ligands 
demonstrated a reduction of TNF-α expression in subsequent LPS challenges. Commercially 
available S100A12, that was efficient in inducing pro-inflammatory activation of monocytic THP-
1 cells, was found to be significantly contaminated with LPS, as revealed by Limulus Amebocyte 
Lysate (LAL) test. Further experiments with endotoxin-free, granulocyte-derived, purified 
S100A12 induced neither a pro-inflammatory activation of human monocytes nor tolerance. Thus, 
only the glycoproteomes of LPS-, Pam3CSK- and MALP2-stimulated monocytes, that induced 
the tolerant state, were analyzed in a mass spectrometry approach.  
Comparable numbers of glycoproteins (1003, 966 and 1033) were identified in purified human 
monocytes from each of the three donors, respectively. Altogether, 1176 annotated proteins were 
Summary 
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identified, originating from various cellular organells. 898 of the 1176 identified glycoproteins 
were predicted to contain at least one transmembrane domain, demonstrating that a high number 
of membrane spanning glycoproteins has been found. The majority of the identified glycoproteins 
were annotated in Gene Ontology (GO) as “plasma membrane” associated including 202 CD 
antigens and 54 GPCRs. Stimulation of the purified human monocytes with LPS, Pam3CSK or 
MALP2 induced significantly differential expression levels of 135 glycoproteins. From 75 
glycoproteins annotated to be involved in glycan processing and maturation, only 4 demonstrated 
significantly expression changes, indicating no major changes in the glycosylation of the proteins 
which might have affected enrichment and quantification during LC-MS/MS analysis. The largest 
subset of differentially expressed glycoproteins was again annotated as plasma membrane-resident 
glycoproteins comprising 35 significantly regulated CD antigens. KEGG pathway analysis 
revealed an enrichment of CD antigens involved in cell adhesion processes (e.g. ITGAV (CD51) 
and ICAM-1(CD54)). Interestingly, all three TLR agonists led to highly similar changes in the 
glycoproteomes of the stimulated cells. Resemblance of the glycoproteomic signature was higher 
among the different stimuli than between the three donors due to interindividual differences in 
glycoprotein expression (e.g. HLA molecules) and donor-dependent sample purity. 75 
glycoproteins demonstrated significantly increased expression levels, with PD-L1 (CD274), 
ITGB8 and IL7R (CD127) among the most highly upregulated glycoproteins. Collectin 12 
(COLEC12) and lysophosphatidic acid receptor 6 (LPAR6) displayed the strongest decrease in 
their expression out of 60 significantly down-regulated glycoproteins. Whereas upregulation of 
PD-L1 and IL7R expression in monocytes of septic patients is a well-described phenomenon in 
the literature, this study identifies, for the first time, strongly upregulated expression of ITGB8 in 
tolerant human monocytes. ITGB8 is involved in the activation of latent TGF-β, a cytokine which 
was shown to contribute to and to be expressed increased during sepsis-induced 
immunosuppression. 
Taken together, the tolerant monocyte cell state is accompanied by differential expression of a 
series of glycoproteins. Changes in the monocytes glycoproteome were highly similar in cases of 
TLR2- and TLR4-mediated tolerance and revealed possible new biomarkers of the tolerant 
monocyte state like ITGB8, which should be validated in future in vivio studies. 
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2. Zusammenfassung 
Eine hohe Zahl septischer Patienten entwickelt eine Immunsuppression, die zu den wichtigsten 
Gründen Sepsis bedingter Todesursachen zählt. Endotoxin Toleranz menschlicher Monozyten 
trägt entscheidend zur Sepsis induzierten Immunsuppression bei und eine Reihe von Studien 
konnte zeigen, dass dieses tolerante Zellstadium in Monozyten mit spezifischen Veränderungen 
der pro- und anti-inflammatorischen Zytokinexpression, der phagozytotischen Aktivität und der 
Expression bestimmter Rezeptor- und Glykoproteine assoziiert ist. Bisher erfolgte jedoch noch 
keine Untersuchung des Glykoproteoms toleranter Monozyten auf globaler Ebene: Dies wäre ein 
vielversprechender Ansatz neue Biomarker des toleranten Zellstadiums zu entdecken, da der 
größte Teil der auf der Zelloberfläche-exprimierten Rezeptoren glykosyliert ist. Diese Biomarker 
könnten einerseits der Unterscheidung toleranter von naiven Zellen dienen und andererseits 
mögliche neue pharmakologische Angriffspunkte darstellen. 
Die vorliegende Studie untersuchte die pro-inflammatorische Aktivierung und Toleranz-Induktion 
in aufgereinigten CD14+ Monozyten durch verschiedene bakterielle Zellwandbestandteile 
(PAMPs). Verwendet wurden (a) PAMPs, die an PRRs der Zelloberfläche binden (TLR4-Ligand 
LPS, TLR2/1-Ligand Pam3CSK, TLR2/6-Ligand MALP2), (b) PAMPs, die an intrazellulär 
lokalisierte PRRs binden (NOD-like receptor (NLR)-Liganden 1 und 2; iE-DAP und MDP) und 
(c) das von Granulozyten synthetisierte Alarmin S100A12, ein Agonist des Receptor for Advanced 
Glycation Endproducts (RAGE) und von TLR4. Veränderungen des Glykoprotein-
Expressionsmusters naiver und LPS-, Pam3CSK- und MALP2-stimulierter Monozyten wurden 
von drei unterschiedlichen Blutspendern mittels Tandem-Massenspektroskopie (LC-MS/MS) 
qualitative und quantitative erfasst und verglichen. 
LPS-Restimulation LPS-, Pam3CSK- und MALP2-(vor)stimulierter Monozyten führte zu einer 
signifikant verminderten Expression pro-inflammatorischer Zytokine (TNF-α, IL-6), ein 
Merkmal, dass sich die entsprechend stimulierten Monozyten im toleranten Zustand befinden. 
Beide NLR-Agonisten, iE-DAP und MDP, induzierten eine messbare pro-inflammatorische 
Aktivierung, resultierten jedoch im Gegensatz zu den oben genannten TLR-Agonisten nicht in der 
Abnahme der TNF-α Expression bei anschließender LPS-Restimulation. Kommerziell erhältliches 
S100A12, zeigte eine pro-inflammatorische Aktivierung monozytärer THP-1 Zellen. Allerdings 
bestätigte der Limulus-Amöbozyten-Lysat (LAL)-Test eine messbare Kontamination mit LPS. 
LPS-freies, von Granulozyten-gewonnen und aufgereinigtes S100A12 zeigte weder ein pro-
inflammatorische Aktivierung noch eine Toleranzinduktion in Monozyten. 
Zusammenfassung 
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Daher wurden in der nachfolgenden massenspektroskopischen Analyse nur die Glykoproteome 
naiver und LPS-, Pam3CSK- und MALP2-stimulierter Monozyten untersucht.  
Insgesamt wurden 1176 Glykoproteine der aufgereinigten Monozyten von annähernd allen 
vorhanden Zellkompartimenten identifiziert und eine vergleichbare Anzahl an Glykoproteinen 
(1003, 966 und 1033) von allen 3 Spendern detektiert. 898 der 1176 identifizierten Glykoproteine 
enthielten mindestens eine Transmembran Domäne, entsprechend gelang es eine hohe Zahl an 
Membran-überspannenden Glykoproteinen zu isolieren. Der größte Anteil identifizierter 
Glykoproteinen wurde mittels Gene Ontology (GO) als „plasma membrane“-assoziiert annotiert 
und enthielt 202 CD Antigene und 54 G-Protein gekoppelte Rezeptoren. Stimulation der 
Monozyten mit LPS, Pam3CSK und MALP2 führte zur signifikant veränderten Expression von 
135 Glykoproteinen. Nur 4 von insgesamt 75 Glykoproteinen, annotiert als involviert in 
unterschiedlichen Schritten der Protein-Glykosylierung, zeigten eine signifikant veränderte 
Expression, weshalb von keiner Beeinflussung der Glykoprotein Anreicherung oder 
massenspektroskopischen Quantifizierung auszugehen ist. Glykoproteine der Plasmamembran 
bildeten auch die größte Gruppe signifikant regulierter Glykoproteine, darunter 35 CD Antigene. 
KEGG Analyse ergab eine Anreicherung von CD Proteinen involviert in Zelladhäsions Prozessen 
(z.B. ITGAV (CD51) und ICAM-1 (CD54)). Interessanterweise resultierte die Stimulation der 
Monozyten mit allen 3 TLR Liganden in sehr ähnlichen Veränderungen des Glykoproteoms. Die 
Ähnlichkeit der Glykoprotein-Expressionsmuster war sogar größer zwischen den einzelnen 
Stimuli als zwischen den verschiedenen Blutspendern, wozu einerseits interindividuelle 
Unterschiede der Glykoproteinexpression (z. B. der HLA Antigene) und andererseits die Spender-
abhängige Reinheit der verwendeten Proben beitrugen. 75 Glykoproteine demonstrierten 
signifikant erhöhte Expressionsraten, wobei sich PD-L1 (CD274), ITGB8 und IL7R (CD127) 
unter den am stärksten herauf regulierten Glykoproteinen befanden. Collectin 12 (COLEC12) und 
Lysophosphatic acid receptor 6 (LPAR6) zeigten unter den insgesamt 60 herunter regulierten 
Glykoproteinen die stärkste Abnahme ihrer Expression. Während die erhöhte Expression von PD-
L1 und IL7R auf Monozyten septischer Patienten, und ihr Beitrag zur Sepsis induzierten 
Immunsuppression, ein in der wissenschaftlichen Literatur bekanntes Phänomen ist, konnte die 
vorliegende Studie zum ersten Mal deutlich erhöhte Expressionsraten von ITGB8 zeigen. ITGB8 
ist in der Aktivierung des latenten, immunsuppressiven TGF-β involviert und stellt somit ein 
möglichen neuen Glykoprotein-Biomarker des toleranten Status von Monozyten dar, der unter 
Umständen sogar von pharmakologischen Interesse sein könnte. Die Validität dieses möglichen 
neuen Biomarkers bleibt jedoch in weiteren in vivo Studien zu überprüfen.  
 5 
  
3. Introduction 
3.1 Host immune response in sepsis 
The inflammatory host response to severe infections, caused by invading pathogens, is defined as 
sepsis (Hotchkiss et al. 2013). Sepsis is one of the most frequent causes of mortality among 
hospitalized patients and responsible for more than 120.000 deaths each year, solely in the USA 
(Reinhart et al. 2012, Martin et al. 2003). In clinical observations, it was recognized that patients, 
who survive the initial hyperinflammatory phase, often enter a prolonged immunosuppressive 
phase. While improved diagnostics and treatments result in increasing survival rates of the first 
hyperinflammatory phase of sepsis, the mortality rate of the subsequent immunosuppressive state 
remains unaffectedly high at about 30% (Jawad et al. 2012). The disability to efficiently control 
the initial infection and the acquisition of secondary hospital-acquired infections are the primary 
causes of death in these patients (Hotchkiss et al. 2013). Generally, a complex interaction of the 
innate and the acquired immune system ensure an efficient and fast elimination of invading 
pathogens. Focusing on the cellular level, especially monocytes, macrophages and granulocytes, 
as important members of the innate immunsystem, play a central role in the early detection of 
microbial infections. Due to the vast variety of highly conserved pathogen-recognition receptors 
(PRRs) expressed on their cell surface, monocytes and macrophages are able to recognize different 
microbes and to initiate an inflammatory response. They can phagocytose pathogens or initiate the 
host response by releasing antimicrobial compounds and pro-inflammatory cytokines. Moreover, 
monocytes and macrophages induce and regulate the activation of an appropriate adaptive immune 
response by presenting antigens to naϊve T cells (reviewed in Aziz et al. 2013, Gordon 2007). 
Additionally to the recognition of broadly shared and conserved structures among bacterial 
species, so called “pathogen-associated molecular patterns” (PAMPs), PRRs have been shown to 
bind endogenous host-derived molecules, the so called “alarmins” that can be either released by 
dying cells or actively secreted by activated immune cells (reviewed in Kumar et al. 2013). Once 
activated by specific ligands, PRRs induce signaling cascades which result in an upregulated 
transcription of various genes encoding molecules that are involved in the pro-inflammatory 
response (e.g. pro-inflammatory cytokines, type I interferons (IFNs), chemokines, antimicrobial 
proteins, proteins involved in the regulation of PRR signaling). All these molecules have 
pleiotropic effects on major cellular functions, e.g. by modifying growth, metabolism, replication 
processes, cell adhesion and migration, and are also directly involved in the regulation of vascular 
endothelial permeability, the production of acute phase proteins, recruitment of blood cells to 
inflamed tissues and cell death occurring in inflamed tissues (Takeuchi und Akira 2010). Due to 
Introduction | Host immune response in sepsis 
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this, a tight regulation of the expression of PRRs and of receptor-downstream signaling cascades 
is necessary in order to achieve an appropriate and efficient elimination of the invading pathogens 
on the one hand, while restoring the immune balance and preventing massive host tissue damage 
on the other hand.  
As mentioned above, sepsis is characterized by an initial dominant and overwhelming hyper-
inflammatory immune response followed by an immunosuppressive state. For years, it was a 
paradigm that hyperinflammation with subsequent immunosuppression was an orderly process, 
while recent studies support the current opinion that both, the pro- and anti-inflammatory host 
response, occur early and simultaneously (Pena et al. 2014, Hotchkiss et al. 2013). The net effects 
of these opposing processes result in an early pro-inflammatory state and a prolonged 
immunosuppressive phase with various mechanisms leading to immune dysfunction and disease 
severity (Fig. 1). Especially, dysfunctional monocytes and macrophages, that become refractory 
to subsequent PAMP activation and enter a state of hyporesponsiveness, seem to play a key role 
in the development of sepsis-associated immunosuppression (Monneret et al. 2004, Biswas and 
Lopez-Collazo 2009). The phenomenon described above is called “endotoxin tolerance” and will 
be described more detailed in the following chapter. 
 
Fig. 1: Theory of host immune 
response in sepsis. Both, pro- and 
anti-inflammatory immune response 
occur early in course of sepsis. Initially, 
the pro-inflammatory activation of the 
cells dominates with upregulated 
expression levels of pro-inflammatory 
cytokines e.g. TNF-α and IL-6. But if 
sepsis persists, the anti-inflammatory 
response prevails, leading to immune 
suppression in septic patients, which is 
linked with an increased risk for 
secondary infections and mortality. 
Fig. 1 represents a modified version of 
the scheme by Das et al. (2014). 
 
3.2 Endotoxin Tolerance: 
       A major mechanism of immunosuppression during sepsis  
The anti-inflammatory response of monocytes dominates rapidly after the initial release of pro-
inflammatory cytokines, inducing a state of immunosuppression. One important aspect among 
many other severe alterations in the innate and adaptive immune system, contributing to this 
immunosuppressive state, is a phenomenon called “endotoxin tolerance” (ET). For example, 
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monocytes/macrophages that are exposed to low concentrations of the TLR4 agonist 
lipopolysaccharide (LPS, endotoxin) enter into a transient state of hyporesponsiveness and are less 
sensitive to respond to further challenges with LPS and other PAMPs. Several studies showed that 
the tolerant phenotype of monocytes is associated with down regulated transcription of genes 
encoding pro-inflammatory cytokines (e.g. tumor necrosis factor (TNF)-α, IL-1β, IL-6), while the 
expression of anti-inflammatory cytokines (like IL-10, IL-1RA, TGF-β) and inhibitory receptors 
(e.g. programmed cell death ligand receptor 1 (PD-L1)) is upregulated (reviewed in Hotchkiss et 
al. 2013). Moreover, tolerant cells display increased phagocytic capability but impaired antigen 
presenting capacity due to the reduced expression of several MHC class II molecules (e.g. HLA-
DR) (del Fresno et al. 2009). Both, decreased HLA-DR expression and enhanced expression of 
anti-inflammatory cytokines have been shown to be associated with a worse outcome in sepsis 
(van Dissel et al. 1998, Hynninen et al. 2003, Gogos et al. 2000). Although LPS tolerance has been 
studied extensively, underlying mechanisms responsible for endotoxin tolerance remain poorly 
understood, but a number of studies suggest first explanations. Previous reports found that the 
activation of several central regulators of gene expression, including nuclear factor kappa B (NF-
κB) and mitogen-activated protein kinases (MAPKs), was reduced in tolerant macrophages (Foster 
et al. 2007). The transcription factor NF-κB and the phosphorylating MAPKs, which regulate a 
variety of immune-relevant transcript factors, are central elements of the PRR/TLR-induced down-
streaming signaling cascades. In addition, epigenetic modifications such as histone modification 
and gene-specific chromatin remodeling seem to play a major role in the impaired immune 
response of tolerant monocytes to secondary stimuli by selectively silencing genes that encode 
pro-inflammatory cytokines. 
Recently published data of Pena et al. (2014) provided a description of a unique endotoxin 
tolerance gene expression profile, already present in the early clinical course of sepsis. Due to its 
specific linkage to sepsis pathogenesis and organ dysfunction, testing for this endotoxin signature 
is a promising approach to identify septic patients with impaired immune functions and, therefore, 
of high diagnostic and therapeutic potential. As mentioned above, several studies already 
demonstrated distinct alterations of cytokine release and phygocytotic capabilities in tolerant 
monocytes, but so far, only few investigations studied monocytes protein expression changes on a 
global protein level. Nevertheless, various studies examined changes of e.g. cell adhesion surface 
receptors and also of HLA molecules, like upregulated expression levels of ICAM-1 and decreased 
abundance of HLA-DR (Sosa-Bustamante et al. 2011, Zhao et al. 2014, Hynninen et al. 2003). 
These changes in protein expression were shown to be of clinical importance as they can be used 
as markers for tolerance or as drug targets interfering with sepsis pathology. Assessing the global 
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glycoproteome of tolerant human monocytes may contribute to a better understanding of the 
phenomenon “endotoxin tolerance” and, thus, could provide helpful information to develop new 
diagnostic strategies and immunmodulatory therapies.  
3.3 PRRs and their ligands: PAMPS and alarmins 
The initial sensing of infection and, thus, the induction of tolerance and cellular reprogramming is 
mediated by innate PRRs, which are highly conserved receptors including transmembrane proteins 
such as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) as well as cyotplasmic 
receptors such as Retinoic acid inducible gene (RIG)-I-like receptors (RLRs) and Nucleotide-
oligomerizatian domain (NOD)-like receptors (NLRs) (reviewed in Takeuchi and Akira 2010). 
Besides the well studied tolerance induction mediated by the LPS-sensing TLR4, several other 
members of the PRR-family (e.g. TLR2) have been shown to be able to induce cellular 
reprogramming as reviewed by Buckley et al. (2006). The following chapter, therefore, 
summarizes key players of tolerance induction within the PRR-family.  
3.4 The Toll-like receptor family and its ligands 
Toll-like receptors (TLRs) were the first PRRs to be identified and are now among the most ex-
tensively studied germline encoded PRRs (Kawai and Akira 2011). So far, eleven members 
(TLR1-11) were described in the human system, each receptor displaying a distinct organ- and 
tissue-specific expression, cellular localization and ligand specifity. These type-1 transmembrane 
proteins play a key role in PAMP recognition and responses to invading pathogens initiating and 
coordinating the innate and adaptive immunity. TLRs are widely expressed in both, immune and 
non-immune cells. They are evolutionary highly conserved membrane-anchored proteins 
consisting of an ecto-, a transmembrane and a cytoplasmic domain. The leucin-rich extracellular 
domain of each TLR mediates the recognition of distinct PAMPs, which are broadly shared and 
conserved components derived from viruses, bacteria, mycobacteria, fungi and parasites including: 
lipoproteins (recognized by TLR1, TLR2, and TLR6) and lipopolysaccharide (LPS, recognized by 
TLR4) as well as components of the microbial cell wall, viral double-stranded (ds)/ single-stranded 
(ss) RNA (TLR3, TLR7 and TLR8),), flagellin (TLR5) and unmethylated CpG motifs (TLR9) 
(Akira et al. 2006). Whereas TLR1, TLR2, TLR4, TLR5 and TLR6 are localized on the cell surface 
for optimal detection of microbial membrane components, all nucleid acid sensing members of the 
TLR family (TLR3, TLR7, TLR8 and TLR9) are expressed within intracellular vesicles. Upon 
activation, the TLR proteins undergo homo- or heterodimeric oligomerization due to 
conformational changes induced by ligand binding. This allows the recruitment of a specific subset 
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of adaptor molecules (e.g. Myd88 and TRIF) to the cytoplasmic Toll-IL-1 receptor (TIR) domain 
with subsequent initiation of downstream signaling events resulting in the regulation of 
transcriptional activity and production of cytokines (e.g. TNF-α, IL-6), chemokines (e.g. IL-8), 
antimicrobial peptides. These mechanisms aim at the fast and efficient elimination of the infection-
causing pathogens. As mentioned above, TLRs are not limited to the detection of PAMPs, but 
seem also capable to sense endogenous ligands of the host, so called alarmins, e.g. high mobility 
group box-1 (HMGB1, recognized by TLR2, TLR4 and RAGE) and S100A12 (recognized by 
TLR4 and RAGE). Thus, and in accordance to the already in 1994 postulated “danger model” from 
Polly Matzinger, PRRs, and TLRs in particular, seem to differentiate between “dangerous” 
(PAMPs and alarmins) and “non-dangerous” rather than between “self” and “non-self/foreign” 
(Matzinger 1994 and 2002, Kono and Rock 2008). 
3.4.1 General aspects of LPS-mediated TLR4 activation in naϊve 
         and tolerant monocytes 
TLR4 is able to sense LPS, a component of Gram-negative bacterial cell walls, although LPS alone 
cannot bind directly to TLR4 efficiently (Park et al. 2009). Thus, the co-receptor MD-2, a 
secretory, lipid binding glycoprotein is necessary in order to enhance the intrinsic affinity of TLR4 
towards LPS. MD-2 contains a large hydrophobic pocket allowing the binding of the lipid A 
domain of LPS (Park et al. 2009). Nevertheless, LPS-binding protein (LBP) and the CD14 are 
additionally required for efficient transfer of LPS monomers to the TLR4:MD-2 dimeric complex 
(1:1 complex). Upon ligand recognition, the LPS:TLR4:MD-2 complex undergoes subsequent 
dimerization with a second TLR4:MD-2 heterodimer. Once activated, four adaptor proteins are 
recruited to the cytoplasmic domain of the TLR4-receptor complex resulting in the activation of 
two distinct pathways: the “MyD88-dependent” pathway, which is shared by all TLRs (except of 
TLR3), and the “TRIF-dependent” pathway (Fig. 2) (Kawai and Akira 2011). Both pathways are 
resulting in the activation of NF-κB and MAP kinases, but differ in their kinetics. Initially, MyD88 
is recruited to the plasma membrane-bound TLR4 with the help of the adaptor protein TIRAP. 
Subsequent activation of IRAKs, TRAF6 and the TAK1 complex by MyD88 lead to an early phase 
activation of NF-κB and MAP kinases (reviewed in Kawai and Akira 2011). After endocytosis of 
TLR4 in bacteria containing phagosomes, internalized TLR4 forms complexes with TRAM and 
TRIF inducing signaling cascades that, on the one hand, lead to IRF3-dependent expression of 
type I IFN and, on the other hand, mediate late phase activation of NF-κB and MAP kinases (Kawai 
and Akira 2011). In tolerant cells, a variety of alterations in the TLR4-mediated intracellular 
signaling were observed affecting the expression of receptor-, adaptor-, signaling-molecules and 
transcription factors, representing a negative feedback loop at multiple levels (Fig. 2) (Bohannon 
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et al. 2013). So far, most of these alterations are mapped to the MyD88-dependent pathway, 
although this might be possibly due to lacking investigations of changes in the TRIF-dependent 
pathway (Biswas and Lopez-Collazo 2009). Changes in TLR4 signaling were associated with 
decreased TLR4-MyD88 complex formation and upregulated expression of several TLR4- and 
NF-κB-inhibitors such as IRAK-M, suppressor of cytokine signaling-1 (SOCS-1) and inhibitor of 
κB (IκB), thereby attenuating translocation and activation of NF-κB (reviewed by Bohannon et al. 
2013, Biswas and Lopez-Collazo 2009). Together with the above mentioned epigenetic changes, 
this phenomenon is referred to as “cellular reprogramming” in the tolerant cell state. 
 
Fig. 2: Simplified model of 
the TLR4 intracellular 
signaling cas-cade and its 
negative regulation in 
endotoxin tolerance. Upon 
binding of LPS, the TLR4-receptor 
complex signals via two different 
pathways using either the adaptor 
protein MyD88 or TRIF. MYD88-
dependent activation of IRAK4, 
IRAK1 and the IKK complex results 
in the activation and nuclear 
translocation of NFκB, which 
induces the transcription of a 
series of pro-inflammatory 
cytokines. TRIF-mediated 
activation of IRF3 induces IFN-
inducible genes e.g. IFN-β and 
CXCL10. In tolerant monocytes, 
alterations in the downstream 
signaling cascades were especially 
found in the MyD88-dependent 
pathway, involving upregulated 
expression levels of inhibitors such 
as SOCS-1, IRAK-M and IκB. The 
figure represents a modified 
version of the scheme by Vaure et 
al. (2014). 
3.4.2 Characteristics of LPS as a PAMP and TLR4 ligand 
Lipopolysaccharides are major components of the outer membrane of Gram-negative bacteria, 
operating as membrane stabilizers and increasing the negative charge of the cell surface (Rietschel 
et al. 1996). Bacterial lipopolysaccharides share a common architecture, although biological 
activity is strongly influenced by structural details, which varies from one bacterium to another. 
LPS comprises three main parts: an inner lipid moiety, called lipid A, which is considered to be 
the endotoxic component, a glycosidic unit consisting of a core of approximately 10 
monosaccharides and, in “smooth-type” lipopolysaccharides, a third region, named O-chain, 
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containing repetitive subunits of one to eight monosaccharides responsible for the 
immunospecificity of the bacterial cell (Caroff and Karibian 2003). Therefore, it can be 
distinguished between the predominantly expressed smooth (S-) LPS-chemotype and a rough  (R-
) LPS-chemotype. LPS can be released into the environment during each cell division and also by 
bacteria killed during phagocytosis, the complement system or antibiotic treatment. Once released, 
LPS molecules form micellar aggregates due to their amphiphilic character when critical micellar 
concentration is exceeded. The type of supramolecular aggregate plays also a crucial role of their 
potential to be recognized by TLR4 (reviewed Brandenburg et al. 2003). Moreover, R-LPS gains 
a considerably higher potential to activate the TLR4:MD-2 receptor complex than the smooth 
chemotype, hence, S-LPS requires CD-14 as a third co-receptor for efficient binding (Jiang et al. 
2005). In addition, LPS-binding protein (LBP) can accelerate the transfer of LPS monomers to 
CD14 molecules, thereby enhancing, LPS mediated TLR4 activation (Yu and Wright 1996, 
Hailman et al. 1994). 
3.4.3 S100A12 as alarmin and TLR4 ligand  
Phagocyte-specific S100A12 (Calgranulin C) is a member of the calcium-binding, EF-handed 
S100-family, expressed by phagocytic myeloid cells, in particular by granulocytes and, to smaller 
amounts, by monocytes (Kessel et al. 2013). Clinical observations demonstrated highly increased 
serum levels of S100A12 correlating to disease activity in patients with sepsis and chronic 
inflammation, which emphasizes a putative role of extracellular S100A12 in the pro-inflammatory 
and chemotactic responses (Achouiti et al. 2013). Until recently, it was widely believed that these 
pro-inflammatory effects of S100A12 were mediated by the receptor for advanced glycation 
endproducts (RAGE). Now, data of the Foell group suggest a monocyte activation by S100A12 
that is mediated via the TLR4 receptor complex rather than RAGE (Foell et al. 2013). Through 
binding to PRRs like TLR4 and RAGE, extracellular S100A12 can act as a prototypic alarmin, 
triggering the transcription of several pro-inflammatory cytokines and chemokines. Tolerance 
induction in monocytes by host-derived alarmins was already shown for HMGB1 that binds to 
TLR4, TLR2 and RAGE. Published data reveal that HMGB1-pretreated THP-1 cells become 
refractory to subsequent LPS- and LTA-challenges (Aneja et al. 2008, Robert et al. 2010). 
Therefore, similar to other TLR4 agonists, S100A12 might have the potential to induce tolerance 
and may contribute to the development of functionally immunosuppressed monocytes during the 
course of sepsis. 
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3.4.4 General aspects of TLR2 activation 
TLR2 plays a central role in the recognition of a wide variety of lipoproteins and peptidoglycans 
(PGNs), found as bacterial cell wall components in both Gram-negative and Gram-positive 
bacteria, in viruses, fungi and parasites. TLR2 forms heterodimeric complexes with TLR1, TLR6 
and several other cell surface molecules (such as Dectin and CD36) in order to discriminate 
between PAMP structures of Gram-positive bacteria (Akira et al. 2006). Both, stimulation of the 
TLR2/TLR1 receptor complex with Pam3CSK, a synthetic triacylated lipopeptide (LP) mimicing 
the acylated amino terminus of bacterial LP, as well as the exposure of TLR2/TLR6 heterodimers 
to mycoplasma-derived MALP2, a 2 kDa synthetic derivate of the macrophage-activating 
lipopeptide, induce the MyD88-mediated activation of NF-κB and the production of various pro-
inflammatory cytokines (reviewed in Takeuchi and Akira 2010). Published data showed that 
TLR2-mediated inflammatory responses differ depending on the pathogen involved: TLR2-
induced type I IFN-production in monocytes was observed when cells were stimulated with 
viruses, but not in the presence of bacteria (Barbalat et al. 2009). 
There are conflicting data about TLR2 agonists inducing tolerance in macrophages and monocytic 
cell lines. Several studies demonstrated that TLR2 agonists can induce self- and cross-tolerance in 
monocytic cell lines and macrophages: Whereas Kreutz et al. (1997) demonstrated Pam3CSK to 
induce tolerance in human monocytes, the group of Dobrovolskaia (2003) observed pretreatment 
of murine macrophages with Pam3CSK not to be efficient in inducing tolerance to a subsequent 
LPS-challenge. Moreover, murine macrophages pretreated with MALP2 showed a subsequent 
hyporesponsiveness towards further MALP2- or LPS-stimulations, which is consistent with the 
cells entering a tolerant state after a first exposure to PAMPs (Sato et al. 2000). 
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3.5 Characterization of the NOD-like receptor (NLR) family 
Among the wide repertoire of conserved PRRs, NLRs are a growing family of intracellular 
sentinels triggering pro-inflammatory and antimicrobial responses in the presence of e.g. bacterial 
peptidoglycan. The presence of NLRs across different species and the linkage of NLR mutations 
to a higher susceptibility of chronic inflammatory disorders (e.g. Cohn’s disease), bacteremia and 
a worse outcome in sepsis patients highlights the essential role of NLRs in inflammatory processes 
(Caruso et al. 2014, Tekin et al. 2012). 
3.5.1 General aspects of the NLR family 
All members of the NLR family share a conserved, tripartite domain structure consisting of: an 
N-terminal protein–protein interaction domain required for signal transduction, a central 
NACHT (or NBD) domain facilitating self-oligomerization, and a C-terminal leucine-rich repeat 
(LRR) that is involved in ligand recognition but also acts as a repressor of NLR signaling in the 
absence of ligand stimulation by masking the N-terminal domain (reviewed in Barbe et al. 2014). 
Most of the diversity in this family is found in the variable N-terminal domain and, so far, five 
classes of mammalian NLRs are defined according to the type of oligomerization-inducing N-
terminal domain: NLRA or Class II transactivator (CIITA) contains an acidic transactivation 
domain, NLRBs or neuronal apoptosis inhibitor proteins (NAIPs) have a baculovirus inhibitor of 
apoptosis protein (IAP) repeat (BIR), NLRCs possess a caspase-activation and recruitment 
domain (CARD), NLRPs a pyrin domain (PYD) and NLRX1 contains a CARD-related X 
effector domain of unknown function (Barbe et al. 2014). Additionally, NLRs can be classified 
according to their ability of inducing inflammasome activation, leading to recruitment and 
activation of caspase enzymes that initiate the activation of IL-1β and IL-18 (Li et al. 2014). As 
mentioned above, unlike TLRs, that sense their ligands at the cell surface or within endosomes, 
NLRs are cytoplasmic receptors forming another level of antimicrobial defense by surveying the 
intracellular environment. 
3.5.2 Signaling of the NOD-like receptors NOD1 and NOD2 
NOD1 (NLRC1, CARD4) and NOD2 (NLRC2, CARD15) are examples for CARD-domain 
containing and non-inflammasome forming NLRs and were first discovered in 1999 and 2001 
(Bertin et al. 1999, Inohara et al. 1999, Ogura et al. 2001). Both receptors detect distinct sub-
structures of internalized bacterial peptidoglycan (PGN): NOD2 that contains one additional 
CARD motif compared to NOD1 and that is almost exclusively expressed in antigen presenting 
cells, senses muramyl dipeptide (MDP, MurNAc-L-Ala-D-isoGln), the largest peptidoglycan 
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motif common in both Gram-negative and Gram-positive bacteria. Whereas NOD1 is 
predominantly expressed in epithelial cells and binds specifically to TriDAP (L-Ala-D-Glu-meso-
DAP)-, TetraDAP (L-Ala-D-Glu-meso-DAP-D-Ala) and iE-DAP (γ -D-Glu-meso-DAP)-
containing structures from Gram-negative bacteria, respectively. 
Upon activation, NOD1 and NOD2 induce NF-κB- and MAP kinases-dependent inflammatory 
responses (Le Bourhis et al. 2007). An involvement of NOD2 in tolerance induction was shown 
in the intestinal mucosa by Hedl et al. (2007). In their study, pretreatment of primary human 
monocytes-derived macrophages with MDP led to a significant decrease in the production of pro-
inflammatory cytokines like TNF-α, IL-1β and IL-8 upon restimulation with NOD2-, TLR4- and 
TLR2-agonists. Therefore, it would be interesting to analyze and compare if NLR ligands are able 
to induce tolerance in primary human monocytes and if the cellular reprogramming by cytoplasmic 
NLRs shows distinct alterations compared to tolerance induced by membrane-bound PRRs.  
3.6 Receptor expression profile and glycoproteomics of human 
      monocytes 
So far, most studies that aim at the description of the tolerant phenotype of monocytes have been 
focusing on transcriptome analysis and cytokine expression analysis by performing whole 
transcriptome sequencing, qPCR and ELISAs, respectively. It was shown that monocytes purified 
from the peripheral blood of septic patients display similar alterations in the transcriptional 
regulation of pro- and anti-inflammatory cytokines and receptor proteins as endotoxin tolerant 
monocytes stimulated in vitro, thus, mimicking the effects of two consecutive bacterial infections 
(reviewed in Biswas and Lopez-Collazo 2009). This immune-compromised state is also 
accompanied by expression changes of several cell surface proteins (e.g. down-regulation of HLA-
DR, CD86 and CIITA), but to date, no comprehensive characterization of the global monocyte 
cell surface protein repertoire (the surfaceome) in the tolerant state was performed. Moreover, the 
correlation between mRNA levels and protein abundance has been proven to be specifically low 
in relation to cell surface proteins due to the intrinsic half-live of membrane proteins (Bausch-
Fluck et al. 2015). All classical approaches to investigate the abundance of cell surface receptors, 
like flow-cytometry, employ antibodies directed against known proteins and, therefore, are limited 
to a small subset of proteins. Due to the key role of cell surface proteins in mediating the cell’s 
interaction with the surrounding environment (cell-cell/cell-matrix interactions, recognition of 
soluble factors) and transducing the manifoldness of signals into the cell, it is of particular interest 
to characterize the cell surface proteome as a whole. Current development of proteomic and 
glycoproteomic technologies allow to perform a global protein expression analysis and to detect 
quantitative changes. Thus, the value of this resource is exemplified by the identification of (1) 
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bio markers determining the fate or functional capability of monocytes/cells, (2) proteins and 
epitopes useful for immunophenotyping and (3) possible drug targets as recently shown for human 
pluripotent stem cells (hPSC) in a study by Boheler et al. (2014).                                                             
Approximately 97% of all membrane proteins, including most relevant receptors of the innate 
immunity (e.g. HLA-DR, TLRs, CLRs), are glycosylated and, therefore, accessible by using a 
method described by Zhang et al. (2003), which targets these glycostructures based on oxidation 
of carbohydrates and hydrazide chemistry for glycoprotein enrichment. Dr. M. Müller in the group 
of Prof. H. Slevogt established an enrichment protocol for the purification of membrane 
glycoproteins from whole cell lysates enabling us to identify and quantify these proteins in a global 
liquid chromatography–tandem mass spectrometry (LC-MS/MS) shot gun proteomic approach. 
Thus, it allows a unique description of the global cellular glycoproteome including cell surface 
plasma membrane associated receptors or intracellular component-derived glycoproteins. 
Glycoproteomic analysis of naϊve and tolerant monocytes might reveal biomarkers for staging the 
patient’s immunsystem and for deciding whether to initiate rather a pro- or anti-inflammatory 
therapy. Moreover, this study might provide possible targets for reversing sepsis-induced 
immunosuppression and, thereby, allowing important advances towards personalized medicine.  
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4. Hypothesis and objectives  
Systemic infections like severe sepsis or septic shock are associated with a pronounced pro-
inflammatory response contributing to organ failure. Subsequently, the immune response becomes 
deregulated and evolves into a state of immunoparalysis when immunosuppressive mediators 
dominate pro-inflammatory factors. This state of immunosuppression is associated with a high risk 
for secondary infections and high mortality of septic patients. Most of the current therapies aim at 
the blockage of pro-inflammatory signaling mediators to control the host response in sepsis, but 
show only little success to reduce the 28-day mortality of septic patients. Therefore, targeting the 
immunosuppressive cell state of immune cells might be an option to prevent the occurrence of 
secondary infections and to reduce mortality. Monocytes and macrophages are one of the first 
defense mechanisms against invading pathogens and functionally altered in immunoparalysis. 
Cellular reprogramming of monocytes is a major contributor to immunosuppression in the course 
of sepsis and has been shown to be evoked by bacterial cell wall components (PAMPs) like LPS 
but also by endogenous factors of the host (alarmins) like HMGB1. Thus, characterization of naϊve 
and tolerant monocytes at the global glycoprotein level may help in the identification of new and 
better suited biomarkers, serving for a better understanding of monocytes functional behavior in 
septic conditions.  
We propose the hypothesis that activation of monocytes with cell surface-associated TLR-ligands 
and intracellular located NLR-ligands causes pro-inflammatory responses, that, consecutively, 
result in the development of an immunosuppressed cell state. This immunosuppressed, tolerant 
cell state is accompanied by transcriptional changes, which also affects the expression of 
glycoprotein cell surface markers. These differential expressions can be identified and analyzed 
by glycoproteomics. Activation by different PAMPs, and in case of the TLR4 also by alarmins, 
may differ in their potency to induce a tolerant phenotype. Although, all stimuli used in the present 
study are known to be pro-inflammatory triggers inducing NF-κB activation and pro-inflammatory 
cytokine release in human monocytes, the usage of diverging secondary and tertiary signal 
transduction pathways may differentially affect the global glycoprotein expression. Therefore, 
receptor signatures might vary between PAMP- and alarmin-stimulated monocytes, but also 
between the different TLR agonists.  
The primary aim of this study is to analyze and compare global alterations in the glycoproteome 
and inflammatory response of naϊve and TLR4-ligand (LPS and S100A12), TLR2-ligand 
(Pam3CSK and MALP2) and NLR-ligand (iE-DAP and MDP)-stimulated human monocytes in 
the tolerant state. Pro-inflammatory responses of naϊve and tolerized cells will be characterized 
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by cytokine expression analysis on transcriptional and protein level for each stimulus to adjust the 
initial activation levels. Glycoproteomics will be performed with highly purified monocyte 
preparations, enriched by sorting magnetically and fluorescently labelled cells (MACS and 
FACS), to discover monocyte activation markers associated with the tolerant state.  
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5. Materials and Methods 
Unless indicated elsewhere, all chemicals were obtained from the following companies: Gibco 
(USA), Invitrogen (Germany), Pierce (USA), ROTH (Germany), Serva (Germany), Sigma-
Aldrich (Germany). 
5.1 Laboratory devices and expendable materials 
Table 1: List of laboratory devices 
Laboratory devices Company 
Automated cell counter Countess™ Invitrogen™, Darmstadt 
Axio Vert.A1 Microscope Carl Zeiss, Jena 
Bio-Plex® 200 Systems 
Bio-Plex Manager™ software 
Bio-Plex Pro™ Wash Stations 
Bio-Rad, Munich 
CAS-1200 pipetting robot Qiagen, Germany 
Centrifuges: 
Type 5810 R (cooling function) 
Type 5804 R 
Type 5415 
Type 5418 R (cooling function) 
Mini centrifuge D-6015 MiniSpin 
 
Eppendorf, Hamburg 
 
 
 
neoLab, Heidelberg 
Cell culture microscope Primo Vert Carl Zeiss Microimaging GmbH, Jena 
Corbett-Rotor Gene 6000 Qiagen, Germany 
Flow cytometer Attune™ auto sampler Applied Biosystems®, USA 
Flow cytometer Aria II™ BD Biosciences, Heidelberg 
Incubator Galaxy 170S New Brunswick, Wesseling-Berzdorf 
Incubator HERA Cell 150 Thermo Scientific, USA 
Incubator Shaker Series I26 New Brunswick, Wesseling-Berzdorf 
Laminar flow Maxisafe™ 2020 Thermo Scientific, USA 
NanoDrop 1000 Spectrophotometer Thermo Scientific, USA 
Neubauer-improved counting chamber Roth, Germany 
4D-Nucleofector X-Unit 
4D-Nucleofector Core Unit 
Lonza Group , Switzerland 
Magnetic heat stirrer VMS-C7 advanced® VWR, Darmstadt 
Multi-imaging system Fusion FX7™ PEQlab, Erlangen 
PCR Thermal cyclers: 
MJ Mini Thermal Cycler 
S1000™ Thermal Cycler 
 
Bio-Rad, Munich 
 
pH meter S20-Seven Easy™ Mettler-Toledo AG, Gießen 
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Pipetboy INTEGRA Biosciences, Fernwald 
Pipettes, Research plus Eppendorf, Hamburg 
Plate reader Tecan infinite® M200 TECAN, Switzerland 
Precision scale M-power Satorius, Göttingen 
Precision scale EWB 620-2M KERN, Balingen 
Shaker VWR, USA 
SpeedVac®SPD1010 Thermo Scientific, USA 
Tank blot system Mini PROTEAN® II Bio-Rad, Munich 
Thermomixer compact Eppendorf, Hamburg 
Vortexer Vortex 1 IKA®, Staufen 
Water bath TW20 Julabo, Seelbach 
Table 2: List of expendable materials 
Expendable materials Company 
Cover glasses Thermo Fisher GmbH 
ELISA: 
Human IL-6 ELISA Kit 
Human TNF alpha ELISA Kit 
 
BD Bioscience, Heidelberg 
Thermo Scientific, USA 
High Capacity cDNA Reverse Transcription Kit Thermo Scientific, USA 
Kinetic Turbidimetric LAL Assay  
PYROGENT™–5000 
Lonza Group AG, Switzerland 
Microtiter plates, flat bottom : 
6-, 12-, 48-, 96-well microtiter plates 
Corning/Life Science, USA  
Mini-Protean TGX Gels 4-15% 15well Bio-Rad, Munich 
Monocyte isolation kit II, human Miltenyi Biotec, Germany 
Plasmid preparation/Isolation kits: 
PureYieldTM Plasmid Midiprep System 
QIAGEN Plasmid Maxi Kit 
 
Promega, USA 
Qiagen, Germany 
Renilla Luciferase Assay System Promega, USA 
Luciferase Reporter Gene Assay, high sensitiyity Roche Diagnostics GmbH, Switzerland 
Transfection kits: 
GeneCellinTM Transfection Reagent 
Lipofectamine® 2000 Transfection Reagent 
P3 primary cell 4d-nucleofector X kit 
SG Cell Line 4D-Nucleofector® X Kit L 
BioCell Challenge, France 
Invitrogen/ Life Technologies, USA 
Lonza Group AG, Switzerland 
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5.2 TLR agonists and recombinant proteins 
Table 3: List of used PRR agonists 
Agonist Species Receptor Company 
LPS 
(Lipopolysaccharide) 
 
Salmonella enterica 
minnesota R595 
Escherichia coli 
O111:B4 
TLR4 
 
Invivogen, USA 
 
Sigma-Aldrich, USA 
MALP2 
(macrophage-activating 
lipopeptide-2) 
Mycoplasma fermentas 
TLR2/6 
 
Enzo Life 
Sciences, USA 
Pam3CSK (Pam3CysSerLys4) Synthetic compound TLR2/1 
 
Invivogen, USA 
S100A12: 
Recombinant Human EN-
RAGE/S100A12
Human S100A12 / CAGC / 
Calgranulin-C Protein 
 
Human 
EN-RAGE/S100A12 
 
Escherichia coli 
 
 
Escherichia coli 
 
 
Human Granulocytes 
TLR4 
(RAGE) 
 
R&D Systems, UK 
 
 
Sino Biological, China 
 
Research group of Prof. 
Dr. med. Dirk Foell 
Human recombinant TNF-α R&D Systems, UK 
Human recombinant LPS-binding protein (LBP) R&D Systems, UK 
Peptide-N-glycosidase F (PNGaseF) Sigma-Aldrich, USA 
Trypsin Thermo Scientific, USA 
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5.3 Primers used for semi-quantitative and real-time PCR studies 
Table 4: Primer list 
Gene Primer pairs Product length (bp) 
CD14 
forw. 5`-GCAGCCGAAGAGTTCACAAG-3`  
rev. 5`-ATCGTCCAGCTCACAAGGTT-3` 
206 
DPEP2 
forw. 5`-AAGGGCGTCCACTCCTTCTA -3`  
rev. 5`-ACAGCATCTGAGACATGGGA -3` 
119 
GPR84 
forw. 5`-TGATCTCCTCTACTGCACGC -3`  
rev. 5`-AAGGAGGAGCCCAAATACCC-3` 
106 
HPRT1 
forw.5`-GACCAGTCAACAGGGGACAT-3` 
rev. 5`-AACACTTCGTGGGGTCCTTTTC-3` 
195 
IL-1β 
forw.5`-AGGAAGATGCTGGTTCCCTG-3` 
rev. 5`-GCATCGACATAAGCCTC-3` 
128 
IL-6 
forw. 5`-GAGGAGACTTGCCTGGTGAA-3`  
rev. 5`-TGGGTCAGGGGTGGTTATTG-3`  
186 
IL-10 
forw. 5`-GCTGAGAACCAAGACCCAGA-3`  
rev. 5`-GCATTCTTCACCTGCTCCAC-3`  
143 
ITGB8 
forw. 5`-GTCCAGAATGTGGATGGTGTG -3`  
rev. 5`-ACTGAGCAGCCTTTGCTTATTAAA -3` 
103 
LAMP3 
forw. 5`-AGTGGGAGCCTATTTGACCG -3`  
rev. 5`-TGGAGGCTCTGTTCACTCAC -3` 
123 
LY96 
forw. 5`-GCTCTGAAGGGAGAGACTGT-3`  
rev. 5`-GAGCATTTCTTCTGGGCTCC-3` 
120 
MMP9 
forw. 5`-CAACTACGACACCGACGACC-3`  
rev. 5`-TGGCCTTGGAAGATGAATGGA-3` 
111 
NOD1 
forw. 5`-GCCTTTGATGGCAAGAGGTG-3`  
rev. 5`-GCGCAGCCCCTTTTTAAGTTT-3` 
204 
NOD2 
forw. 5`-AGGCAACACCTCCTTGCAGT-3`  
rev. 5`-CATGACGTTCTTTGCCAGCATC-3` 
181 
PPIB 
forw. 5`-ATGTAGGCCGGGTGATCTTT-3` 
rev. 5`-TGAAGTTCTCATCGGGGAAG-3` 
219 
RAGE 
forw. 5`-GACCAGGAGACACCCTGAGA-3`  
rev. 5`- CTGGGCTGAAGCTACAGGAG-3` 
110 
TLR1 
forw. 5`-CAGGCCCTCTTCCTCGTTAG-3`  
rev. 5`-TGGCAAAATGGAAGATGCTAGT-3` 
157 
TLR2 
forw. 5`-TGCATTCCCAAGACACTGGA-3`  
rev. 5`-AGGGAGGCATCTGGTAGAGT-3` 
131 
TLR4 
forw. 5`-CAACCTCCCCTTCTCAACCA-3`  
rev. 5`-CTGGATGGGGTTTCCTGTCA-3` 
196 
TLR6 
forw. 5`-GCCCTGGTATCTCAGGATGG-3`  
rev. 5`-TCACTTTTCACCCAGGCAGA-3` 
144 
TNF-α 
forw.5`-TTCTCCTTCCTGATCGTGGC-3`  
rev. 5`-ACTCGGGGTTCGAGAAGATG-3`  
150 
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5.4 List of antibodies for flow cytometry and western blot 
Table 5: Primary antibodies 
Antigen 
(all human) 
Epitope 
specifity 
Host/isotype/ 
clone 
Format/ 
Conjugate 
Applied 
concentration Company 
FACS WB 
anti-CD14 
mono-
clonal 
Mouse/ IgG1,κ / 
61D3 
FITC 
0.5 
μg/50 μl 
 
eBioscience, 
USA 
anti-CD3 
mono-
clonal 
Mouse/ IgG1,κ / 
MOPC-21 
PE 1:50 all  
BD Bioscience, 
Germany 
anti-CD19 
mono-
clonal 
Mouse/ IgG1,κ / 
HIB19 
PE   
BD Bioscience, 
Germany 
anti-CD42b 
(GPIbα) 
mono-
clonal 
Mouse/ IgG1 / 
HIP1 
PE   
Immuno Tools, 
Germany 
anti-CD54 
(ICAM-1) 
mono-
clonal 
Mouse/ IgG2b / 
1H4 
APC   
Immuno Tools, 
Germany 
anti-CD80 
mono-
clonal 
Mouse/  IgG1,κ  / 
2D10 
PE   
Miltenyi Biotec, 
Germany 
anti-CD86 
mono-
clonal 
Mouse/ IgG1,κ / 
FUN-1 
PerCP-Cy™5.5   
eBioscience, 
USA 
anti-CD127 
(IL7R) 
mono-
clonal 
Mouse/  IgG1,κ / 
eBioRDR5 
APC   
eBioscience, 
USA 
anti-CD274 
(PD-L1) 
mono-
clonal 
Mouse/  IgG1,κ / 
MIH1 
APC   
eBioscience, 
USA 
anti-CD319 
(SLAMF7) 
mono-
clonal 
Mouse/ IgG2a,κ / 
RUO 
Alexa Fluor® 
647 
  
BD Bioscience, 
Germany 
anti-CD371 
(CLEC12A) 
mono-
clonal 
Mouse/  IgG1,κ / 
HB3 
PE   
eBioscience, 
USA 
anti-CEACAM6 
(1H4-4B) 
mono-
clonal 
Mouse   1:2000 
Merck 
Millipore, 
Germany 
anti-PECAM-1 
(M-200) 
polyclonal Rabbit   1:2.500 Santa Cruz, USA 
anti-TLR4 
(H80) 
polyclonal Rabbit   1:1000 Santa Cruz, USA 
xvd  
Table 6: Secondary antibodies used in Western Blot (WB) analysis 
Antigen 
Epitope 
specifity 
Host 
Applied 
concentration 
Company 
anti-mouse IgG polyclonal goat, peroxidase 40 ng/ml Jackson ImmunoResearch, USA 
anti-rabbit IgG polyclonal goat, peroxidase 1:5000 Jackson ImmunoResearch, USA 
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5.5 Cell culture methods 
5.5.1 Conditions of eukaryotic cell cultivation 
All human cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2, 
ensuring sterile conditions by using sterile materials and by working under a laminar flow hood. 
Cells were counted either using a Neubauer-improved counting chamber or with assistance of the 
automated cell counter Countess™ from Invitrogen™ (Germany). In this context cell viability was 
determined via the trypan blue exclusion assay. 
5.5.2 THP-1 cells (ATCC®-TIB-202™, USA) 
THP-1 is a human monocytic leukemic cell line and was first described by Tsuchiya et al. in 1980 
and was derived from the peripheral blood of a 1-year old male patient suffering from acute 
monocytic leukemia.  
THP-1 cells were maintained in RPMI 1640 supplemented with 10% heat inactivated fetal bovine 
serum (FBS), 50 U/ml penicillin and 50 µg/ml streptomycin. They were passaged every 2-3 days. 
After 3-5 min centrifugation at 150x g, the cell pellet was resuspended in fresh RPMI medium and 
afterwards diluted in order to adjust a cell density of 2-3*105 cells/ml. 
5.5.3 HEK-Blue™-hTLR4 cells (Invivogen, USA) 
The HEK-Blue™-hTLR4 cell line is a genetically modified human embryonic kidney 293 
(HEK293) cell line, stably co-expressing all components of the TLR4 receptor complex (TLR4, 
MD2 and CD14)  and  an NF-κB-inducible SEAP (secreted embryonic alkaline phosphatase) 
reporter gene. With this cell line it is possible to detect TLR4 agonists that are activating the NF-
κB downstream signaling pathway by measuring the amount of SEAP. In the presence of a TLR4 
agonist, NF-κB will translocate into the nucleus, where it then specifically binds to the promoter 
region of the SEAP reporter gene. The expression of SEAP directly correlates with the activation 
and nuclear translocation of NF-κB. 
HEK-Blue™-hTLR4 cells were grown in 75 cm2 cell culture flask in DMEM-medium containing 
10% heat-inactivated fetal calf serum and 1% Penicillin/Streptomycin (P/S) and, thereafter, 
incubated in 5% CO2 at 37°C. When reaching confluency at about 80-90%, cells were passaged 
(all 3-4 days), using Trypsin/EDTA solution (0.025% and 0.01% in DPBS, respectively) for 
detachment.  
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5.5.4 Cell freezing and thawing 
Cell pellets (3-5*106 cells) were resuspended in 1 ml medium containing 10% DMSO and 20% 
FCS, and added into a cryotube. Cells were first frozen overnight in an iso-propanol freezing box 
at -80°C, following long-term storage in liquid nitrogen. Thawed cells were immediately 
transferred in 5 ml pre-warmed medium, centrifuged and resuspended in fresh medium 
supplemented with 20% FCS. Cells were further cultivated in medium containing 10% FCS in cell 
culture flasks. 
5.5.5 Isolation of human peripheral blood monocytes  
Human monocytes were isolated from buffy coats, obtained from healthy male donors of the 
Institute for Transfusion Medicine in Jena (Jena University Hospital, Germany).  
50 ml Leucosep™ falcon tubes (Greiner Bio-One, Germany) were prefilled with 15 ml Ficoll 
solution (Ficoll-Paque™ Premium, GE Healthcare, UK) and shortly centrifuged at 1000x g to 
place Ficoll medium below the separation membrane. After mixing the buffy coat with DPBS 
(1:1), 20 ml of the diluted cell suspension was transferred into each Leucosep™ falcon tube. The 
following gradient density centrifugation (800x g, 15 min., without brake) led to the separation of 
the cell suspension into several distinguishable fractions. Beginning with lowest fraction, these 
were: a) cell fraction 1 (erythrocytes, granulocytes), b) ficoll reagent, c) cell fraction 2 (PBMCs), 
d) plasma. 
PBMCs were carefully removed using a Pasteur pipette and collected into a new 50 ml falcon tube, 
placed on ice. Repeated washing steps aimed at the removal of contaminants (erythrocytes, 
thrombocytes, granulocytes) from the PBMC isolate. After diluting PBMCs in ice-cold 0.45% 
sodium chloride (w/v)) solution and centrifugation (300x g, 4°C, 10 min), cells were resuspended 
in 5 ml ammonium-chloride-potassium (ACK) lysing buffer (Gibco®, USA). The co-incubation 
of hypotonic ACK lysing buffer for 5 min at 4°C resulted in the bursting of remaining erythrocytes. 
Depending on the amount of remaining erythrocytes, this step was repeated. PBMCs were washed 
three times with cooled DPBS, intermitted by centrifugation (250x g, 4°C, 10 min). Cell number 
and purity was assessed using the Neubauer improved chamber for microscopy. 
Monocytes, which represent 5-10% of the whole peripheral blood leucocytes, were isolated from 
the collected PBMCs via MACS® monocytes isolation kit II (Miltenyi Biotec, USA). Fc receptors 
(FcRs) were blocked with FcR blocking reagent and, to separate them from other mononuclear 
cells (T and B lymphocytes, dendritic cells, NK cells), PBMCs were incubated (15 min., 4°C) with 
a biotinylated antibody cocktail, specific for surface markers (CD3, CD7, CD16, CD19, CD56, 
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CD123 and Glycophorin A) of non-monocytes. Anti-biotin MicroBeads, as secondary labeling 
reagent, were added. The cell suspension was poured onto the columns of the MACS separator 
after another incubation period of 20 min at 4°C. Magnetically labeled non-monocytic cells were 
bound in the magnetic field of the MACS separator, while the flowthrough was collected 
containing the purified monocyte fraction (negative selection). During the labeling procedure a 
buffer consisting of cooled DPBS supplemented with 2 mM EDTA and 2% FCS was used to 
prevent cell agglutination. Purified monocytes were counted with the Neubauer-improved 
chamber, centrifuged (300x g, 10 min) and resuspended in RPMI 1640 with 20% heat-inactivated 
human serum.  
5.5.6 Purity of monocytes for glycoproteomic analysis (MACS and FACS) 
MACS-sorted monocytes that were left untreated or stimulated with either LPS (50 ng/ml), 
Pam3CSK4 (200 ng/ml) or MALP2 (10 ng/ml) for 24 h or 48 h, were labeled with an anti-CD14 
antibody and sorted again using fluorescence activated cell sorting (FACS analysis). To deplete 
platelets (anti-CD42b) and lymphocytes (anti-CD3 against T-lymphocytes and anti-CD19 against 
B-lymphocytes), they were stained and separated from CD14 positive cells in order to enrich the 
monocytic population. 
5.5.7 Cell stimulations 
5.5.7.1 Kinetic studies of TNF alpha gene expression 
THP-1 cells (2*106/ml cells in 1.5 ml RPMI + 10% FCS)  and human monocytes (8*106 cells in 2 
ml RPMI + 10%FCS) were cultivated in 12- and 6-well plates and stimulated for 1, 2, 3 and 4 h at 
37°C with or without LPS E. coli  O111:B4 (20 ng/ml). Cell lysates were prepared for RNA 
isolation. Transcriptional regulation of TNF-α expression was examined in qPCR analysis using 
gene-specific primers. 
5.5.7.2 Adjusting the concentrations of the stimuli used 
Human monocytes (2*106 cells in 0.5 ml RPMI supplemented with 20% human serum) were 
seeded in 24-well-plate and treated with one of the following stimuli: LPS E. coli O111:B4, 
Pam3CSK, MALP2 for 24 hours at 37°C. Supernatants were transferred into new tubes and detrital 
material removed by several steps of centrifugation. All samples were performed as triplicates. 
Untreated monocytes, as negative control, were always included. 
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5.5.7.2 Induction of endotoxin tolerance in human monocytes 
Human monocytes (2 ml of 4*106cells/ml for qPCR-analysis and 2*106 cells in 500 µl for ELISA) 
were cultured in 6- or 24-well-plates at 37°C. Cells were prestimulated with one of the following 
stimuli: LPS E. coli O111:B4 (50 ng/ml), S100A12 (10 µg/ml), Pam3CSK4 (100 ng/ml or 200 
ng/ml), MALP2 (10 ng/ml), iE-DAP (1 µg/ml) or MDP (10 µg/ml) for 20 h and 24 h, always 
including untreated cells as negative control. Pretreated monocytes were either re-stimulated or 
left untreated. Further, adherent cells were washed in the wells, while non-adherent cells were 
transferred into new tubes and washed three times with fresh RPMI (+ 20% heat-inactivated human 
serum) before restimulation (LPS E. coli O111:B4 (50 ng/ml), S100A12 (10 µg/ml)) for 1 h in 
case of further qPCR-analysis and for 16 h when supernatants were analyzed by ELISA. 
For qPCR analysis cell lysates were prepared to isolate RNA and to examine the cytokine mRNA 
expression. Supernatants of the 24 h prestimulated and of the additionally 16 h restimu-lated 
monocytes were collected and frozen at -20°C. 
5.5.7.3 Stimulation of human monocytes for mass spectrometry analysis 
Human monocytes (1*107 cells in 2 ml RPMI + 20% heat inactivated human serum) were 
stimulated with either LPS E. coli O111:B4 (50 ng/ml), Pam3CSK4 (200 ng/ml) or MALP2 (10 
ng/ml) for 24 h and 48 h. Un-stimulated cells as negative control were included for each time point. 
Before performing further sample preparation for mass spectrometry analysis, the already MACS-
sorted and stimulated monocytes were purified again via fluorescence-activated cell sorting 
(Chapter 6.5). 
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5.6 Methods in molecular biology 
5.6.1 Cell lysis and RNA extraction 
Depending on cell type and experimental setting, different cell concentrations (1*106 – 1*107) 
were washed once with DBPS before the corresponding amount of lysis buffer (about 1*106 cells/ 
200 μl lysis buffer) was added. 
RNA isolation from eukaryotic cells was performed according to the manufacturer’s protocol 
(RNeasy® Mini Kit, Qiagen). Briefly, RNA was precipitated and bound to a silica membrane 
providing high salt conditions. DNA, proteins, guanidinium thiocyanate and other contaminants 
were removed by several washing steps, including a DNase digestion step. Samples were eluted 
by centrifugation and solved in 40 μl RNase-free H2O. RNA was stored at -20°C or -80°C. 
5.6.2 Determination of RNA concentration and purity 
Concentration (in ng/µl) and purity of the obtained RNA were examined using the 
spectrophotometer NanoDrop 1000. Since nucleic acids absorb at 260 nm, their concentration can 
be calculated by making use of the Lambert-Beer law. Contaminations may limit down-stream 
application and thus, information about the RNA purity is required. Detrimental contaminants, like 
proteins and guanidinium thiocyanate have their maximum absorbance at 280 and 230 nm, 
respectively purity is assessed by estimating the 260/280 and 260/230 ratios. 
Pure RNA:  260/280 OD ratio: 1.8 – 2.2 
260/230 OD ratio: 2.0 
 
5.6.3 Reverse transcription (RT) of RNA into cDNA 
Retroviral RNA-dependent DNA polymerases, so-called reverse transcriptases, generate 
complementary DNA templates from RNA. Two micrograms of THP1-RNA and one-point-five 
micrograms of monocytic RNA were reverse transcribed to cDNA for each sample and experi-
ment. The synthesized cDNA was resuspended in 0.5 M Tris/EDTA buffer in a ratio of 1:10 for a 
final volume of 200 μl. Mix composition and program of the thermocycler used for cDNA 
synthesis are listed in more detail table 7 and table 8. 
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Table 7: Mix composition using the High Capacity cDNA Reverse Transcription Kit (Thermo Scien., USA) 
Reagents Volume (µl) 
Buffer (10x) 2 
dNTPs (25x, 100 mM) 0,8 
Random primers (10x) 2 
RNase Inhibitor 1 
Reverse Transcriptase (50 U/µl) 1 
RNA (sample) Corresponding to 2 µg (THP-1), 1.5 µg (monocytes) 
Nuclease-free H2O Up to total vol. 20 µl 
Table 8: Program of the thermo cycler used for cDNA synthesis 
Step in synthesis 
 
Thermal cycler condition
 
                 [°C]                                    [min] 
Primer annealing 25 10 
Reverse transcription 37 120 
Enzyme inactivation 85 5 
Storage 4 ∞ 
5.6.4 Primer Design 
The synthesis of the complementary strand through the DNA polymerase requires the binding of 
a short oligonucleotide sequence (primer) to the template DNA. Thus, primers have to be 
orientated in sense and antisense direction, corresponding to their binding at 3` and 5` end on the 
DNA strand, respectively, for the duplication of one DNA molecule. Primer pairs were designed 
utilizing the genome browser Ensembl and the primer designing software Primer-Blast. All 
primers used in this study are listed in table 4.  
Primer specificity was ensured considering the following aspects in primer design: (1) primer 
sequence length: 15-25 bp, (2) G/C content: 40-60%, (3) no matching properties to other 
homologue sequences. To maximize amplification efficiency, the formation of secondary 
structures during primer annealing was most widely avoided by controlling the folding structure 
with the mfold Web Server. The primer melting temperature was always set to about 60°C. In 
addition, the binding sites of all primers were placed at exon:exon boundaries of the target gene. 
This prevents the co-amplification of possible genomic DNA contaminants which would, 
otherwise, strongly limit gene expression studies. 
5.6.5 Polymerase chain reaction (PCR) 
Expression levels of TLR1, TLR2, TLR6 as well as the TLR4, MD-2, CD14 and NOD1 and NOD2 
were measured by PCR analysis in unstimulated monocytes. Complementary DNA was amplified 
using the PCR amplification kit Perfect Taq Plus DNA Polymerase (5PRIME, Germany). Each 
PCR reaction was set up to a final volume of 20 μl containing 1x Perfect Taq Plus buffer, 1x 
Materials and Methods | Methods in molecular biology 
29 
  
PerfectLoad Dye concentrate, 0.2 mM of each dNTP, Perfect Taq Plus DNA polymerase (1.25 U), 
0.2 μM of each primer and 5 μl cDNA (ca. 30 ng/ml). The PCR cycler conditions are depicted in 
table 9. The Taq polymerase used herein has a 5`-3` exonuclease activity. The kit is based on the 
hot-start/cold-stop technology, in which a thermostable inhibitor competitively blocks the DNA 
polymerase at temperatures below 40°C in order to prevent nonspecific product amplification. 
Table 9: PCR cycler conditions running on sqPCR 
Step in amplification [°C] Time [min.]  
Initialization 94 2:00  
Denaturation 94 0:30  
Primer annealing 60 0:30 35 cycles 
Elongation 72 0:20  
Final extension 72 2:00  
Final hold 10 ∞  
5.6.6 PCR product analysis using agarose gel electrophoresis  
The separation of nucleic acid sequences according to their molecular mass can be achieved with 
agarose gel electrophoresis. A 3% agarose gel was loaded with the PCR products already 
containing 1x loading dye. Agarose was diluted in Tris-acetate-EDTA (TAE) buffer by heating 
and ethidium bromide, that visualizes DNA through intercalation, was added during cooling (Table 
10). The gel was run for 1.5 h at a voltage of 130 V. Images were taken using the Multi-imaging 
system Fusion FX7™ device. The amplicon size was estimated with a Low Range DNA Ladder 
(50 bp - 1 kb) (Jena Bioscience GmbH). 
Table 10: Contents of agarose gel 
TAE buffer: 0,04 M Tris-HCl, pH 8,5 
0,1% acetic acid 
2 mM EDTA 
Agarose gel: 3% agarose in TAE buffer  
0,4 mg/ml ethidium bromide  
(Sigma-Aldrich) 
1 x loading dye 
5.6.7 Gene expression analysis with real-time PCR (qPCR) 
Real-time PCR was used for quantitative analysis of gene transcription. This method is based on 
visualizing the amplification of a targeted gene during PCR reaction cycles by an intercalating 
fluorescent dye (e.g., SYBR green). The PCR cycle at which the fluorescence signal raises above 
a defined threshold (Ct), and which is commonly placed slightly above the background 
fluorescence, enables the estimation of relative fold changes of potential genes. qPCR samples 
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were pipetted using the CAS-1200 pipetting robot (Qiagen). The PCR reaction volume was set to 
20 μl containing 1x SensiMix SYBR No-Rox (Bioline), 0.2 μM of each primer and 4 μl of cDNA. 
Each sample was analyzed in duplicate on the Corbett-Rotor Gene 6000 (Qiagen). PCR cycling 
conditions were adjusted with an initial denaturation step at 95°C for 10 min followed by 40 cycles 
at 95°C for 15 sec, 60°C for 20 sec and 72°C for 20 sec. For each experiment, a RT-negative 
sample was included, adding water instead of SensiMix. The specificity of the PCR reaction was 
verified by melting curve analysis. The relative gene expression was calculated according to the 
efficiency correction method developed by Pfaffl (2001). The Ct-values of the target genes were 
normalized to housekeeping genes, whereby either PPIB (peptidylpropyl isomerase B) and/or 
HPRT1 (hypoxanthine phosphoribosyl-transferase 1) was used. Primer efficiency of all genes was 
tested beforehand by using a cDNA standard curve for each primer pair. The efficiency was 
calculated according to the equation m = -(1/log E), whereas m represents the slope of the 
calibration curve and E, the efficiency. An optimal efficiency in the exponential phase is achieved, 
when E = 2 (= one duplication/cycle). The stable expression of the housekeeping genes during 
different treatment conditions was clarified using the BestKeeper algorithm (Pfaffl et al. 2004). 
5.6.8 Cultivation of Escherichia coli 
E. coli were grown in LB medium with or without ampicillin (50 µg/ml). Bacterial cultures were 
incubated at 37°C either on agar plates (1.5% agar in LB medium) or in liquid LB-medium in 
shaking flasks at 220 rpm. Single colonies picked from petri dishes were used for the sterile 
inoculation of cultures. Ingredients of LB medium are listed in table 11. 
Table 11: LB medium 
10 g/l peptone 
 5 g/l yeast extract 
10 g/l NaCl 
 LB-plates: adjustment of the ph value to 7 and adding 15 g/l agar. 
5.6.9 Establishing of competent bacteria 
Bacteria were made competent to incorporate plasmids and foreign DNA when treated with CaCl2.  
Therefore, 100 ml LB medium were inoculated with 1 ml of an overnight culture and grown to a 
density of 0.2 OD600. After 10 minutes of incubation on ice, cells were pelleted via centrifugation 
(6.000 rpm, 10 min, 4°C). While the supernatant was discarded, the bacterial pellet was 
resuspended in 20 ml of 100 mM ice-cold CaCl2 solution and incubated for another 30 min on ice. 
Cells were centrifuged again and resuspended in 500 µl ice-cold CaCl2 solution. E. coli cells were 
frozen at -80°C or immediately used for transformation. 
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5.6.10 Plasmid preparation and isolation 
Plasmid preparation and isolation was performed according to the manufacturers’ protocols using 
two different standard kits. In both cases, a single colony of transformed E. coli was grown 
overnight in 50 ml LB medium containing 50 µg/ml ampicillin at 37°C.  
5.6.10.1 Plasmid preparation with PureYieldTM Plasmid Midiprep Systems 
             (Promega, USA)  
Bacterial cells were harvested by centrifugation (5.000x g, 10 min) and the pellet resuspended in 
Cell Resuspension Solution. After adding and incubating bacterial cells with the provided Cell 
Lysis Solution, the reaction was stopped using Neutralization Solution and the cell lysate was 
centrifuged (15.000x g, 15 min). The supernatant was poured onto a Pure YieldTM Clearing 
Column, placed above a Pure YieldTM Binding Column to remove remaining debris. Bound 
plasmid DNA was washed by an endotoxin Removal Wash step. After further washing, plasmid-
DNA was eluted by elution buffer and centrifugation (2000x g for 5 min). In a last step, quantity 
and purity of the purified plasmid DNA were measured using the NanoDrop 1000 Spectro-
photometer (ThermoScientific, USA). Purified plasmid DNA was stored at -20°C. Vectors are 
listed in table 12. 
Table 12: Purified plasmids 
pGL4.32 [luc2P/NF-κB-RE/Hygro] Vector 
pGL4.74 [hRluc/TK] Vector 
 
5.6.11 Ethanol precipitation of DNA 
Ethanol precipitation is a method used for the purification and concentration of DNA and RNA. 
Due to the highly negative charged phosphate backbone, DNA precipitates when mixed with less 
polar substances, e.g. pure ethanol. To 1 volume of DNA, 1/10 volume of 3 M sodium acetate (pH 
5.2, final concentration of 0.3 M) was added in order to adjust the correct concentration of positive 
ions and to ensure complete recovery of the DNA. After adding 2 volumes of 95% ethanol, all 
contents were thoroughly mixed and incubated at -20°C for at least 30 minutes (or overnight). 
Precipitated DNA was centrifuged (13.000 rpm, 15 min, 0°C) and the supernatant carefully 
discarded. The DNA pellet was washed with 70% ethanol to remove residual salts. Finally, the 
DNA pellet was air-dried and afterwards redissolved in the appropriate amount of water or Tris-
EDTA (TE) buffer (table 13). Purity and concentration of the DNA was measured with NanoDrop 
1000 Spectrophotometer (Thermo Scientific, USA). 
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Table 13: TE buffer 
95% Ethanol 
3 M Sodium acetate (C2H3NaO2) 
10 mM Tris, pH 8.0 
1 mM EDTA 
5.6.12 Transfection of cells 
5.6.12.1 Transfection with GeneCellinTM Transfection Reagent 
The GeneCellinTM Transfection Reagent is polymer-based and, together with plasmid DNA, it 
builds nanoparticles that can be endocytosed by eukaryotic cells. 1.5 µg of the previously isolated 
plasmid DNA was diluted in 100 µl cell culture medium (pure RPMI medium), before adding 6 µl 
of the GeneCellinTM Transfection Reagent. This solution was shortly vortexed and then incubated 
for 15 min at RT. The GeneCellinTM/DNA mixture was added dropwise onto 1*106 cells that were 
seeded in 1.5 ml cell culture medium (RPMI medium supplemented with 10% FCS) in a 12-well 
tissue plate. After 24 h of incubation at 37°C in a CO2-
 incubator, gene expression of target cells 
was analyzed by measuring luminescence with the help of Plate reader Tecan infinite® M200 
(TECAN, Switzerland ). 
5.6.12.2 Transfection with Lipofectamine® 2000 Transfection Reagent 
This chemical-based transfection method uses the stable formulation of liposomes, consisting of 
cationic lipids, which aggregate with the negatively charged DNA. The thereby formed vesicles 
with positively charged surface are able to fuse with the negatively charged cell membrane 
allowing the plasmids to enter the cell. 
Cells were transfected according to the manufacturer’s protocol. In short: Appropriate dilutions of 
the plasmid DNA (1.5 µg) in Opti-MEM® Medium (50 µl) and of Lipofectamine® 2000 
Transfection Reagent (7.5 µl) in Opti-MEM® Medium (42.5 µl) were made. After 5 min of 
incubation at RT, the diluted DNA was combined with the diluted Lipofectamine® 2000 Reagent 
and incubated for another 20 min at RT. Then, 100 µl of the formed complexes was added dropwise 
to 1*106 cells in 1.5 ml RPMI medium supplemented with 10% FCS. Medium was replaced after 
4 h and gene expression was analyzed after 24 h of incubation at 37°C with the luminometer. 
5.6.12.3 Transfection via electroporation  
THP-1 cells and human monocytes were washed once in serum-free cell culture medium and 
counted (required number of cells: 1*106 THP-1 cells, 5*106 monocytes per sample). Mean-while, 
pmaxGFP vector as a provided positive control vector, as well as other plasmids were diluted in 
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100 µl NucleofectorTM Solution. After centrifugation and complete removal of the supernatant, 
cells were carefully resuspended in the DNA/Nucleofector solution and transferred to the bottom 
of the NucleovetteTM Vessels. Electroporation was carried out using the 4D-Nucleofector X-Unit 
(Lonza Group AG, Switzerland) (Table 14). For recovery of the stressed cells, 1 ml cell culture 
medium (RPMI 1640) containing 20% FCS or human serum was directly added to the cells in the 
cuvette and cells incubated for 2 h at 37°C. Then, cells were transferred into a 12-well cell culture 
plate and incubated for 24 h at 37°C before gene expression was analyzed via luminometer. Cells 
that were transfected with the NF-κB-containing plasmid pGL4.32 [luc2P/NF-κB-RE/Hygro] 
Vector were incubated again for 24 h with or without one of the following stimuli: LPS E. coli 
O111:B4 (100 ng/ml), Pam3CSK (200 ng/ml), MALP2 (10 ng/ml) or S100A12 (0,5 µg/ml). 
Transfection efficiency was calculated as percentage of transfected cells from all cells. Images 
were taken on a Zeiss Axio Vert.A1 fluorescent microsope using the filter set 38 for fluorescein 
isothiocyanate (FITC) (excitation: BP 470/40, beamsplitter: FT 495, emission: BP 525/50) at 20x 
magnification. 
Table 14: Transfection conditions and kits 
Monocytes:   
Kit P3 primary cell 4d-nucleofector X kit,  
Lonza Group AG, Switzerland 
Cell number 5*106  
Plasmids 
 
Positive control 
Vector 
pmax GFPTM 
pGL4.74 [hRluc/TK] 
pGL4.32 [luc2P/NF-κB-RE/Hygro] 
Used amount 
2 µg 
2,5 µg 
2,5 µg 
THP-1 cells:   
Kit SG Cell Line 4D-Nucleofector® X Kit L,  
Lonza Group AG, Switzerland 
Cell number 1*106  
Plasmids 
 
Positive control 
Vector 
pmax GFPTM 
pGL4.74 [hRluc/TK] 
pGL4.32 [luc2P/NF-κB-RE/Hygro] 
Used amount 
0,5 µg 
0,5 µg 
0,5 µg 
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5.6.13 Luminescence measurement 
Luminescence measurement was used to control the transfection efficiency of plasmid pGL4.74 
[hRluc/TK ], constitutively expressing a luciferase, and to adjust the concentrations of PAMPs in 
correlation to their pro-inflammatory response, using cells transfected with plasmid pGL4.32 
[luc2P/NF-κB-RE/Hygro], expressing luciferase after a NF-κB promoter construct. 
5.6. 13.1 Luminescence measurement with the Renilla Luciferase Assay 
               System  
The Renilla Luciferase Assay System (Promega, USA) was used to examine the transfection 
efficiency by measuring the expression of the constitutively expressed Renilla luciferase-gene 
encoded on plasmid pGL4.74 [hRluc/TK]. 
Transfected THP-1 cells (1*106 cells per sample) and human monocytes (5*106 cells per sample) 
were transferred from a 12-well cell culture plate into 1.5 ml tubes after 24 h of incubation (37°C, 
5% CO2) and were washed once with DPBS. After centrifugation and complete decantation of the 
supernatant, 30 µl of 1/5 diluted Renilla Luciferase Assay Lysis Buffer (in distilled water) were 
added to the cells, which then were incubated for 15 min at RT. To remove cellular debris, the cell 
lysate was centrifuged (microcentrifuge, maximum speed: 21.130x g, 10 sec) and the supernatant 
was transferred into new 1.5 ml tubes. 20 µl of the supernatant were transferred into a Nunc™ 
FluoroNunc™/LumiNunc™ 96-well plate(Thermo Scientific, USA) and then 100 µl of the 1/100 
in Renilla Luciferase Assay Buffer diluted Renilla Luciferase Assay Substrate was added. Light 
emission was measured immediately after adding the Luciferase Assay Substrate for a period of 
800 ms with Tecan infinite® M200. 
5.6.13.2 Luminescence measurement with the Luciferase Reporter Gene 
              Assay, high sensitivity 
THP-1 cells (1*106 cells per sample) and human monocytes (5*106 cells per sample) were 
transfected with an NF-κB promoter construct-containing plasmid, were stimulated and incubated 
for 24 h at 37°C with or without one of the following stimuli: LPS E. coli O111:B4 (50 ng/ml or 
100 ng/ml), Pam3CSK4 (200 ng/ml) or MALP2 (20 ng/ml). Cells were washed once with DPBS, 
before they were centrifuged again and the supernatant was completely discarded. Then, 30 µl of 
previously 1/5 in redist. water diluted lysis buffer were added to the cell pellet and incubated for 
15 min at RT. To remove cellular debris, the cell lysate was centrifuged (microcentrifuge, 
maximum speed: 21.130x g, 10 sec) and the supernatant was transferred into new 1.5 ml tubes. 
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Expression of the inducible luciferase was carried out using the Luciferase Reporter Gene Assay, 
high sensitivity (Roche, Switzerland). The luciferase assay reagent was prepared by adding 10 ml 
of the reaction buffer to the lyophilized luciferase substrate. Not required material was stored in 1 
ml aliquots at -20°C. Light emission was measured immediately after adding 100 µl of the 
luciferase assay reagent to 20 µl of the supernatant placed into a Nunc™ 
FluoroNunc™/LumiNunc™ 96-well plate (Thermo Scientific, USA) for a period of 800 ms with 
Tecan infinite® M200. 
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5.7 Methods of protein biochemistry 
5.7.1 Enzym linked immunosorbent assay (ELISA) 
Commercially available ELISA kits as listed in table 2 were used to measure and compare the 
amounts of produced cytokines (IL-6 and TNF-α) in supernatants of stimulated monocytes 
according to the manufacturersʼ recommendations.  
Briefly, ELISA plates (Immuno Platte Maxi Sorp 96 well, VWR International, USA) were coated 
with the specific capture antibody, which binds specifically to the test antigen, diluted in coating 
buffer and incubated at 4°C overnight. After several washing steps, plates were blocked using a 
solution of non-reacting protein (DPBS with 10% FCS), in order to cover any plastic surface in 
the well which remains uncoated by the antibody in further steps. Reconstituted standard and 
appropriate dilutions of the samples were transferred to the wells and incubated for at least two 
hours at room temperature. Unbound material was removed by washing. Then, plates were 
incubated with the appropriate enzyme-linked detection antibody for one hour at RT. After 
washing, added tetramethylbenzidine (TMB)-solution was converted by the horseradish 
peroxidase (HRP). The reaction was stopped by adding 100 µl 2N H2SO4 and the read-out was 
done in a Tecan infinite® M200 Plate reader (Switzerland) measuring the absorbance at 450 nm. 
5.7.2 Cell lysis and isolation of the total cellular protein content 
Typically, cell counts of 1-3*106 cells/ml were used for protein extraction from human monocytes 
and THP-1 cells. Cells were harvested by scraping or centrifugation, washed once with DPBS to 
remove redundant serum proteins and then lysed (about 1*106 cells/ 200 μl lysis buffer; ingredients 
of lysis buffer are depicted in table 15). After one hour on ice, cell lysate was centrifuged for 10 
min at 16,000x g. The supernatant contained all soluble cellular components, including 
cytoplasmic and numerous solubilized membrane proteins, and was either directly used for 
subsequent analysis or stored at -20°C. The use of Triton X-100 as detergent allows the 
solubilization of membrane proteins effecting only slightly the native conformation of most 
proteins. 
Table 15: Lysis buffer      HBSM buffer (Hepes-buffered saline magnesium): 
  20 mM Hepes, pH 7.2  
150 mM NaCl  
    5 mM MgCl2   
1% Triton X-100  
 Protease inhibitors: Protease inhibitor cocktail (1:200, Sigma-Aldrich, USA) 
                                     1 mM PMSF (Phenylmethylsulfonylfluorid) 
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5.7.3 SDS-polyacrylamide gel electrophoresis (SDS-page) 
Separation of proteins according to their apparent molecular weight was performed using SDS-
page in a TRIS-glycine buffer system (Table 16) using the Mini-PROTEAN®Trans cell 
electrophoresis system of Bio-Rad. Mini-PROTEAN TGX precast gradient (4-15%) gels (Bio-
Rad) allowed an optimal protein separation between 20 and 200 kDa. Protein samples were diluted 
in 4x SDS sample buffer in a ratio of 4:1 and boiled for 5 min at 95°C. Sample preparation occurred 
either under non-reducing conditions or under reducing conditions by adding dithiothreitol (DTT) 
to a final concentration of 10 mM. DTT reduces protein disulfide bounds. The gel was run at a 
constant voltage of 180 V for 20-30 min. The molecular weights of isolated proteins were 
compared to marker proteins using a prestained marker (1 µl of PageRuler Prestained, 1-250 kDa, 
Thermo Scientific). 
Table 16: 10x Running buffer 
0.25 M Tris 
1.92 M Glycine 
1% SDS (w/v) 
5.7.4 Staining of protein gels 
5.7.4.1 Coomassie Brilliant Blue (CBB G250)-staining 
Proteins in gels can be stained using Coomassie Brilliant Blue (CBB G250). The minimum 
detection size is limited to 200 – 400 ng protein per band.  
After performing electrophoresis, gels were incubated for at least 20 min with CBB at RT on a 
tilting table. To destain the gel, it was swiveled in destaining solution for 2 h or overnight. CBB 
staining solutions are listed in detail in table 17. 
Table 17: CBB-gel-staining solutions 
 
CBB-staining solution: 
40% Ethanol (v/v) 
10% Acetic acid (v/v) 
1‰ Serva Brilliant Blue G-250 (w/v) 
CBB-destaining solution: 
40% Ethanol (v/v) 
7,5% Acetic acid (v/v) 
 
5.7.4.2 Silver staining 
Silver staining of proteins is based on the formation of complexes between Ag+-ions and Glu-, 
Asp- and Cys-groups of the proteins. These complexes will be reduced to Ag by adding alkaline 
formaldehyde. Silver staining is a very sensitive method for the detection of even lowest protein 
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concentrations (detection limit: ~5 ng protein per band). Protein amounts cannot be quantified due 
to the fact that the signaling intensities of different proteins show large variations. Another 
disadvantage is that besides proteins also nucleic acids, lipopolysaccharides, lipids and glycolipids 
can be stained. 
The gel was incubated in fixing solution for at least 20 min (or was previously stained with CBB) 
to get rid of interfering compounds and was then washed three times with 50% ethanol/H2O bidest. 
for 5 min to shrunk the gel. Then, the gel was incubated for 1 min in thiosulfate solution in order 
to prevent a silver mirror on the outside of the gel decreasing the sensitivity and contrast of the 
staining. Before and after incubation of the gel with silver-nitrate solution for 12 – 30 min the gel 
was washed three times with H2O bidest. for 20 sec. Then, the gel was incubated in developing 
solution until reaching the desired color intensity. The reaction was stopped with fixing solution 
(Table 18). 
Table 18: Silver-gel staining solutions 
 
Fixing solution: 
50% Methanol 
12% Acetic acid 
 
Thiosulfate solution: 
0,02% Sodium thiosulfate 
 
Silver nitrate solution: 
0,08 g AgNO3 
0,02% Formaldehyde 
ad 50 ml 
Developing solution: 
3% Sodium carbonate 
0,05% Formaldehyde 
0,0005% Sodium thiosulfate 
5.7.5 Western blot 
Protein immunoblotting describes the transfer of proteins from a polyacrylamide gel matrix to a 
nitrocellulose (or PVDF) membrane, enabling the detection of proteins via antibody-based 
methods or diverse staining dyes. The transfer was achieved using the electroblotting tank system 
from Bio-Rad (Mini Trans-Blot®Cell) and carried out at a constant current of 280 mA at 4°C for 
1.5-2 h. To verify successful transfer, proteins on the nitrocellulose membrane were visualized 
with Ponceau S (Table 19). After 1 minute Ponceau S staining, the membrane was washed with 
1% acetic acid solution until protein bands were visible. Destaining was done with TBS. 
Table 19: Buffer and staining solution for Western Blot analysis 
10x Transfer buffer: 
150 mM Glycine 
20 mM Tris-HCl 
 
Ponceau S staining: 
2% Ponceau red (w/v) 
30% TCA (v/v) 
30% Sulfosicylic acid (w/v) 
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The transfer buffer was applied in a 1x concentration containing 10% ethanol (v/v). The Ponceau 
S staining was diluted 1:4 in double distilled water before usage. 
5.7.6 Immunochemical tests for the detection of proteins on blot membranes 
For the detection of specific proteins, the blot membrane was blocked with 10% skimmed milk 
powder in Tris-buffered saline (TBS) for at least 2 h at 4°C or overnight. All following washing 
steps were carried out using either TBS or TBS supplemented with 0.1% Tween 20 (TBS-T) buffer 
(Table 20). 
The blot membrane was washed and then incubated with an appropriate dilution of the primary 
antibody in TBS-T for 2 h at 4°C (or overnight). Afterwards, the blot was washed three times with 
TBS-T, before the secondary antibody (1:5000 in TBS-T) was added for another 2 h at 4°C. All 
secondary antibodies were conjugated with horseradish peroxidase (HRP) which catalyzes the 
oxidation of the chemiluminescent substrate luminol to 3-aminonaphthalate. To remove excessive 
secondary antibody, the blot was washed three times with TBS-T and then three times with TBS.  
The wet blot membrane was transferred into a transparent plastic foil, before the chemiluminescent 
solution, a 1:2 dilution of solution A (luminol, enhancer) and B (peroxidase buffer; SuperSignal 
West Pico Chemiluminescent Substrate, Thermo Scientific Pierce™), was added to the blot. The 
image was directly developed using the multi-imaging system Fusion FX7™. Exposure times 
varied and depended on the protein amount in the sample and the primary/secondary antibody 
combinations. 
Table 20: TBS and TBS-T buffer 
 
TBS buffer: 
150 mM NaCl 
10 mM Tris-HCl, pH 7,6 
TBS-T buffer: 
TBS buffer + 0,1% Tween 20 
 
5.7.7 Flow cytometry analysis of human monocytes 
This laser-based, biophysical technology allows the simultaneously counting and sorting of cells 
as well as the detection of previously antibody-labeled target structures on or in the cells. 
Therefore, suspended single cells in a stream of fluid are passing a laser beam while the measured 
light scattering provide information of cell size (FSC = Forward Scatter) and intracellular 
granularity (SSC = Side Scatter). Antibodies, coupled to fluorescent dyes, may be used for 
additional data about cell type, state of the cells and their protein expression (antibody list see table 
5). 
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Monocytes (1*106) were washed at least once with serum-free RPMI and once with FACS buffer 
(1% FCS, heat-inactivated (v/v) in DPBS). Meanwhile, appropriate dilutions of primary labeled 
antibodies in FACS buffer were prepared. Cells were resuspended in 100 µl of the prepared 
antibody dilutions per sample and incubated for 30 min on ice in the dark. To reduce the amount 
of unbound antibodies and prevent clotting, cells were washed with 5 mM EDTA in 10 ml PBS. 
Samples were washed once more with FACS buffer to eliminate remaining unbound antibodies 
and then analyzed in the Flow cytometer Aria II™ (BD Biosciences, Heidelberg). Unstained and 
isotype-labeled cells were included as negative controls and treated in the same manner. Cells were 
always kept on ice to limit endocytosis of surface receptors.  
5.7.8 Sample Preparation for Mass Spectrometry 
Mass Spectrometry can be used for qualitative and quantitative identification of cells or cell 
fractions (Fig. 3).   
Cell preparation:  MACS-separated and, thereafter, stimulated monocytes were purified once 
again by Fluorescence-Activated Cell Sorting (FACS). After several washing steps with DPBS, 
cells were lysed in 100 µl 4% SDS/DPBS and boiled for 5 min at 95°C. Cell lysates could be 
stored at -20°C and were thawed for further sample preparation.  
Glycoprotein enrichment: DNA was digested by adding 1 µl Benzonase for 30 minutes at 37°C. 
To remove further contaminants, samples were centrifuged at high speed (21.000x g for 20 min). 
Supernatants were buffer exchanged by Size Exclusion Chromatography (SEC). In order to 
oxidize cis-diol-groups in sugars of polysaccharide moieties, 20 µl of 60 mM sodium meta-
periodate (NaIO4) were added to the flow-through containing proteins. After a 30 minute 
incubation period in darkness, samples were again buffer exchanged against PBS by SEC. 
Aldehydes of the oxidized glycoproteomic samples can react spontaneously with hydrazide groups 
on UltraLink Hydrazide-Beads forming stable hydrazone bonds. This coupling process is 
supported by aniline (9 µl/ml) as catalyst. 
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Fig.3:  Workflow of sample 
preparation for LC-MS/MS. 
(A) Cell lysates of monocytes, that 
were stimulated with either LPS, 
Pam3CSK, MALP2 or left untreated 
for 24 h or 48 h, are incubated with 
hydrazide beads. Aldehydes of the 
previously oxidized glycoproteins 
bind stably to hydrazide groups on 
the beads. In a first on-bead 
digestion step the tryptic peptide 
fraction (TPF) is gained. The N-
glycosylated peptide fraction 
(NPF) is gained in a second 
incubation with PNGase F. Both 
peptide fractions are submitted to 
LC-MS/MS for peptide 
identification and further analysis. 
 
(B) Steps of glycoprotein 
enrichment at day I., II. and III. 
during sample preparation for LC-
MS/MS. Black letters indicate the 
experimental procedure, used 
solutions and concentrations are 
given in red letters. 
After overnight incubation at RT, beads were first washed with DPBS to remove aniline and in a 
second step with 8 M urea in 100 mM Tris/HCl (pH 7.5). This step is followed by disulfide 
reduction using dithiothreitol (50 mMDTT in 8 M urea in 100 mM Tris/HCl). The free sulfhydryl 
groups on the cysteine residues are then alkylated with iodoacetamide to irreversibly prevent the 
free sulfhydryl groups from reforming disulfide bonds. Extensive washing (five times with (1.) 
1% SDS/Tris/HCl, (2.) 8 M urea in 100 mM Tris/HCl, (3.) 2 M NaCl/Tris/HCl, (4.) 100 mM 
NaAcetat and 150 mM NaCl, pH 2.8-3.0, (5.) H2O, (6.) 30% acetonitrile/ H2O and for two times 
with (7.) 50 mM ammonium carbonate, pH 8.0 in protein low-binding tubes (Protein LoBind 
Tubes, 1.5 ml, Eppendorf)) reduces non-specific binding  of non-glycosylated proteins. The 
denatured, reduced and alkylated glycoproteins are digested by the endoproteinase trypsin in an 
overnight incubation at 37°C. Beads were washed twice with ammonium hydrogen carbonate 
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buffer, once with 30% acetonitrile buffer and supernatants, containing the tryptic peptides, were 
collected in new tubes. Then, supernatants were either kept at -20°C or dried using the Speed Vac 
(Thermo Scientific™ Savant™ SPD1010). In order to remove unbound tryptic peptides from 
glycopeptides, that are still bound to the UltraLink Hydrazide-Beads, beads were washed a second 
time as described above. After the last two washing steps with ammonium carbonate in new protein 
low-bind-tubes, glycopeptides are digested by adding Peptide-N-Glycosidase F (PNGase F, 1 U 
per sample), that cleaves between the innermost N-Acetyl-glucosamine (GlcNAc) and asparagine 
residues of high mannose hybride and complex oligosaccharides from N-linked glycoproteins in 
an overnight incubation (or 4-6 hours-incubation period) at 37°C. Again, beads were washed twice 
with ammonium hydrogen carbonate buffer, then once with 30% acetonitrile buffer and all 
supernatants, containing the glycopeptide fraction, were collected in new tubes and dried in a 
Speed Vac. 
Each dried fraction was reconstituted in 0.3% formic acid and peptide concentrations were 
measured using a NanoDrop spectrometer. 2 µg of tryptic peptides and 0.5 µg of deglycosylated 
peptides were analyzed in each LC-MS/MS run in duplicates on an Orbitrap Fusion (Thermo 
Scientific) coupled to a Dionex Ultimate 3000 (Thermo Scientific) nanoelectrospray ion source. 
Samples were loaded on a 2 cm C18 trap column (Acclaim PepMap100, Thermo Scientific) and 
separated using a 2.5 h non-linear gradient (2-80% acetonitrile/ 0.1% formic acid, flow rate 300 
nl/min) on a 50 cm C18 analytical column (75 µm i.d., PepMap RSLC, Thermo Scientific). Full 
MS scans were acquired with resolution 120.000 at m/z 400 in the Orbitrap analyzer (m/z range 
400-1600, quadrupole isolation). MS1 parent ions were fragmented by higher energy collisional
dissociation (HCD, 30% collision energy) and fragment ion spectra were acquired (in the order 
highest charge to least charge and least intense to highest intensity during a max. 4 sec cycle time) 
in the ion trap in rapid mode (m/z start 110). The following conditions were used: spray voltage 
of 2.0 kV, heated capillary temperature of 275°C, S-lens RF level of 60%, ion selection threshold 
of 50,000 counts for HCD, maximum ion accumulation times of 50 ms (AGC 5 x 105) for full 
scans and 35 ms (AGC 1 x 104) for HCD.  
5.7.9 Limulus Amebocyte Lysate (LAL) test 
The Limulus Amebocyte Lysate assay is a well-established method for the quantitative detection 
of even smallest amounts of endotoxin in samples. In the presence of endotoxin a protease cascade 
is activated. It catalyzes the cleavage of p-nitroaniline (pNA), resulting in yellow color, which can 
be quantified by measuring the absorbance at 405 nm (A405). In order to test whether the used 
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S100A12 is LPS-contaminated or not, the Kinetic Turbidimetric LAL Assay (PYROGENT™, 
Lonza) was performed according to the manufacturerʼs recommendation. 
Briefly, Control Standard Endotoxin (CSE) was reconstituted and diluted in LAL Reagent Water 
(LRW) to prepare a standard series. Samples containing different dilutions of S100A12 of the 
different manufacturers, CSE standards and LRW as a negative control were dispensed as 
duplicates into the appropriate wells of a microplate. After incubating the microplate at 37°C for 
10 min, the previously reconstituted LAL Reagent was added to all wells. Immediately after adding 
the LAL Reagent, color development was measured at 405 nm with the plate reader (Tecan 
infinite® M200, Switzerland). 
5.7.10 Quantitative analysis of NF-κB activation in HEK-Blue-hTLR4 cells 
Recruitment of transcription factors to DNA-binding sites can be analyzed using a promoter-
reporter-gene construct. In general, reporter genes, e.g., those that encode for secreted embryonic 
alkaline phosphatase (SEAP), luciferases or fluorescence proteins, are coupled to the promoter 
sequences of the pathway of interest. SEAP is a widely used reporter gene that is secreted into cell 
culture supernatant and is therefore detectable by luminescent, fluorescent or colorimetric assays. 
The nuclear translocation and promoter-binding of NF-κB was herein quantified using the reporter 
SEAP expressed by HEK-Blue-hTLR4 cells.  
HEK-Blue-hTLR4 cells were stimulated with constant concentrations of LPS E.coli O111:B4 (1 
ng/ml or 10 ng/ml) and commercially available S100A12 (0.5 µg/ml) in the presence of different 
concentrations of LBP (none, 10 ng/ml, 100 ng/ml) or FCS (5%) in serum-free medium for 20 h. 
The second assay investigated the influence of polymyxin B (PMB) coincubation on LPS- and 
S100A12-stimulated cells. PMB is a well described inhibitor of LPS by binding to lipid A, the 
toxic component of LPS and, thus, inhibiting the LPS induced TLR4 activation. Cells were treated 
with either 10 ng/ml LPS E.coli O111:B4 or 0.5 µg/ml S100A12 with or without 100 µg/ml PMB 
for 20 h. 
For all experiments, 3*104 cells/200 μl were seeded in a 48-well plate and SEAP expression was 
quantified after 20 h of incubation at 37°. Since alkaline phosphatase is secreted into the cell 
culture supernatant, 10 and 20 μl of cell medium, each in triplicates, were removed and incubated 
with 200 μl of QUANTI-Blue™ detection solution (Invivogen) at 37°C. The colorimetric shift of 
the detection medium was measured at 635 nm at different time points after 15, 30 and 60 min. 
Untreated cells were included into all experiments as negative controls and their absorbance was 
substracted from all positive samples. 
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5.8 Statistical analysis 
This chapter lists all statistical tests used for data interpretation of: 1) qPCR-, ELISA-, 2) Western 
blot- , 3) FACS- and 4) Mass spectrometry-based analysis. All differences with a p value <0.05 
were considered as statistically significant. Statistical tests that were used to evaluate revealed data 
are also stated within each experiment. 
5.8.1 Analysis of qPCR data and cytokine expression via ELISA 
In a first step, variance heterogeneity between sample replicates was minimized by transforming 
real-time PCR data into log NRQ values (NRQ-normalized relative quantities) (Rieu and Powers 
2009). Statistical comparisons between untreated and treated samples or between different 
treatments were assessed with the mean values of at least three sample replicates using the repeated 
measures one-way analysis of variance (ANOVA) and including the Bonferroni’s post-hoc test. 
5.8.2 Densitometric analysis of Western blot data 
Protein expression measured by western blotting was quantitatively analyzed using ImageJ. 
Subsequently, densitometric data of the differently treated samples were compared applying the 
one-way ANOVA and the Bonferroni’s post-hoc test. 
5.8.3 Analysis of FACS data 
MFIs of the different treatments were calculated in relation to the MFI of the untreated control for 
each donor in order to determine the relative fold change (FC). Afterwards, the mean value of all 
determined FCs per donor was calculated. 
5.8.4 Analysis of mass spectrometry-based proteomic data 
Protein identification and quantification were performed by matching all RAW files with the 
human UniProt database (Version 05.2016, reviewed sequences) using the MaxQuant version 
1.5.5.1 (Max Planck Institute of Biochemistry (Cox and Mann 2008). The parameters were set as 
follows: main search peptide tolerance: 4.5 ppm; enzyme: trypsin, max. 2 missed cleavages; static 
modification: cysteine carbamidomethylation; variable modification in the tryptic peptide fraction: 
methionine oxidation; variable modification in PNGase F fractions: methionine oxidation and 
asparagine deamidation. PSM (peptide specific matches) and protein FDR was set to 0.01. For 
advanced identification the Second Peptide Search in MS2 spectra and the Match Between Runs 
feature were enabled. Label-free quantification of proteins with normalization was done in 
MaxQuant (Cox et al. 2014). LFQ min. ratio count was set to one. Peptides from both fractions 
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were integrated in the LFQ intensity calculations. Only unique and razor peptides, unmodified or 
modified, were used for quantification. LFQ protein intensities were then loaded into the Perseus 
framework (Max Planck Institute of Biochemistry (Tyanova et al. 2016)). Known contaminants 
(keratins and human plasma proteins) and reverse identified peptides/ proteins were discarded. 
Intensities were log(2) transformed and missing values were imputed from the normal distribution 
of the data set (width: 0.3, downshift 1.8). Two-sample t-test was used to calculate statistical 
differences of protein abundances in the control and LPS-treated groups. P-values were adjusted 
according to Benjamini and Hochberg (Benjamini and Hochberg ) and proteins demonstrating at 
least a two-fold expression difference and an adjusted p-value < 0.05 were considered to be 
significantly changed in expression by LPS-, Pam3CSK- or MALP2- treatment.  
Protein groups identified by MaxQuant were filtered for proteins annotated as “glycoproteins” in 
the UniProt data base and those annotated as transient O-GlcNAc-modified without any other N- 
or O-glycosylation annotated were discarded. Data analysis was performed in R using packages 
provided by Bioconductor. Putative TMDs were predicted using the transmembrane hidden 
Markov model (TMHMM) algorithm (TMHMM 2.0 server) (Krogh et al. 2001). For gene 
ontology classification the R-package “org.Hs.eg.db” version 3.1.2 was used and results were
manually compiled. Functional annotation clustering was performed with DAVID (Huang da et 
al. 2009), Version 6.8. 
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5.9 Software 
 Adobe Photoshop 6.0  
 BestKeeper algorithm 
 DAVID Bioinformatics Resources 6.8, NIAID/NIH 
 Ensembl Genome Browser 
 Graph Pad Prism 5.0 
 ImageJ2 
 Image Studio Lite 3.0 
 MaxQuant, Max Planck Institute of Biochemistry 
 mfold Web Server 
 Microsoft Office Excel 2007 
 Multiple Condition qPCR Manager 
 PANTHER Classification System 
 Perseus framework, Max Planck Institute of Biochemistry 
 Primer-Blast software 
 Rotor-Gene Q Series software 2.0.2 
 TMHMM v2.0 server 
 UniProt database 
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6. Results 
6.1 Characterization of human monocytes 
To investigate the phenomenon of endotoxin tolerance (ET), all experiments were carried out using 
either the acute monocytic leukemia cell line THP-1 or primary human peripheral blood 
monocytes isolated from healthy volunteers. 
6.1.1 Human monocytes express TLR1, TLR2, TLR6, TLR4, CD14, MD-2,  
         RAGE and NLRs 
In order to assess the capability of monocytes to detect all stimuli used in this study (LPS E. coli 
O111:B4, Pam3CSK, MALP2, S100A12, iE-DAP and MDP) RT-PCR was performed to measure 
the basal gene expression of the required extra- and intracellular PRRs. All components of the 
TLR4 receptor complex (including TLR4, CD14 and MD-2) and of the TLR2 heterodimers 
(TLR1/TLR2 and TLR2/TLR6) as well as the receptor for advanced glycation endproducts 
(RAGE) and the nucleotide-binding oligomerization domain (NOD-) like receptors (NLRs: NOD1 
and NOD2) showed a distinct basal gene expression in unstimulated, MACS-separated human 
monocytes (Fig. 4). Notably, NOD1 expression in human monocytes of all three donors analyzed 
was only faintly detectable in RT-PCR. 
 
Fig. 4: Basal expression of TLR1, TLR2, TLR6, TLR4, CD14, MD2, RAGE and NLRs in primary 
human peripheral monocytes. Detection of TLR1 (157 bp), TLR2 (131 bp), TLR6 (144 bp), TLR4 (196 bp), 
CD14 (206 bp), MD-2 (120 bp), RAGE (110 bp), NOD1 (204 bp) and NOD2 (181 bp) in MACS-separated, 
unstimulated monocytes by RT-PCR and gel electrophoresis. Cells were lysed immediately after MACS separation. 
Data are representative for three independent experiments and donors. 
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6.2 Pro-inflammatory response and tolerance induction in 
      monocytes by TLR- and NLR-agonists 
Specific receptor agonists were proven to activate monocytes and to induce an adequate and 
similar pro-inflammatory response. 
6.2.1 TNF-α mRNA expression of LPS-, Pam3CSK-, MALP2-, iE-DAP- or 
         MDP-stimulated monocytes 
To test for monocyte activation by the used PRR ligands, TNF-α expression in LPS-,  Pam3CSK-
, MALP2-, iE-DAP- or MDP-stimulated monocytes was examined on the transcriptional level 
using RT-qPCR in pilot experiments (Fig. 5).  
 
Fig. 5: TNF-α mRNA expression in LPS-, 
Pam3CSK-, MALP2-, iE-DAP- and MDP-
stimulated human monocytes. Human 
monocytes (8*106 cells/2 ml medium) were 
incubated for 2 h with either 50 ng/ml LPS, 100 
ng/ml Pam3CSK, 5 ng/ml MALP2 or for 4 h with 
iE-DAP 1 µg/ml or MDP 10 µg/ml or were left 
untreated. Total mRNA was isolated, reverse 
transcribed into cDNA and subjected to qPCR 
analysis. The results represent one experiment. 
The gene expression was normalized to the 
housekeeping gene HPRT. The fold ratio of 
mRNA levels relative to unstimulated cells was 
cal-culated according to Pfaffl et al. (2004). 
A two-hour incubation period of monocytes with LPS, Pam3CSK and MALP2 led to increased 
expression of TNF-α compared to the non-treated control cells. Monocytes treated with either 50 
ng/ml LPS or 100 ng/ml Pam3CSK showed a comparable ~33.- to 35.-fold upregulated TNF-α 
expression, whereas 5 ng/ml of MALP2 induced only a ~6.-fold upregulation. NOD-like receptor 
ligands, iE-DAP and MDP, did not affect TNF-α expression after 4 h in a significant manner (1.5- 
to 1.6-fold upregulation). 
6.2.2 Kinetic analysis of the pro-inflammatory immune response of LPS- 
         treated human monocytes 
In order to determine the best suited time-period for pro-inflammatory and for tolerance induction 
on transcriptional level, human monocytes were stimulated with LPS for different times and the 
transcriptional regulation of TNF-α expression was analyzed by qPCR. TNF-α expression reached 
maximum levels with a 37.8-fold upregulation after stimulating cells for one hour with 50 ng/ml 
LPS (Fig. 6). Afterwards, expression levels of TNF-α declined and were already at 50% after two 
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hours. Therefore, LPS-restimulation over a period of one hour displays to be the most sensitive 
time point for the detection of TNF-α transcriptional changes. 
Fig. 6: Transcriptional regulation of TNF-α gene expression in LPS-stimulated monocytes. 
 
Human monocytes (8*106 cells) were stimulated for either 
1, 2, 3, or 4 hours with 50 ng/ml LPS. Untreated controls 
were included for each time point. TNF-α gene expression 
was analyzed by qPCR and normalized to the 
housekeeping gene HPRT. The fold ratio of mRNA levels 
relative to untreated cells was calculated according to the 
Pfaffl method (2004). Data represent values from one 
experiment performed as pilot study. 
6.2.3 TNF-α mRNA expression is suppressed in LPS-, Pam3CSK- or MALP2- 
        prestimulated monocytes but not when pre-stimulated with a NLR-ligand 
To test if TLR agonists induce the tolerant state in monocytes, tolerance induction in human 
monocytes by different PRR agonists was examined in a new experimental setting: Cells were 
exposed to either LPS (50 ng/ml), Pam3CSK (100 ng/ml), MALP2 (10 ng/ml), iE-DAP (1 µg/ml), 
MDP (10 µg/ml) or left untreated for 20 h and then restimulated with 50 ng/ml LPS for one hour. 
TNF-α mRNA expression was analyzed to reveal tolerance induction. TNF-α mRNA was 
significantly down-regulated in monocytes that were either prestimulated with LPS (1.9-fold, 
p<0.001) or with the TLR receptor agonists Pam3CSK (12.3-fold, p<0.001) or MALP2 (6.4-fold, 
p<0.001) compared to naϊve monocytes that were stimulated with LPS for only one hour during 
the restimulation period (Fig. 7, white column, 69.15-fold). 
 
Fig. 7: Reduction of TNF-α gene expression in LPS-, Pam3CSK- and MALP2-prestimulated monocytes 
in qPCR analysis. Monocytes (8*106cells/ml) were prestimulated with one of the following stimuli: LPS E. coli 
O111:B4 (50 ng/ml), Pam3CSK (100 ng/ml), MALP2 (10 ng/ml), iE-DAP (1 µg/ml) or MDP (10 µg/ml) for 20 h, 
always including untreated cells as negative control, shown on the right part of the graph (M = medium). 
Pretreated monocytes were washed and incubated again with or without LPS E. coli O111:B4 (50 ng/ml) for 1 h. 
Data represent mean values (± SD) from three independent experiments. *** p<0.001, ns-not significant.  
However, no reduction of the TNF-α transcript level was observed in monocytes that were pre-
stimulated with one of the nucleotide-binding oligomerization domain (NOD)-like receptor 
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ligands. Neither the NOD-1 agonist iE-DAP nor the NOD-2 activator MDP were successful in 
inducing tolerance in monocytes due to unaltered high TNF-α mRNA expression levels (69.15- 
and 69.9-fold). Contrary, MDP indicated a slight pro-inflammatory trend when used as pre-
stimulus, although significance was not reached. Monocytes that were only pretreated with one of 
the PRR agonists for 20 h but not restimulated showed no increased TNF-α mRNA levels. In 
summary, LPS-, Pam3CSK-, and MALP2-pretreatment of human monocytes led to tolerization of 
TNF-α response. 
6.3 S100A12: an endogenous ligand and possible inducer of 
      tolerance in monocytes 
When NLR ligands iE-DAP and MDP failed in inducing tolerance in primary human monocytes, 
the question arose whether the endogenous RAGE and putative TLR4 agonist S100A12 would be 
able to induce tolerance in monocytes. In a first step, pro-inflammatory activation of monocytic 
THP-1 cells by S100A12 was tested, before further experiments were carried out using primary 
human monocytes. 
6.3.1 Comparison of the pro-inflammatory effects of commercially obtained 
         S100A12 and LPS in THP-1 cells 
Initially, S100A12-stimulation experiments were carried out using commercially available 
S100A12 from R&D Systems (UK). In pilot studies, a two hours-incubation period with a high 
amount of S100A12 (5 µg/ml) or LPS (50 ng/ml) induced a 5.9-fold and 11.9-fold increase of 
TNF-α mRNA expression in THP-1 cells, respectively (Fig. 8). 
 
Fig. 8: Pro-inflammatory effect of commercially available 
S100A12 in THP-1 cells.  
THP-1 cells (1*106 cells in 1 ml medium) were incubated with either 
50 ng/ml LPS, 5 µg/ml S100A12 or left untreated for 2 h. Total mRNA 
was isolated, reverse transcribed into cDNA and subjected to qPCR 
analysis. The results represent one experiment. Gene expression 
was normalized to the housekeeping gene HPRT. The fold ratio of 
mRNA levels relative to unstimulated cells was calculated according 
to Pfaffl et al. (2004).  
The result indicates that S100A12 has pro-inflammatory effects in THP-1 cells. 
 
 
Results | S100A12: an endogenous ligand and possible tolerance inducer 
51 
  
6.3.2 Confirmation of the purity of S100A12 
Reconstituted proteins expressed in E. coli strains are often contaminated with LPS. To test the 
purity of S100A12 from R&D Systems and Sino Biological, two assays were developed to test for 
residual LPS concentrations. LPS-binding protein (LBP) is well-known to mediate and accelerate 
the binding of LPS to the TLR4:MD-2:CD14 receptor complex (Hailman et al. 1994). Thus, LBP- 
and FCS-dependency of LPS- and S100A12-signaling via TLR4 was tested in a first experimental 
approach using NF-κB reportergene expressing HEK-Blue-hTLR4 cells under serum free 
conditions.  
As shown in Fig. 9, NF-κB activation in HEK-Blue-hTLR4 cells, grown in serum-free medium 
and stimulated with constant concentrations of LPS E.coli O111:B4 (1 ng/ml or 10 ng/ml), was 
considerably enhanced with increasing amounts of LBP (10 ng/ml, 100 ng/ml). Comparable effects 
were observed for exogenously-added FCS, which contains LBP as an essential serum component. 
Unexpectedly, S100A12-induced NF-κB activation was also enhanced in a similar concentration-
dependent manner in the presence of increasing amounts of LBP or in the presence of 5% serum. 
This was observed for both commercially available S100A12 proteins derived from R&D Systems 
and Sino Biological. 
A B 
S100A12 from R&D Systems (UK) S100A12 from Sino Biological (China) 
  
Fig. 9: Effects of LBP on S100A12 mediated NF-κB activation. A+B: HEK-Blue-hTLR4 cells (3*104/200 µl 
medium) were incubated in serum-free medium with different concentrations of LPS E.coli O111:B4 or with 
S100A12 purchased from either (A) R&D Systems (UK) or from (B) Sino Biological (China). NF-κB activation was 
studied in the presence of FCS or with increasing amounts of LBP. SEAP expression was quantified after 20 h of 
incubation. Medium treated cells as negative controls were always included. Data represent one experiment, 
measured in triplicates, respectively. 
The second assay investigated the influence of polymyxin B (PMB) co-incubation on LPS- and 
S100A12-stimulated cells. PMB is well described to be a specific inhibitor of LPS through binding 
to lipid A, the toxic, negatively charged component of LPS. PMB inhibits the interaction with 
TLR4 receptor complex and, hence, LPS-mediated NF-κB signaling. 
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As expected, LPS-stimulated HEK-Blue-hTLR4 cells that were co-incubated with PMB, showed 
a strong, although not significant decrease of NF-κB activation. A similar effect of PMB on 
S100A12 stimulation was observed when cells were stimulated with 0.5 µg/ml S100A12 
purchased from R&D Systems in the presence of PMB, leading to a significant reduction of 80.5% 
of the NF-κB activation (Fig. 10). 
 
Fig. 10: Polymyxin B coincubation decreases 
the signaling of S100A12 on HEK-Blue-hTLR4 
cells. Cells (3*104/200 µl medium) were stimulated 
with either LPS E.coli O111:B4 or S100A12 from R&D 
Systems (UK) in the presence or absence of 100 µg/ml 
polymyxin B. SEAP expression was quantified after 20 
h of incubation at 37°C. Medium-treated cells as 
negative controls were always included and their 
absorbance substracted from all positive samples. Data 
represent two experiments measured in triplicates. 
6.3.3 Confirmation of LPS contamination in commercially obtained S100A12 
         by LAL assay 
According to the previously shown data, doubts about the purity of the commercially obtained 
S100A12 arose. Thus, purity of commercially obtained S100A12 from R&D Systems (UK) and 
from Sino Biological (China), as well as of S100A12 provided by Dirk Foell’s (DF) working group 
was analyzed by Limulus Amebocyte Lysate (LAL-) assay, a specific and well-established method 
for the quantitative detection of even smallest amounts of endotoxin in biological material. The 
results show that both purchased S100A12 preparations, but not the one of the Foell’s group were 
LPS-contaminated (about 0.39 ng LPS per 1 µg S100A12 of R&D Systems, and 0.3 ng LPS per 1 
µg S100A12 of Sino Biological, Fig. 11). 
 
Fig. 11: Determination of possible endo-
toxin contamination of commercially ob-
tained S100A12 in the Limulus Amebocyte 
Lysate (LAL)-test.  LAL-assay of S100A12 
allocated from Dirk Foellʼs group and obtained 
of R&D Systems (UK) or Sino Biological (China) 
was carried out according to the 
manufacturer’s protocol. Data represent one 
experiment.                                                                        
In summary, LPS contamination of S100A12 reconstituted proteins could be verified by:           (1) 
enhanced signaling of S100A12 in HEK-Blue-hTLR4 cells when cells were co-incubated with 
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LBP, (2) reduction of S100A12-mediated NF-κB-activation in the presence of PMB and (3) the 
quantifiable proof performing the LAL-test. 
Therefore, all further experiments were conducted using the LPS-free S100A12 of Dirk Foellʼs 
working group to ensure that all effects seen were caused by S100A12 itself and not by its LPS 
contamination. 
6.3.4 Endotoxin-free S100A12 does not induce TNF-α expression on  
         transcriptional level in THP-1 cells 
In a first preliminary study, THP-1 cells were stimulated with three different concentrations of 
LPS-free S100A12 (0,5 µg/ml, 2 µg/ml or 5 µg/ml) or with LPS (50 ng/ml), included as positive 
control. Whereas the TNF-α mRNA expression of LPS-treated THP-1 cells was increased after  1 
h, S100A12 did not induce an enhanced TNF-α expression at any test concentration (Fig. 12). 
Since THP-1 cells may differ from human monocytes in their responsiveness towards S100A12, 
further experiments were carried out using freshly isolated human monocytes. In a new 
experimental approach to rule out different kinetics in the responses of LPS and S100A12, 
secretion of TNF-α was measured after stimulating monocytes with a high dose of S100A12 (10 
µg/ml) in three independent experiments performing cytokine-specific ELISA after 24 h of 
incubation.  
Similar to the results obtained in the THP-1 cell model, S100A12 was not inducing TNF-α 
production, while LPS treatment increased TNF-α production. 
A         THP-1 cells Fig. 12: LPS- and S100A12-induced TNF-α expression in 
THP-1 cells and human monocytes.   
A: THP-1 cells (2*106 cells/1.5 ml medium) were incubated 
with increasing concentration of S100A12 and 50 ng/ml LPS 
for 1 h at 37°C. Total mRNA was isolated, reverse transcribed 
into cDNA and subjected to qPCR analysis. Data represent 
one experiment. 
                          
 
B          Human monocytes B: Human monocytes (2*106 cells/500 µl medium) were 
incubated with either LPS E.coliO111:B4 (50 ng/ml) or 
S100A12 (10 µg/ml) for 24 h at 37°C. TNF-α secretion was 
measured on protein level by specific ELISA measuring 
concentrations in supernatants of the stimulated human 
monocytes. The results are shown as the mean (±SD) of three 
independent experiments. *** p<0.001, Paired t-test. 
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Previously published data indicated that, besides TNF-α, gene expression of IL-1β and IL-6 is 
induced when monocytes are exposed to S100A12 (Foell et al. 2013). To test this, monocytes were 
stimulated with different concentrations of S100A12 and mRNA production of IL-1β and IL-6 
was analyzed by qPCR. As shown in Fig. 13, cytokine gene expression remained nearly unaltered 
until high concentrations of 10 µg/ml S100A12 were used. Especially, the TNF-α gene expression 
was almost unchanged, whereas transcript levels of IL-1β (11.4-fold) and IL-6 (12.7-fold) were 
up-regulated when monocytes were stimulated with 10 µg/ml S100A12 (Fig. 13). 
 
Fig. 13: qPCR analysis of S100A12-induced TNF-
α, IL-1β and IL-6 gene expression in human 
monocytes.                                      
 Human monocytes (8*106 cells/2 ml medium) were 
incubated for 4 h with 0.4 µg/ml, 2 µg/ml, 10 µg/ml 
S100A12 or left untreated. The results represent one 
experiment. The gene expression was normalized to 
the housekeeping gene HPRT. The fold ratio of mRNA 
levels relative to unstimulated cells was calculated 
according to Pfaffl et al. (2004). 
To prove if S100A12 can induce monocyte tolerance similar to LPS, IL-6 expression was chosen 
as new read out for subsequent experimental settings. LPS- or S100A12-pretreated monocytes 
were restimulated after 24 h with LPS or left untreated. IL-6 secretion was measured by ELISA in 
the supernatants after the pre- and restimulation period, respectively. Naϊve monocytes that were 
stimulated only one-time with LPS showed increased IL-6 expression, whereas IL-6 production 
and release remained nearly unchanged when cells were exposed to S100A12. Moreover, the up-
regulation of IL-6 expression on protein level remained completely unaffected when S100A12-
pretreated monocytes were restimulated with LPS, particularly in comparison to the significantly 
down-regulated answer of LPS pretreated cells (Fig. 14). 
A          Pro-inflammatory 
answer 
B Tolerance induction in human monocytes 
 
 
Fig. 14: Pro-inflammatory response and tolerance induction by S100A12 in human monocytes.     
Human monocytes (2*106 cells in 500 µl medium) were pretreated with either LPS E.coli O111:B4 (50 ng/ml) or 
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S100A12 (10 µg/ml) or left untreated for 24 h at 37°C. Cells were carefully washed and allowed to rest for 30 min 
before they were restimulated with 50 ng/ml LPS for another 16 h. Unstimulated cells were included as control 
for each experiment. IL-6 production was measured on protein level by specific ELISA systems in supernatants of 
(A) the prestimulated human monocytes after 24 h and in (B) of the also restimulated or untreated monocytes 
after 40 h (24 h prestimulation+ 16 h restimulation), (M= medium). The results are shown as the mean (±SD) of 
three independent experiments. ***p<0.05, (Repeated measurements one-way ANOVA, Bonferroni post-hoc test 
(B)). 
In summary, the results revealed that S100A12-(pre-)stimulation of human monocytes neither led 
to a detectable strong pro-inflammatory activation, nor was S100A12 stimulation  able to induce 
the tolerant phenotype in monocytes as revealed by unaltered high protein expression levels of IL-
6 in S100A12-pre- and LPS-restimulated cells. Thus, further experiments with the putative 
endogenous TLR4 agonist S100A12 were discontinued. 
6.4 Adjustment of stimulation concentrations of TLR agonists 
After confirming successful tolerance induction for the TLR4 agonist LPS E.coli O111:B4 and the 
TLR2 agonists Pam3CSK and MALP2 on transcriptional level, further tests were necessary to 
adjust the above-mentioned stimuli for equally strong pro-inflammatory responses for subsequent 
glycoproteomic experiments.   
6.4.1 Standardization by an NF-κB-promoter reporter gene assay is not 
        possible due to malfunctioning transient transfection  
Several attempts were made to transfect THP-1 cells and monocytes in order to adjust 
concentrations of the used stimuli performing an NF-кB promoter reporter gene assay in dose-
response experiments. Due to the fact, that gene transfer into primary cell lines and THP-1 cells 
has proven difficult (Gresch et al. 2004), different protocols, aiming at the transient insertion of 
plasmids into the cells, were tested.  
Both, GeneCellinTM Transfection Reagent and Lipofectamine® 2000 Transfection Reagent, as 
chemical-based transfection methods failed in transfecting the purified NF-κB reporter gene 
containing plasmid (pGL4.32 [luc2P/NF-κB-RE/Hygro] Vector) and the Renilla-luciferase gene 
containing plasmid  (pGL4.74 [hRluc/TK] Vector as positive control) into THP-1 cells and human 
monocytes. Many of the GeneCellin- and Lipofectamin-treated cells were considerably damaged 
and underwent apoptosis, while surviving cells showed no detectable luminescence in subsequent 
control experiments (data not shown). 
Therefore, electroporation was used in a new experimental approach. Pmax GFP (green 
fluorescent protein) vector served as an additional positive control to determine transfection 
efficiency. Once inserted, the pmax GFP vector is constitutively expressed and, thus, GFP-labeled, 
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green fluorescent cells can be easily identified via fluorescence microscopy. Transfection 
efficiency by electroporation of monocytes was due to the pmax GFP vector only about 12-30%, 
dependent on the experiment and donor (Fig. 15). 
 
A        Phase Contrast B        Fluorescence (pmaxGFP) 
  
Fig. 15: Fluorescence and phase contrast micrographs of monocytes transfected with plasmid pmax 
GFP. Cells (5*106) were suspended in 100 µl Nucleofector solution containing 2 µg of the constitutively expressed 
pmax GFP vector. Transfection by electroporation was carried out according to the manufacturerʼs instructions. 
GFP expression was analyzed by fluorescence microscopy after incubating cells for 24 h at 37°C. Transfection 
efficiencies were of about 12-30%. 
Similar attempts to insert the Renilla-luciferase gene containing plasmid or the NF-κB reporter 
gene containing plasmid in THP-1 cells and monocytes by using electroporation led to no 
successful transfection. Subsequent luminescence measurements, based on the activity of the 
constitutively expressed Renilla-luciferase gene containing plasmid (pGL4.74 [hRluc/TK]), 
showed no increased light emission of the actually transfected cells. Thus, further approaches of 
adjusting the stimuli by transfecting THP-1 cells and monocytes with an NF-κB reporter gene 
containing plasmid were discontinued. 
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6.4.2 TNF-α- and IL-6-production by naϊve and prestimulated monocytes  
Next, the adjustment of the utilized pro-inflammatory stimuli was tried by examining the cytokine 
production and release of TNF-α and of IL-6 by ELISA. 
6.4.2.1 Monocytes show an upregulated IL-6- and TNF-α-secretion   
The pro-inflammatory responsiveness of monocytes was tested by stimulating the cells with either 
LPS (50 ng/ml), Pam3CSK (100 ng/ml) or MALP2 (10 ng/ml) for 24 hours. IL-6 and TNF-α 
expression and secretion were analyzed in the supernatants of the stimulated monocytes by 
cytokine specific ELISA. The basal expression of both cytokines varied strongly among the donors 
and led to different intensity levels in the stimulus-induced upregulation of both cytokines. 
Nevertheless, IL-6 as well as TNF-α concentrations were highly increased after stimulation with 
LPS, Pam3CSK or MALP2 compared to non-stimulated monocytes (Fig. 16). 
 
Fig. 16: Analysis of TNF-α and IL-6 release by LPS-, Pam3CSK- and MALP2-stimulated human 
monocytes. Monocytes (2*106 cells in 500 µl medium) were incubated with either LPS E. coli O111:B4 (50 ng/ml), 
Pam3CSK (100 ng/ml) or MALP2 (10 ng/ml) for 24 h at 37°C. TNF-α and IL-6 expression were analyzed in the 
collected supernatants by cytokine specific ELISA. Data represent mean values from two independent 
experiments (± SD).  
6.4.2.2 TNF-α- and IL-6-production by monocytes after tolerance induction 
It was further examined if the already described phenomenon of tolerance induction seen on 
transcriptional level was reproducible on protein level. Therefore, the pro-inflammatory cytokines, 
IL-6 and TNF-α, were measured in the supernatants of LPS (50 ng/ml)-, Pam3CSK (100 ng/ml)- 
and MALP2 (10 ng/ml)-prestimulated and LPS-restimulated monocytes. The data demonstrate a 
significant down-regulation of IL-6 as well as TNF-α for all three different pretreatments (LPS, 
Pam3CSK and MALP2) on protein level in three independent experiments (Fig. 17). In the case 
of IL-6, the expression levels were comparably reduced to about 15-18%, no matter which stimulus 
was used for prestimulation. Whereas the decrease of TNF-α seems to be stronger when 
prestimulation was carried out with LPS as Gram-negative stimulus or MALP2 as Gram-positive 
stimulus compared to a prestimulation with the second Gram-positive stimulus Pam3CSK. 
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A 
Fig. 17: Significant down re-
gulation of cytokine produc-
tion in tolerant human 
mono-cytes. Monocytes 
(2*106 cells in 500 µl medium) 
were incubated with either LPS 
E. coli O111:B4 (50 ng/ml), 
Pam3CSK (100 ng/ml) or MALP2 
(10 ng/ml) for 24 h at 37°C and 
restimulated with LPS E. coli 
O111:B4 (50 ng/ml) again for 16 
h (M = medium). 
(A) TNF-α and (B) IL-6 
expression were analyzed in the 
collected supernatants by 
cytokine specific ELISA. Data 
represent mean values from 
three independent experiments 
(± SD). *** p<0.001, **p<0.01, 
**p<0.05 (Repeated 
measurements one-way 
ANOVA, Bonferroniʼs post-hoc 
test). 
 
B 
 
In order to obtain comparable data, stimulus equalization was attempted by using different 
concentrations of each PRR agonist. In pilot studies, human monocytes (2*106 cells) were treated 
with different concentrations of one of the following stimuli: LPS E. coli O111:B4, Pam3CSK or 
MALP2 for 24 hours at 37°C. Untreated monocytes served as negative control.  IL-6 and TNF-α 
expression and secretion were analyzed in the supernatants of the stimulated monocytes by 
cytokine specific ELISAs (Fig. 18). Again, the heterogeneous background among the donors led 
to great differences between the intensities in the stimulus-induced upregulation of cytokine 
expression. As depicted in Fig. 18, the expression of IL-6 and TNF-α proteins is shown for one 
individual donor. Similar results were observed for two more donors.  
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A B 
  
Fig. 18: Concentration series of LPS, Pam3CSK and MALP2 on human monocytes.  
Monocytes (2*106 cells in 500 µl medium) were incubated with different concentrations of either LPS E. coli 
O111:B4 (2.5, 5 and 10 ng/ml), Pam3CSK (50, 100 and 200 ng/ml) or MALP2 (1.25, 2.5 and 5 ng/ml) for 24 h at 
37°C. TNF-α (A) and IL-6 (B) expression were analyzed in the collected supernatants by cytokine specific ELISA. 
Data represent one experiment. 
As shown in Fig. 18, already 2.5 ng/ml of LPS initiated higher IL-6- and TNF-α-secretion levels 
in monocytes compared to those stimulated with biological relevant high amounts of the TLR2 
agonists MALP2. Moreover, simultaneously performed experiments showed that LPS 
concentrations (of 5 ng/ml and 10 ng/ml) that on the one hand were low enough to induce 
equivalent pro-inflammatory answers in monocytes as the TLR2 agonists did, on the other hand, 
were unable to reliably induce tolerance when monocytes were prestimulated with those amounts 
of endotoxin (data not shown). Although, measurement of cytokine expression turned out to be 
not sufficient in adjusting the concentrations of the TLR agonists, the usage of higher MALP2 
concentrations than 5 ng/ml and as low concentrations of LPS as possible were indicated by the 
observed data. 
6.4.3 Intercellular adhesion molecule-1 (ICAM-1) expression as a marker of 
         the activation level of stimulated human monocytes  
Next, the cell surface expression of ICAM-1 (CD54) was investigated by FACS analysis in order 
to determine the activation level of monocytes after PAMP stimulation and to ensure a comparable 
pro-inflammatory state of the differently treated cells that were used in further glycoproteomic 
analysis. ICAM-1 expression is a well-known parameter to identify the pro-inflammatory state of 
cells (Audran et al. 1996, Anbarasan et al. 2015). Concentrations of LPS, Pam3CSK and MALP2 
were chosen due to the tendencies determined in previously performed experiments, e.g. cytokine 
concentration series and experiments of tolerance induction (see Chapter 6.4.2). Purified 
monocytes were additionally stained with FITC-labeled anti-CD14 antibody (eBioscience, USA) 
to discriminate the monocytes population from other blood cells. Stimulated cells were either left 
unstained or stained with an APC-labeled anti-CD54 antibody (ImmunoTools, Germany) and 
subjected to flow cytometry analysis. As shown in Fig. 19, a high basal expression of ICAM-1 
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was found in unstimulated monocytes (MFI=3.2*103). ICAM-1 expression was significantly 
upregulated (3.8-fold for donor 1 and 3.9-fold for donor 2 as can be seen in Fig. 19), when 
monocytes were stimulated with the 50 ng/ml LPS (MFI=12.6*103), 200 ng/ml Pam3CSK 
(MFI=12.6*103) or 10 ng/ml MALP2 (MFI=12.0*103), indicating equivalent activation levels. 
This was observed in two independent experiments. 
A    MFI LPS = 12.6*103 B    MFI P3C = 12.6*103 C    MFI MALP2 = 12.0*103 
   
D Fig. 19: ICAM-1 expression in stimulated 
human monocytes. A-C: Monocytes (1*107 
cells/2 ml medium) were stimulated with 50 ng/ml 
LPS (A), 200 ng/ml Pam3CSK (B) or 10 ng/ml MALP2 
(C) or left untreated for 24 h at 37°C. Cell surface 
expression of ICAM-1 (CD54) was analyzed by flow 
cytometry with a mouse monoclonal APC-labeled 
anti-CD54 antibody.  
D: Statistical analysis and comparison of the 
upregulated ICAM-1 expression in stimulated 
monocytes. The mean fluorescence intensities (MFI) 
are given in arbitrary units. Data are representative 
for two independent experiments. 
 
Therefore, further glycoproteomic studies were carried out using these concentrations of the 
stimuli named above.  
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6.5 Purity of monocytes for glycoproteomic analysis 
Samples tested in the following glycoproteomic analysis have to be very pure and should contain 
exclusively monocytes. This is why the already MACS-sorted monocytes that were used for the 
stimulations with either LPS (50 ng/ml), Pam3CSK (200 ng/ml) or MALP2 (10 ng/ml) for 24 h or 
48 h, were additionally labeled with an anti-CD14 antibody for a second purification step using 
fluorescence activated cell sorting (FACS analysis). To deplete contaminating platelets (anti-
CD42b) and lymphocytes (anti-CD3 against T-lymphocytes and anti-CD19 against B-
lymphocytes), these populations were labeled with the indicated antibodies and separated from 
CD14 positive cells in order to enrich the monocytic population (Fig. 20). Purity of CD14+ cells 
was increased to more than 97%. Unstimulated monocytes, that were always included as negative 
controls, showed poor survival after 48 hours of cultivation (data not shown). 
 
Fig. 20: Purification of monocytes via MACS® monocyte isolation kit and CD14+ fluorescence acti-
vated cell sorting (FACS). Purity of monocytes was assessed measuring the volume (FSC= forward scatter) and 
granularity (SSC=sideward scatter) of unstained cell fractions by flow cytometry analysis at different time points: 
1. After MACS-separation and before incubation of the cells with the above-named stimuli.                                        2.  
After FACS-separation and prior to subsequent sample preparation for mass spectrometry analysis.              High 
quality of monocyte isolation was ensured by additional staining against the monocyte surface marker CD14. 
6.6 Mass spectrometry-based glycoprotein expression in monocytes 
Analysis of whole membrane receptor profile of the differently treated monocytes was carried out 
in a glycoproteomic approach. Glycoproteomic data were assessed of monocytes stimulated with 
either LPS (50 ng/ml), Pam3CSK (200 ng/ml) or MALP2 (10 ng/ml) for 24 h and 48 h at 37°C in 
three independent experiments. Untreated cells were included for each experiment. Next, two 
different peptide fractions were gained by digesting the denatured, reduced and alkylated proteins 
bound to the UltraLink Hydrazide-Beads, first by the endoproteinase trypsin and in a second step 
by the added Peptide-N-Glycosidase F (PNGase F) (Details see chapter 5.8.8). Both fractions, the 
tryptic peptide fraction (TPF) from the first trypsin-digestion and the N-glycosylated peptide 
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fraction (NGF) from the second PNGase F-digestion, were subjected to subsequent analysis by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS).      Each biological replicate was 
measured in 3 technical replicates. Due to the poor survival rates of (especially not-stimulated) 48 
hours-cultured monocytes, precise statistical data could be not obtained from the 48 hours-cultured 
monocytes. Only data of the 24 hours-cultured and stimulated monocytes were taken into 
consideration.  
A similar number of glycoproteins (1003, 966 and 1033) were identified from each of the three 
biological replicates with a FDR of <0.01, respectively. These data were observed analyzing the 
whole data set and assuming 1 peptide being required for the identification of one protein. When 
using the threshold of a minimum of two unique peptides for the identification of one protein, we 
identified 802, 782 and 839 glycoproteins of donor 1, 2, and 3, respectively, but at the risk of 
missing possible glycoproteins, which contain only one glycosylation site (analysis based on the 
PNGase fraction). In total, 1210 annotated proteins were identified and quantified in the combined 
analysis of the NGP and TPG fractions of all stimulations, including 34 transient O-glycosylated 
(O-GlcNAc-modified) proteins which were excluded from further analysis. The hydrophobic 
transmembrane helix prediction algorithm (TMHMM v2.0 Server) revealed that 898 of the 
identified glycoproteins were predicted to contain at least one transmembrane domain (TMD) (Fig. 
21). 
 
Fig. 21: Distribution of identified 
glycopro-teins according to the number 
of predicted transmembrane domains 
(TMDs).  
Upper part: glycoproteins containing ≥1 or 0 
TMD.                       
Lower part: TMD-comprising glycoproteins 
tabulated by number.                                         
While the majority of 552 glycoproteins comprised one TMD, 346 (29.4%) glycoproteins were 
predicted to comprise two or more TMDs. Moreover, 61 of them were found to belong to the group 
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of seven transmembrane domain-containing proteins, which includes the group of drug-relevant 
G-protein coupled receptors being of major biomedical interest. 
Next, we were interested in the subcellular localization of the identified glycoproteins. Based on 
subcellular compartment analysis, 617 glycoproteins (52%), and, therefore, the most abundant 
group, were annotated by gene ontology (GO) as “plasma membrane” associated (Fig. 22).  
 
Fig. 22: Gene ontology-based cellular 
compo-nent analysis of all glycoproteins 
identified in monocytes.  
Based on the identified glycoproteins in LC-
MS/MS. 
Proteins derived from the endoplasmic reticulum (264) and the golgi apparatus (205) formed 
together the second largest subset of about 40% when taking into account the non-exclusive 
assignment of the proteins to different subcellular compartments by gene ontology. Glycoproteins 
located in the lysosome (158), nucleus (123), endosome (107), mitochondrion (28) and peroxisome 
(2) were also identified. Besides these intracellular proteins, 223 glycoproteins were annotated as 
“extracellular space”, including secretory proteins, and 55 proteins were found to be part of the 
extracellular matrix.  
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6.6.1 LPS-, Pam3CSK- and MALP2-stimulated monocytes exhibit changes in  
        their glycoprotein expression 
For the purpose of identifying changes of the glycoprotein expression induced by LPS-, 
Pam3CSK- and MALP2-treatment, the glycoproteomes of untreated monocytes were compared to 
those stimulated for 24 hours. Fig. 23 shows differentially expressed glycoproteins in human 
monocytes depicted in a testing after stimulation with either LPS, Pam3CSK or MALP2. In total, 
117 glycoproteins could be identified to be significantly regulated by at least one stimulus, of 
which the majority of 67 proteins was found upregulated. As the previously mentioned FACS 
analysis indicated, ICAM-1 that was previously chosen as marker-protein to adjust the 
concentrations of LPS, Pam3CSK and MALP2 stimuli showed very similar upregulated 
expression levels (3.56-fold, 3.23-fold and 3.10-fold, respectively) in the analyzed cells again. 
 
Fig. 23: Unpaired analysis: Significant up- or downregulated glycoproteins in LPS-, MALP2- 
and Pam3CSK-stimulated human monocytes. Heat map of glycoproteins significantly up- or 
downregulated in human monocytes post LPS, MALP2 or Pam3CSK treatment at 24 h according to unpaired 
analysis. As shown in the legend green, yellow and red boxes indicate upregulation, blue indicates 
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downregulation. Black boxes indicate either no fold change or fold changes reaching no significance. Gene names 
are given. 
6.6.2 Comparison of the glycoprotein expression patterns of all three donors 
         by Principal Component Analysis (PCA) 
In order to visualize and compare the entire data set generated by combination of the glycoprotein 
expression patterns revealed for each donor and each stimulation, PCA was carried out reducing 
the dimensionality of the complex data (Fig. 24). The first two principal com-ponents (PC) 
accounted for >53% of the total data variance. Unstimulated control cells of all three donors 
showed considerably lower PC2 values compared to stimulated cells with either LPS, Pam3CSK 
or MALP2.  
 
Fig. 24: Principal Component Analysis of 
the glycoprotein expression patterns all 
3 replicates.  
Each spot on the plot corresponds to one cell 
subpopulation of a donor, which was exposed to 
LPS (red), MALP2 (green) or Pam3CSK (blue) or 
left untreated (black) for 24 h.  Replicate one is 
represented by circles, replicate two by triangles 
and replicate three by squares. 
Although, PC2 values differed remarkably between the three controls, stimulated monocytes of all 
three donors, irrespective which stimulus was used, displayed similar shifts to higher PC2 values. 
Especially, the LPS-, Pam3CSK- and MALP2-treated cells of replicate 1 and 2 clustered in a very 
narrow range, indicating that these stimulated monocytes show similar glycoprotein expression 
profiles. The second observation one can make considering the whole spectra shown in Fig. 24 is 
that the values of the PC1 are widely scattered among the donors. In particular, PC1 values of 
donor 3 differ from those of replicate 1 and 2 and, therefore, causing the main variance of principal 
component 1. Besides contaminating non-glycosylated proteins, also differentially expressed 
HLA-proteins, were the glycoproteins found to have a major influence on PC1. This indicates that 
there is a higher variability among the different donors (interindividual differences + sample 
purity) than between the different stimuli. Therefore, a paired analysis was performed additionally. 
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6.6.3 Results of paired analysis 
After paired analysis, all together, 135 glycoproteins showed significant alterations in their 
expression upon stimulation with either LPS, Pam3CSK or MALP2. LPS-treatment resulted in a 
significant up- or down-regulation of 119 glycoproteins, whereas both TLR2 agonists, Pam3CSK 
and MALP2, led to distinct changes in the expression of 83 and 75 glycoproteins, respectively 
(Fig. 25).  
 
Fig. 25: Volcano plot of glycoproteins in LPS-, MALP2- and Pam3CSK-stimulated monocytes.                The 
negative log of the t-test p-value was plotted against the protein fold change of differentially expressed 
glycoproteins after 24h of LPS (left), MALP2 (middle) and Pam3CSK (right) treatment. Red spots display 
significantly up- (upper right quadrant) or down- (upper left quadrant) regulated glycoproteins, while grey data 
points represent not significantly or unchanged proteins. Gene names are given. 
Most of the glycoproteins displayed unaltered expression levels or alterations reached no 
significance (grey data points in the volcano plot; Fig. 25).  
In total, 75 of 135, and, therefore, the majority of the significantly regulated glycoproteins, showed 
increased expression levels upon stimulation (Heat map, Fig. 26). 65 of them were integral 
members of the plasma membrane, while a large subset of 27 glycoproteins of the down regulated 
60 glycoproteins was secreted or luminal localized. Expression of the LPS-sensing TLR4-receptor 
complex (consisting of TLR4, CD14 and MD-2) and the heterodimeric receptor complexes 
TLR2/1 and TLR2/6 for Pam3CSK and MALP2 were not affected in the course of the stimulation. 
Database for Annotation, Visualization and Integrated Discovery (DAVID) functional annotation 
clustering mapped 79 differentially expressed glycoproteins to 7 different Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways, however, functional annotation clustering revealed no 
significant enrichment of these pathways. 18 glycoproteins were found to be involved in “cell 
adhesion” processes of which 11 demonstrated upregulated expression levels (CD274 molecule, 
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CD274; Integrin subunit beta 8, ITGB8; Atypical chemokine receptor 3, ACKR3; CD80 molecule, 
CD80; CD276 molecule, CD276; CD40 molecule, CD40; Integrin subunit alpha V, ITGAV; 
Scavenger receptor class F member 1, SCARF1; CD44 molecule, CD44; Intercellular adhesion 
molecule 1, ICAM1 and Poliovirus receptor, PVR (CD155 molecule)). Downregulated 
glycoproteins take mainly part in “complement and coagulation” signaling pathways (Alpha-2-
macroglobulin, A2M; Complement C1r subcomponent, C1R; Complement factor H, CFH; 
Fibrinogen gamma chain, FGG; Complement C4-A, C4A; Prothrombin, F2; Plasminogen 
activator inhibitor 1, SERPINE1 and Complement factor B, CFB). Moreover, glycoproteins 
involved in the “acute phase” (F2; Fibronectin, FN1; Haptoglobin, HP and Inter-alpha-trypsin 
inhibitor heavy chain H4, ITIH4) and “inflammatory immune response” (C4A; Hepatitis A virus 
cellular receptor 2, HAVCR2 and Stabilin-1, STAB1) showed significantly decreased expression 
levels. HLA-DRA was not affected as previous data suggest (Wolk et al. 2000, del Fresno et al. 
2009). The only MHC II-associated glycoprotein found to be significantly downregulated was 
CD74. 
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Fig. 26: Paired analysis: Significant up- or downregulated glycoproteins in LPS-, MALP2- or 
Pam3CSK-stimulated human monocytes. Heat map of glycoproteins significantly up- or downregulated 
in human monocytes post LPS, MALP2 or Pam3CSK treatment at 24 h according to paired analysis. As shown in 
the legend green, yellow and red boxes indicate upregulation, blue indicates downregulation. Black boxes indicate 
either no fold change or fold changes reaching no significance. Gene names are given. 
Data of the heat map (Fig. 26) may, at first sight, give the impression of some glycoproteins (e.g. 
CD276; Signaling lymphocytic activation molecule family member 8, SLAMF8) to be spe-
cifically regulated by only one stimulus, because of 55 glycoproteins displaying altered expression 
levels that reach significance only in one of the three treatments (43 by LPS-, 8 by Pam3CSK- and 
4 by MALP2-stimulation). However, these trends and tendencies might be artificial, taking into 
account that stimulation with one of the two other stimuli led to similar up- or downregulation of 
the glycoprotein expression, although these alterations did not reach significance (black boxes in 
the heat map). As can be seen in table 21, fold changes of these glycoproteins are comparable 
irrespectively of the stimulus. 
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Table 21: LPS-, Pam3CSK- and MALP2-regulated glycoproteins and their FCs at 24 h compared to 
unstimulated controls.  
A: Significantly upregulated glycoproteins, at least one protein demonstrating more than >2 FC.                                                                                           
B: Significantly downregulated glycoproteins. 
A Upregulated glycoproteins FC 
(Stimulus vs. ctrl) 
Gene name  Accession Protein name LPS MALP P3C 
Membrane bound 
    
CD274 Q9NZQ7 Programmed cell death  ligand 1 1781,20 905,32 1431,59 
CA12 O43570 Carbonic anhydrase 12 453,95 190,17 430,94 
SLCO4A1 Q96BD0 
Solute carrier organic anion transporter family 
member 4A1 
153,26 108,22 147,79 
ITGB8 P26012 Integrin beta-8 150,34 80,42 101,49 
SLAMF1 Q13291 Signaling lymphocytic activation molecule 107,23 11,46 33,46 
LAMP3 Q9UQV4 Lysosome-associated membrane glycoprotein 3 70,00 28,06 27,26 
IL7R P16871 Interleukin-7 receptor subunit alpha 63,16 15,41 22,20 
KREMEN1 Q96MU8 Kremen protein 1 59,75 33,51 86,90 
FAM20A Q96MK3 Protein FAM20A 45,23 9,68 19,19 
GGT5 P36269 Gamma-glutamyltransferase 5 34,90 7,18 4,26 
SLAMF8 Q9P0V8 SLAM family member 8 32,77 12,03 2,93 
ACKR3 P25106 Atypical chemokine receptor 3 32,22 10,34 30,19 
MET P08581 Hepatocyte growth factor receptor 29,64 51,10 29,02 
CD80 P33681 T-lymphocyte activation antigen CD80 23,57 10,31 11,70 
CD276 Q5ZPR3 CD276 antigen 23,07 3,90 4,62 
GPR68 Q15743 Ovarian cancer G-protein coupled receptor 1 19,78 24,09 18,84 
SLC7A11 Q9UPY5 Cystine/glutamate transporter 19,59 20,84 18,93 
SLC7A1 P30825 High affinity cationic amino acid transporter 1 16,43 30,15 37,96 
NT5E P21589 5-nucleotidase 15,30 13,29 10,97 
PROCR Q9UNN8 Endothelial protein C receptor 13,01 13,77 14,50 
SIGLEC10 Q96LC7 Sialic acid-binding Ig-like lectin 10 12,14 1,90 3,97 
MARCO Q9UEW3 Macrophage receptor MARCO 11,32 9,71 9,48 
PLXNA1 Q9UIW2 Plexin-A1 10,34 7,27 8,08 
ACVRL1 P37023 Serine/threonine-protein kinase receptor R3 9,17 2,02 5,20 
TNFRSF21 O75509 
Tumor necrosis factor receptor superfamily member 
21 
8,75 2,22 5,88 
HRH2 P25021 Histamine H2 receptor 8,40 1,94 5,67 
EREG O14944 Proepiregulin; Epiregulin 8,14 7,30 14,96 
SLC7A5 Q01650 
Large neutral amino acids transporter small subunit 
1 
6,73 3,10 4,19 
ST3GAL1 Q11201 
CMP-N-acetylneuraminate-beta-galactosamide-
alpha-2,3-sialyltransferase 1 
6,69 7,54 8,71 
TPST1 O60507 Protein-tyrosine sulfotransferase 1 6,69 6,92 5,56 
SLC43A3 Q8NBI5 Solute carrier family 43 member 3 6,00 5,05 6,32 
B3GALT4 O96024 Beta-1,3-galactosyltransferase 4 5,98 3,26 2,29 
DSEL Q8IZU8 Dermatan-sulfate epimerase-like protein 5,42 5,13 7,56 
ABCA1 O95477 ATP-binding cassette sub-family A member 1 5,41 4,08 4,58 
ITGAV P06756 Integrin alpha-V 5,39 2,91 3,53 
ENTPD7 Q9NQZ7 Ectonucleoside triphosphate diphosphohydrolase 7 5,08 1,86 3,68 
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SCARF1 Q141623 Scavenger receptor class F member 1 4,96 2,40 1,72 
SIGLEC10 Q96LC7 Sialic acid-binding Ig-like lectin 10 4,73 1,73 2,30 
SEMA4A Q9H3S1 Semaphorin-4A 4,63 4,50 3,77 
GPR84 Q9NQS5 G-protein coupled receptor 84 4,51 2,51 3,27 
OSCAR Q8IYS5 Osteoclast-associated immunoglobulin-like receptor 4,46 1,94 3,85 
SLC43A2 Q8N370 
Large neutral amino acids transporter small subunit 
4 
4,03 3,79 4,20 
CD82 P27701 CD82 antigen 3,92 2,25 2,08 
TFRC P02786 Transferrin receptor protein 1 3,64 2,40 4,60 
EMR2 Q9UHX3 
EGF-like module-containing mucin-like hormone 
receptor-like 2 
3,60 2,67 3,60 
CD44 P16070 CD44 antigen 3,60 3,58 3,95 
ICAM1 P05362 Intercellular adhesion molecule 1 3,56 3,23 3,10 
FCRLB Q6BAA4 Fc receptor-like B 3,40 6,96 5,27 
ST3GAL2 Q16842 
CMP-N-acetylneuraminate-beta-galactosamide-
alpha-2,3-sialyltransferase 2 
3,35 1,92 2,81 
PANX1 Q96RD7 Pannexin-1 3,28 2,69 2,87 
CLEC4E Q9ULY5 C-type lectin domain family 4 member E 3,21 1,97 2,30 
EMR1 Q14246 
EGF-like module-containing mucin-like hormone 
receptor-like 1 
3,19 2,07 2,58 
PVR P15151 Poliovirus receptor 3,12 2,91 2,39 
SLC43A3 Q8NBI5 Solute carrier family 43 member 3 2,81 3,05 3,10 
PLXNA3 P51805 Plexin-A3 2,81 2,54 2,61 
CD40 P25942 
Tumor necrosis factor receptor superfamily member 
5 
2,78 1,57 1,90 
THBD P07204 Thrombomodulin 2,71 1,79 1,66 
FAM20C Q8IXL6 
Extracellular serine/threonine protein kinase 
FAM20C 
2,61 1,63 1,95 
IL4R P24394 Interleukin-4 receptor subunit alpha 2,57 1,55 1,90 
PLAUR Q03405 Urokinase plasminogen activator surface receptor 2,45 2,43 3,28 
SEMA4B Q9NPR2 Semaphorin-4B 2,43 2,55 1,93 
ITGA5 P08648 Integrin alpha-5 2,40 2,05 1,87 
ECE1 P42892 Endothelin-converting enzyme 1 2,29 1,67 1,63 
ABCD1 P33897 ATP-binding cassette sub-family D member 1 1,84 1,66 2,67 
Secreted or luminal localized    
CEMIP Q8WUJ3 
Cell migration-inducing and hyaluronan-binding 
protein 
69,35 21,56 85,53 
PTGS2 P35354 Prostaglandin G/H synthase 2 60,76 35,28 74,21 
PLAU P00749 Urokinase-type plasminogen activator 10,03 6,85 6,96 
PLOD2 O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 9,18 4,59 5,92 
ANGPTL4 Q9BY76 Angiopoietin-related protein 4 6,86 2,01 4,55 
MMP9 P14780 Matrix metalloproteinase-9 6,67 12,23 8,07 
ADAMDEC1 O15204 ADAM DEC1 5,85 2,85 2,65 
IL4I1 Q96RQ9 L-amino-acid oxidase 4,74 2,99 3,08 
SERPINB2 P05120 Plasminogen activator inhibitor 2 2,37 3,04 2,36 
SMPDL3A Q92484 Acid sphingomyelinase-like phosphodiesterase 3a 1,54 3,15 4,37 
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B Downregulated glycoproteins FC 
(Stimulus vs. ctrl) 
Gene name Accession Protein name LPS MALP P3C 
Membrane bound     
COLEC12 Q5KU26 Collectin-12 0,02 0,04 0,02 
LPAR6 P43657 Lysophosphatidic acid receptor 6 0,05 0,09 0,06 
TREM2 Q9NZC2 Triggering receptor expressed on myeloid cells 2 0,06 0,07 0,13 
PIK3IP1 Q96FE7 Phosphoinositide-3-kinase-interacting protein 1 0,09 0,30 0,17 
NRG1 Q02297 Neuregulin-1 0,10 0,19 0,06 
RNASE1 P07998 Ribonuclease pancreatic 0,11 0,19 0,11 
MSR1 P21757 Macrophage scavenger receptor types I and II 0,11 0,09 0,11 
GPNMB Q14956 Transmembrane glycoprotein NMB 0,12 0,16 0,13 
LY6G6F Q5SQ64 Lymphocyte antigen 6 complex locus protein G6f 0,12 0,16 0,41 
TNFSF13B Q9Y275 
Tumor necrosis factor ligand superfamily member 
13B 
0,13 0,11 0,05 
CD109 Q6YHK3 CD109 antigen 0,15 0,19 0,14 
CLEC10A Q8IUN9 C-type lectin domain family 10 member A 0,15 0,09 0,10 
FGG P02679 Fibrinogen gamma chain 0,20 0,28 0,33 
AMICA1 Q86YT9 Junctional adhesion molecule-like 0,23 0,78 0,43 
FCGR2B P31994 
Low affinity immunoglobulin gamma Fc region 
receptor II-b 
0,23 0,26 0,18 
DAG1 Q14118 Dystroglycan; Alpha-dystroglycan;Beta-dystroglycan 0,24 0,33 0,30 
HAVCR2 Q8TDQ0 Hepatitis A virus cellular receptor 2 0,24 0,24 0,24 
CD36 P16671 Platelet glycoprotein 4 0,24 0,26 0,23 
SLC46A2 Q9BY10 Thymic stromal cotransporter homolog 0,24 0,20 0,05 
HGFAC Q04756 Hepatocyte growth factor activator 0,24 0,24 0,31 
MPEG1 Q2M385 Macrophage-expressed gene 1 protein 0,25 0,58 0,51 
TNFSF13 O43508 Tumor necrosis factor ligand superfamily member 13 0,26 0,38 0,34 
C16orf54 Q6UWD8 Transmembrane protein C16orf54 0,28 0,33 0,26 
CD74 P04233 HLA class II histocompatibility antigen gamma chain 0,30 0,32 0,23 
CECR1 Q9NZK5 Adenosine deaminase CECR1 0,30 0,39 0,37 
STAB1 Q9NY15 Stabilin-1 0,32 0,45 0,48 
RNASE6 Q93091 Ribonuclease K6 0,36 0,53 0,42 
ITIH1 P19827 Inter-alpha-trypsin inhibitor heavy chain H1 0,36 0,36 0,35 
EPHB2 P29323 Ephrin type-B receptor 2 0,36 0,28 0,26 
PLD3 Q8IV08 Phospholipase D3 0,37 0,44 0,36 
ITGA2B P08514 Integrin alpha-IIb 0,38 0,41 0,49 
ICOSLG O75144 ICOS ligand 0,43 0,57 0,46 
SIGLEC1 Q9BZZ2 Sialoadhesin 0,65 0,06 0,04 
LAMP2 P13473 Lysosome-associated membrane glycoprotein 2 0,66 0,03 0,66 
Secreted or luminal localized    
DPEP2 Q9H4A9 Dipeptidase 2 0,05 0,09 0,04 
FN1 P02751 Fibronectin 0,07 0,16 0,05 
THBS1 P07996 Thrombospondin-1 0,08 0,53 0,53 
FGL2 Q14314 Fibroleukin 0,15 0,15 0,13 
A2M P01023 Alpha-2-macroglobulin 0,15 0,24 0,19 
C1R P00736 Complement C1r subcomponent 0,15 0,17 0,25 
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IGFBP7 Q16270 Insulin-like growth factor-binding protein 7 0,18 0,22 0,32 
CFH P08603 Complement factor H 0,19 0,14 0,25 
LOXL3 P58215 Lysyl oxidase homolog 3 0,19 0,24 0,42 
MMRN1 Q13201 Multimerin-1 0,20 0,24 0,22 
FCN1 O00602 Ficolin-1 0,23 0,31 0,23 
FN1 P02751 Fibronectin 0,23 0,33 0,16 
FUCA1 P04066 Tissue alpha-L-fucosidase 0,24 0,27 0,25 
LTBP1 Q14766 
Latent-transforming growth factor beta-binding 
protein 1 
0,26 0,24 0,36 
HP P00738 Haptoglobin 0,27 0,19 0,21 
C4A P0C0L4 Complement C4-A 0,27 0,38 0,34 
CTSD P07339 Cathepsin D 0,31 0,36 0,33 
ACP5 P13686 Tartrate-resistant acid phosphatase type 5 0,32 0,33 0,28 
F2 P00734 Prothrombin 0,32 0,32 0,45 
HPX P02790 Hemopexin 0,33 0,33 0,32 
PTX3 P26022 Pentraxin-related protein PTX3 0,34 0,13 0,02 
ITIH3 Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 0,38 0,21 0,23 
ITIH4 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 0,40 0,43 0,50 
APOH P02749 Beta-2-glycoprotein 1 0,43 0,28 0,45 
BTD P43251 Biotinidase 0,43 0,50 0,64 
SERPINE1 P05121 Plasminogen activator inhibitor 1 0,50 0,30 0,30 
CFB P00751 Complement factor B 0,54 0,31 0,48 
The previous findings already indicated that changes of the monocytes glycoproteome tend to be 
very similar among the different stimuli (see FC table above). In a new statistical approach, fold 
changes (FCs) of significantly regulated glycoproteins induced by LPS treatment were calculated 
against FCs of significantly regulated glycoproteins from monocytes exposed to MALP2 or 
Pam3CSK (Fig. 27). The same was done with FCs of glycoproteins measured in MALP2- and 
Pam3CSK-stimulated cells, respectively. In this linear regression model we obtained a pearson 
ratio (ρ) of 0.949, 0.965 and 0.955 analyzing LPS vs. MALP2, MALP2 vs. Pam3CSK and 
Pam3CSK vs. LPS stimulation. The data indicate that most of the glycoproteins found to be 
regulated by LPS treatment of monocytes, were also regulated highly similar in cells that were 
stimulated with Pam3CSK or MALP2. 
 
Fig. 27: Linear regression model of the glycoprotein expression of the differently treated 
monocytes. Pearson correlation was carried out calculating fold changes (FCs) of significantly up- or 
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downregulated glycoproteins of the different stimulations (Left: LPS vs. MALP2, Middle: MALP2 vs. Pam3CSK, 
Right: Pam3CSK vs. LPS) against each other. Pearson correlation coefficient (ρ) is given. 
6.6.4 Subcellular localization of significantly regulated glycoproteins 
In a next step, we analyzed if the distribution of significantly regulated glycoproteins among the 
different stimuli showed a distinct expression pattern regarding their subcellular location. 
Glycoproteins annotated as “plasma membrane” associated were not only the most abundant group 
of identified proteins, but included also the largest number of significantly regulated glycoproteins 
(Fig. 28). Upon exposure towards LPS, Pam3CSK and MALP2, the majority of regulated proteins 
derived from the plasma membrane, golgi apparatus and endoplasmic reticulum demonstrated 
increased expression levels. The second largest subset of proteins, showing distinctly altered 
expression levels, was annotated as “extracellular space”. Together with glycoproteins denoted as 
belonging to the “extracellular matrix”, they exhibited a slight tendency to be down regulated more 
often. Minor expression changes were detectable in proteins derived from the nucleus, lysosome 
and endosome. The different TLR agonists resulted in comparable expression changes of 
glycoproteins located in different cellular organells. 
 
Fig. 28: Cellular component analysis 
of LPS-, MALP2- and Pam3CSK-
regulated gly-coproteins.  
Distribution of significantly different 
expressed glycoproteins after 
LPS (light grey bar),  
MALP2 (dark grey bar) or 
Pam3CSK (black bar) treatment  
in cellular organells assessed by LC-MS/MS. 
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6.6.5 Comprehensive analysis of CD antigen expression in the tolerant 
         monocyte cell state      
The majority of proteins affected by LPS, Pam3CSK and MALP2 treatment belonged to the subset 
of “plasma membrane” associated glycoproteins as shown in Fig. 29. Therefore, we further 
analyzed the CD antigen expression profile of unstimulated and treated monocytes in order to 
distinguish a specific CD antigen phenotype associated with the tolerant state. 
 
Fig. 29: CD antigen expression in stimulated monocytes. Heat map of CD antigens significantly up- or 
down-regulated in human monocytes by LPS, MALP2 or Pam3CSK treatment at 24 h. As shown in the legend 
green, yellow and red boxes indicate upregulation, blue indicates downregulation. Black boxes indicate either no 
fold change or fold changes reaching no significance. Gene names are given. 
Altogether, 202 CD antigens expressed by human monocytes were identified, of which 32 showed 
distinct alterations in their expression when the cells were exposed to LPS, Pam3CSK or MALP2. 
Thus, CD antigens represent with 23.7% a large part of all 135 significantly up- or downregulated 
glycoproteins. The tolerant state after 24 h of prestimulation was predominantly associated with 
increased expression of CD molecules as 22 of the 32 detected and significantly regulated CD 
antigens showed a distinct upregulation of their expression, including Programmed cell death-
ligand 1 (PD-L1, CD274), SLAM family member 1 (SLAMF1, CD150), Lysosome-associated 
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membrane glycoprotein 3 (LAMP3, CD208), Interleukin-7 receptor subunit (IL7R, CD127) as 
well as several others. Database for Annotation, Visualization and Integrated Discovery (DAVID) 
functional annotation clustering mapped 19 of the 22 upregulated CD molecules to 5 different 
KEGG pathways. As already described above, especially, CD antigens involved in cell adhesion 
processes like CD274, CD80, CD276, ITGAV (CD 51), CD44, ICAM-1 (CD54), PVR (CD155) 
and CD40 were observed to be significantly enriched and highly upregulated in the tolerant state, 
when significantly regulated CD antigens were searched against all 1176 identified glycoproteins 
(data not shown). However, adjusted p-values received by Benjamini-Hochberg multiple testing 
revealed no significant enrichments. Functional annotation clustering of the 10 down regulated 
CD antigens, e.g. Macrophage scavenger receptor types I and II (MSR1, CD204), TNF super 
family member 13B (CD257) and CD109 antigen, did not reveal any enrichment in functionality.  
6.6.6 Modification of glycosylation enzyme expression in tolerant monocytes 
The glycosylation pattern of glycoproteins is well-known to have a great impact on processes like 
enzyme activity, cell signaling, cell adhesion and numerous other processes (Dewald et al. 2016). 
Moreover, changes in the glycosylation might derogate the enrichment and quantification on 
protein level. Thus, we examined if expression levels of enzymes involved in the post-translational 
glycan maturation (GO-category: “protein glycosylation”; GO:0006486) showed distinct 
alterations in monocytes stimulated with LPS, Pam3CSK or MALP2 (Fig. 30). In total, 75 
glycoproteins involved in glycosylation activities could be identified and quantified in the whole 
data set with only four showing altered expression levels.  Three of them were upregulated (ST3 
beta-galactoside alpha-2,3-sialyltransferase 1, ST3GAL1; Beta-1,3-galactosyl-transferase 4, 
B3GALT4 and ST3 beta-galactoside alpha-2,3-sialyltransferase 2, ST3GAL2) and just one 
(Thrombospondin 1, THBS1) displayed decreased expression levels upon stimulation with LPS, 
Pam3CSK and MALP2. 
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Fig. 30: Overview of 75 proteins 
annotated as being involved in various 
steps of “protein glycosylation” 
(GO:0006486).  
Significance according to the color given 
in the legend. 
Among the 3 elevated enzymes, two golgi apparatus-resident sialyltransferases, ST3GAL1 and 
ST3GAL2, could be identified, catalyzing the transfer of sialic acid in an α-2,3-linkage to terminal 
galactose residues on glycoproteins or glycolipids and, thereby, contributing to cell adhesion 
processes (Wu et al. 2016). The third upregulated glycosylation enzyme, B3GALT4, exhibits 
diverse enzyme functions, using different donor and acceptor sugars. The downregulated THBS1, 
annotated by GO to the category “proteins involved in protein glycosylation”, is a subunit of a 
disulfide-linked homotrimeric, adhesive glycoprotein that, besides mediating cell-cell interaction, 
plays a major role in the activation of latent TGF-β (Schultz-Cherry et al. 1994). In summary, these 
results indicate no major changes in the glycosylation of the proteins which might have affected 
enrichment and quantification in course of LC-MS/MS analysis. 
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6.6.7 Changes of G protein-coupled receptor expression in tolerant monocytes 
G protein-coupled receptors (GPCRs), a family of N-glycosylated seven-transmembrane domain 
receptors, act as the targets of over 40% of marketed drugs and, therefore, display to be of special 
biomedical interest (Lu and Wu 2016). Thus, expression and expression changes were examined 
in more detail revealing 54 proteins annotated as proteins with “G protein-coupled receptor 
activity” (GO:0004930) to be expressed in unstimulated monocytes (Fig. 31). Seven of them 
showed significantly up- or downregulated expression levels upon stimulation with LPS, 
Pam3CSK or MALP2. Lysophosphatidic acid receptor 6 (LPAR6) was found to be strongly down 
regulated whereas all other altered GPCRs, including Atypical chemokine receptor 3, ACKR3; G 
protein-coupled receptor 68, GPR68; G protein-coupled receptor 84, GPR84; Egf-like module 
containing, mucin-like, hormone receptor-like 1 and 2, EMR1, EMR2  and Histamine receptor H2, 
HRH2 demonstrated upregulated expression levels. 
 
Fig. 31: Overview of 54 proteins annotated as 
proteins with “G protein-coupled receptor 
activity” (GO:0004930).  
Significance according to the color given in the 
legend. 
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6.7 Confirmation of glycoproteomic data via qPCR, FACS and 
      immunoblot analysis 
In order to confirm the results obtained from mass spectrometry analysis, protein expression of 
several identified glycoproteins were checked by qPCR, FACS or western blot analysis.  
Expression of ITGB8, LAMP3, MMP9, GPR84 and DPEP2 were measured by qPCR analysis in 
purified human monocytes stimulated with or without 50 ng/ml LPS for 2, 8, 24 or 48 h (Fig. 32). 
qPCR analysis revealed significantly upregulated expression levels of ITGB8 and LAMP3 in LPS-
stimulated monocytes at all time points (ITGB8: 14, 36, 25 and 10 FCs and LAMP3: 10, 16, 29 
and 22 FCs after 2, 8, 24 and 48 h of LPS-stimulation, respectively). MMP9 expression was not 
increased at the first two time points (FCs of about 1 after 2 h and 8 h), but significantly enhanced 
after 24 and 48 h of LPS-treatment (34 and 29 FCs, respectively). Although expression levels of 
GPR84 reached not significance, qPCR analysis demonstrated upregulated transcriptional levels 
of GPR84 at all time points. DPEP2, a glycoprotein found significantly downregulated in our 
glycoproteomic analysis, showed decreased expression levels of 0.06, 0.22 and 0. 66 FCs when 
monocytes were stimulated for 8, 24 or 48 h with LPS. However, only the 8 h-LPS-incubation 
period, which led to the greatest decrease of DPEP2 expression in monocytes, reached 
significance. Altogether, qPCR analysis revealed gene expression of differentially expressed 
glycoproteins of our glycoproteomic data set to be similarly regulated on transcriptional level. 
A     ITGB8 B     LAMP3 C     MMP9 
   
D     GPR84 E     DPEP2  
  
 
Fig. 32: qPCR analysis of LPS-induced ITGB8, LAMP3, MMP9, GPR84 and DPEP2 gene 
expression in purified human monocytes.  A-E: Monocytes (4*106cells/2 ml) were stimulated with or 
without LPS E. coli O111:B4 (50 ng/ml) for 2, 8, 24 and 48 h, always including untreated cells as negative control. 
The gene expression was normalized to the housekeeping gene HPRT. Data represent mean values (± SD) from 
three independent experiments. ** p<0.01*** p<0.001. 
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Moreover, differential expression of 6 further identified glycoproteins was confirmed by FACS 
analysis. Therefore, MACS-separated monocytes gained from two different donors were 
stimulated with or without 50 ng/ml LPS for 24 or 48 h (Fig. 33). FACS analysis demonstrated 
upregulated cell surface expression of CD80, IL7R (CD127), PD-L1 (CD274) and SLAMF7 
(CD319) at both time points, which have also shown increased expression levels in the previously 
obtained glycoproteomic data. LC-MS/MS-analysis has revealed reduced expression of CLEC12A 
(CD371) and FACS analysis confirmed decreased protein abundance of CLEC12A on the cell 
surface at both time points. CD86 that has been observed to be not regulated in monocytes 
stimulated for 24 h with LPS in our glycoproteomic data set, also showed unaltered cell surface 
expression after 24 h and decreased expression levels after 48 h of LPS-treatment.  
 
Fig. 33: Verification of proteomic results by FACS analysis: cell surface expression of CD80, 
IL7R, PD-L1, SLAMF7, CD86 and CLEC12A. Monocytes were stimulated for  24 h or 48 h with or without 
LPS E. coli O111:B4 (50 ng/ml) and labeled with specific fluorescent-dye conjugated antibodies (anti-CD14, anti-
CD80, anti- CD127(IL7R) , anti-CD274 (PD-L1), anti- CD319 (SLAMF7), anti-CD86, anti-371 (CLEC12A)). White 
graphs: isotype controls, in light grey: expression at the indicated time point of unstimulated controls, in dark 
grey: expression at the indicated time points after LPS treatment. The data shown are representative of two 
different donors independently analyzed. Depicted are the intensity levels of the indicated proteins expressed 
on the CD14+ cell population. 
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In a third approach to confirm the obtained glycoproteomic data, expression of CEACAM-6 and 
TLR4 were quantitatively measured by western blot analysis (Fig. 34). MACS-separated 
monocytes were stimulated for 24 h with either LPS (50 ng/ml), Pam3CSK (200 ng/ml), MALP2 
(10 ng/ml) or were left untreated. Mass spectrometry analysis has revealed unaltered expression 
levels for both selected target proteins. As shown in Fig. 34, LPS-, Pam3CSK- and MALP2-
treatment of monocytes did not modulate the expression of CEACAM-6 and TLR4.  
A Fig. 34: CEACAM-6 and TLR4 expression in 
LPS-, Pam3CSK- and MALP2- stimulated 
monocytes.   A-C: Monocytes (2*106 cells/2ml) 
were incubated with LPS (50 ng/ml), Pam3CSK (200 
ng/ml), MALP2 (10 ng/ml) or were left untreated for 
24h at 37°C. Cell lysates were subjected to 
immunoblot analysis for CEACAM-6 and TLR4 
detection. Pan 14-3-3 served as loading control. Data 
are representative for three independent 
experiments. 
B, C: Semiquantitative analysis of CEACAM-6 and TLR4 
expression in LPS-, Pam3CSK- and MALP2- stimulated 
monocytes. Data represent mean values from three 
independent experiments. Densitometric analysis was 
performed using ImageJ. 
 
 
B         CEACAM-6 H17-B4 C         TLR4 
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7. Discussion 
Immunodeficiency in septic patients surviving the initial hyperinflammatory phase is linked to an 
increased risk for secondary infections and mortality and one contributing mechanism of this 
phenomenon is monocyte tolerance. Monocytes exposed to low concentrations of PAMPs undergo 
a cellular reprogramming, which leads to decreased expression of pro-inflammatory cytokines, 
increased expression of anti-inflammatory cytokines and significantly altered expression of 
various (glyco-) proteins in subsequent encounters with PAMPs or pathogens. Due to 
glycosylation being one of the most common posttranslational modifications of cell surface-
associated proteins, glycoproteins serve as an ideal source for the discovery of biomarkers and 
almost all of the frequently used biomarkers for disease detection, histological diagnosis and 
prognosis, as well as therapeutic intervention in diseases belong to the group of glycoproteins 
(Bausch-Fluck et al. 2015). Until now, no global characterization of the glycoprotein expression 
patterns of tolerant human monocytes has been carried out. An early identification of monocytes 
in the tolerant cell state based on differentially expressed cell surface markers might be a promising 
approach to detect patients suffering from sepsis-induced immunosuppression and could result in 
initiating a prompt treatment in order to improve the outcome of septic patients. We therefore 
induced tolerance in isolated and purified primary human monocytes and applied glycoprotein 
enrichment with subsequent mass-spectrometry analysis to investigate for changes of naϊve and 
tolerized monocyte glycoproteomes. 
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7.1 Tolerance induction in human monocytes 
The TLR4 agonist LPS is a well-described inducer of pro-inflammatory responses and also of 
tolerance in human monocytes and macrophages, resulting in the down regulation of pro-
inflammatory cytokine expression and an upregulated anti-inflammatory cytokine expression in 
subsequent activations. Pro-inflammatory activation and tolerance induction in purified human 
monocytes were assessed by analyzing the regulation of TNF-α and IL-6 cytokine gene expression 
to investigate whether or not this capability is shared by TLR2 and its specific receptor ligands. 
Increased expression of TNF-α and IL-6 mRNA were observed in naϊve monocytes exposed to the 
membrane-bound TLR agonists: LPS (TLR4), Pam3CSK (TLR2/1) and MALP2 (TLR2/6). LPS-
restimulation of monocytes which were pretreated with either LPS, Pam3CSK or MALP2, led to 
a significant decrease of TNF-α and IL-6 production. While several studies consistently describe 
TLR4 agonist LPS to be capable in inducing tolerance in human monocytes, only few studies have 
been conducted using TLR2 agonists Pam3CSK and MALP2. Published reports examining TLR2 
agonists to be potent tolerance inducers reveal conflicting data. Our findings support those of 
Kreutz et al. (1997), who were the first to describe TLR2/1 agonist Pam3CSK to induce tolerance 
in human monocytes to subsequent LPS- or Pam3CSK- challenges (cross- and homo-tolerance). 
This is also consistent with data of Siedlar et al. (2004), showing Pam3CSK to be an efficient 
cross-tolerance inducer in human monocytic Mono Mac 6 cells, while the group of Dobrovolskaia 
(2003) observed Pam3CSK to solely induce homo-tolerance in murine macrophages, but failed to 
induce cross-tolerance to a subsequent LPS-challenge. 
Data on MALP2-mediated tolerance induction in human monocytes are even rarer: To our 
knowledge, there is no prior study examining TLR2/6 agonist MALP2 to be efficient in tolerance 
induction in human monocytes. Deiters et al. (2003) and two studies by Sato et al. (2000, 2002) 
found MALP2 to be a potent inducer of tolerance to a second LPS challenge in murine 
macrophages. Only one study using MALP2 as a PAMP was carried out in human monocytes by 
the group of Fernandes (2010) and showed that monocytes pretreated with LPS become refractory 
to further MALP2 challenges. The current study demonstrates TLR2/6 agonist MALP2 to induce 
cross-tolerance to further LPS-stimulation in human monocytes. 
PAMP concentrations of LPS, Pam3CSK and MALP2 had to be adjusted to ensure, that they, on 
the one hand, were efficient in inducing (cross-) tolerance with comparable changes in monocytes 
and, on the other hand, were low enough to simulate biological relevant concentrations as close as 
possible to the ones observed in sepsis pathology. Previous studies by Kritselis et al. (2013) 
measured the concentrations of circulating LPS in blood samples from 
Discussion | Tolerance induction in human monocytes 
83 
  
septic patients on the first day of sepsis. They observed that LPS had to be present above a critical 
level of more than 1.60 Endotoxin Units (EU)/ml to induce significant endotoxin tolerance in 
monocytes of these patients. This is in accordance with our findings: low levels of 5-10 ng/ml LPS 
were not inducing tolerance in human monocytes reliably. Concentration adjustment of the 
different PRR ligands was first tried by transfecting primary human monocytes with an NF-κB-
promoter gene containing plasmid and subsequent measurement of NF-κB activation by LPS, 
Pam3CSK and MALP2 in dose-response experiments. Although several attempts were made with 
different transfection protocols (GeneCellinTM Transfection Reagent, Lipofectamine® 2000 
Transfection Reagent and electroporation), the transfection efficiency of human monocytes 
remained very low giving inconsistent results in subsequent experiments. Thus, transfection rates 
of human monocytes were too low to produce meaningful data for stimulus adjustment. Analysis 
of cytokine expression by qPCR in LPS-, Pam3CSK- and MALP2-concentration series revealed 
that very high concentrations of TLR2/6 agonist MALP2 (more than 5 ng/ml) were needed in order 
to obtain similar activation levels seen by LPS- and Pam3CSK-stimulated monocytes. 
Concentrations of 50 ng/ml LPS, 200 ng/ml Pam3CSK and 10 ng/ml MALP2 demonstrated a 
similar upregulation of the cell surface associated cell adhesion molecule 1 (ICAM-1) in FACS 
analysis, which is a well-known parameter to identify pro-inflammatory activation of cells 
(Audran et al. 1996, Anbarasan et al. 2015). The determined concentrations of TLR2 and TLR4 
ligands were therefore used in later performed glycoproteomic analysis.  
Besides LPS, Pam3CSK and MALP2 which are ligands of membrane-bound PRRs, the synthetic 
NOD-like receptor ligands 1 and 2 (iE-DAP and MDP) were also tested to induce comparable pro-
inflammatory responses in human monocytes. Both, NLR1 and NLR2, are located in the cytosol 
and, therefore, represent a mechanism for intracellular microbe sensing. Although monocytes were 
shown to express NLR1 and NLR2 on mRNA level (Fig. 4) and pro-inflammatory responses were 
described (Strober et al. 2006, Kufer et al. 2006), incubation of the cells with 1 µg/ml iE-DAP or 
10 µg/ml MDP for 4 hours revealed marginal increased TNF-α mRNA expression levels ( ~1.5-
fold, Fig. 5). The lack of pro-inflammatory TNF-α mRNA induction might be due to differences 
in the kinetics of PAMP sensing by intracellular and membrane-bound PRRs, and, thus, longer 
incubation periods with intracellular acting ligands would have been necessary to observe a strong 
pro-inflammatory activation of TNF-α at mRNA level in stimulated monocytes. However, if there 
would have been a pro-inflammatory activation of the cells by the used NLR ligands, not seen 
after 4 hours, but leading to a subsequent tolerant state towards a further LPS challenge, inhibition 
of pro-inflammatory TNF-α expression would have been detectable in the endotoxin tolerance 
model, which included a 20 hours-pretreatment with the NLR ligands. Unaltered induction of 
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TNF-α in monocytes, pretreated with either iE-DAP or MDP and restimulated with LPS, 
demonstrated no detectable tolerance induction by the NOD1 and NOD2 ligands (TNF-α FC 
levels: 69.15- and 69.9-fold, respectively; Fig. 7). In accordance with previously reported data, 
human monocytes of all three analyzed donors exhibited lesser expression levels of the cytosolic 
PRR NOD1 compared to NOD2 (Fig. 4), which might also contribute to the to the low pro-
inflammatory activation by iE-DAP (Granland et al. 2014).  
Moreover, we hypothesized that S100A12 can act as tolerance inducer. This host-derived 
endogenous alarmin and, as recently shown, putative TLR4 agonist, might be able to mediate a 
TLR4-dependent pro-inflammatory response, and, thereby, also a TLR4-dependent tolerance 
induction. Treatment of monocytic THP-1 cells with recombinant S100A12 proteins led to slightly 
augmented TNF-α levels. The recombinant proteins used in this study were produced in E. coli 
strains. As recombinant proteins derived from E. coli strains are often endotoxin contaminated, 
several experiments were performed to test the purity of the purchased S100A12 in order to ensure 
that the observed activation of the cells was truly caused by the protein S100A12 itself. Both, 
S100A12 preparations from R&D System (UK) and S100A12 preparations from Sino Biological 
(China), induced NF-κB activation in HEK-Blue-hTLR4 cells. Supplementation of LPS-binding 
protein (LBP), which mediates the binding of LPS to the TLR4 receptor complex, to S100A12-
stimulated HEK-Blue-hTLR4 cells accelerated NF-κB activation, while co-incubation of 
S100A12 with polymyxin B, a well-known inhibitor of LPS, was found to decrease NF-κB 
activation. Together these findings hinted at a possible LPS-contamination in the commercially 
obtained S100A12 obtained from R&D Systems and Sino Biological, which was finally confirmed 
by Limulus Amebocyte Lysate (LAL) assay. The results indicated that    1 µg S100A12 protein 
from R&D Systems contained 0.39 ng LPS and 1 µg S100A12 protein from Sino Biological 
contained 0.3 ng LPS. As recently published, even these low levels of endotoxin contamination 
can lead to a notable activation and also to priming of human monocytes and dendritic cells 
(Schwarz et al. 2014).  
S100A12 provided by Dirk Foellʼs group was also tested in the LAL assay and was found to be 
absolutely LPS-free. Unfortunately, this S100A12 preparation failed to induce a significant pro-
inflammatory response (unchanged TNF-α expression on mRNA and protein level) in THP-1 cells, 
and only slightly enhanced the expression levels of IL-1β (~11-fold) and IL-6 mRNA (~13-fold) 
in monocytes using highest concentrations of S100A12 (10 µg/ml). Consistently, IL-6 protein 
secretion remained almost unaffected (~4 pg/ml IL-6) in further stimulations of monocytes with 
LPS-free S100A12 and no down-regulation of the upregulated IL-6 production (~304 pg/ml IL-6) 
in S100A12-pretreated and LPS-restimulated monocytes was observable (Fig. 14). Although the 
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correct folding of the used proteins could not be tested and denaturing during the transport and 
repeated freeze/thaw-cycles might have affected protein functionality, S100A12 was not further 
studied in the current study. 
 
The results indicate that S100A12 treatment of THP-1 cells and human monocytes did not induce 
strong pro-inflammatory signaling with detectable increases of pro-inflammatory cytokines on 
mRNA level.  
Moreover, the role of alarmins as putative pro-inflammatory signaling and tolerance inducers is 
lately conversely debated due to divergent findings. For example, several studies suggested 
HMGB1-preconditioning to be effective in inducing monocytes refractive to subsequent 
stimulations with LPS or LTA (Aneja et al. 2008, Robert et al. 2010). Other reports indicated that 
the pro-inflammatory effects of HMGB1-treatment were only due to LPS contaminations (Qin et 
al. 2009). Qin et al. found that HMGB1, which contained only low concentrations of LPS, failed 
in pro-inflammatory activation of mouse macrophages and TNF-α secretion of macrophages was 
positively correlated with the amount of contaminating LPS contained in several of the purchased 
HMGB1 preparations. 
 
 
 
 
 
 
 
 
 
 
Discussion 
86 
  
7.2 Glycoproteomic analysis of naϊve and tolerant monocytes 
7.2.1 Donor-dependent purity of isolated cells and impact on glycoproteomic 
         analysis 
Experiments performed with whole blood cell populations, PBMCs or monocyte subpopulations 
of heterogeneous purity are often difficult to interpret: Several cytokines can be produced both by 
mononuclear and polymorphonuclear cells present in whole blood cell populations and the 
responsiveness of each individual cell population may be differently affected by the performed 
treatment. Moreover, the presence of unknown factors within the plasma may mask or influence 
the individual behavior of leukocytes. In different donors also the ratio of leukocyte 
subpopulations can vary. Thus, an initial aim of our study was to establish an enrichment protocol 
to gain a highly purified CD14++CD16- monocyte population out of buffy coats from healthy 
donors. This way, it should be guaranteed that all measured effects are exclusively based on 
changes in the responsiveness of the major monocytes subset, CD14++ CD16- monocytes. The 
first step of monocyte enrichment and purification was performed by negative selection using the 
MACS isolation Kit II (Miltenyi Biotec, Germany). Although Zhou et al. (2012) reported positive 
selection to provide a higher purity of the enriched population of monocytes, we decided to use 
negative selection in order to prevent possible alterations of gene and protein expression caused 
by activation of the cells during the (CD14) antibody-mediated positive selection. FACS analysis 
of MACS-separated monocytes revealed a poor donor-dependent enrichment efficiency of about 
66-70% purity. One possible reason for the low and different purities might be the significantly 
varying amounts of cell populations and also starting cell numbers between the different donors’ 
buffy coats, leading to a possible subsequent overload of the cell separation columns during MACS 
purification. To gain higher purity, a second purification step was included. Remaining platelets 
(anti-CD42b) and lymphocytes (anti-CD3 against T-lymphocytes and anti-CD19 against B-
lymphocytes) were stained with antibodies after MACS separation and separated from CD14 
positive cells by an additional FACS sort. This increased the purity of the CD14++CD16- cell 
population to more than 97%.  
Principal Component Analysis (PCA) of the glycoproteomic data from the 3 donors demonstrated 
that the three different stimuli LPS, Pam3CSK and MALP2 showed a higher resemblance of the 
global glycoproteomic expression patterns (in monocytes of one donor) than the different donors 
compared to each other. PC1 values were widely scattered among the three donors due to different 
amounts of contaminating proteins that arised from different numbers of contaminating leukocytes 
and platelets and also because of differential expression of glycosylated HLA molecules. Thus, 
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interindividual expression differences and purity of purified monocytes varied slightly and 
affected the statistical analysis causing a higher variance. Therefore, statistical analysis of the 
glycoproteomic monocyte data set was carried out with paired t-test analysis.  
7.2.2 Changes in the glycoproteomes of LPS-, Pam3CSK- and MALP2- 
         tolerized monocytes 
In total, the mass spectrometry-based analysis of the CD14+ monocytic glycoproteome identified 
1176 glycoproteins (~1000±33 annotated glycoproteins/donor) in the combined analysis of the 
NGP and TPG fractions using hydrazide enrichment and subsequent LC-MS/MS analysis. 
According to the hydrophobic transmembrane helix prediction algorithm (TMHMM v2.0 Server), 
898 of the 1176 identified glycoproteins were predicted to contain at least one or more 
transmembrane domains (TDs), demonstrating that the glycoprotein enrichment protocol with 
SDS as a detergent was efficient in solubilizing a significant number of membrane-spanning or 
GPI-anchored glycoproteins from the cell surface and from various cellular organells. Identified 
glycoproteins derived from almost all cellular and subcellular compartments; the most abundant 
compartments were plasma membrane (671) and endoplasmic reticulum (264). Minor subsets of 
glycoproteins originated from the golgi apparatus, lysosome, nucleus, endosome, mitochondrion 
and peroxisome. Additionally to these intracellular glycoproteins, also 278 glycoproteins were 
detected, annotated as “extracellular matrix” and “extracellular space” including soluble and 
secreted glycoproteins. Besides the purified glycoproteins, a substantial number of non-
glycosylated proteins, e.g. human keratins, histones and plasma proteins that were not completely 
removed by the numerous washing steps, were also detected by LC-MS/MS analysis. Non-
glycosylated proteins and serum contaminants were excluded from further analysis since they 
represent contaminants and the performed experiments were not intended to find new 
glycoproteins that were to date not annotated as such.  
Although several steps had been implemented in the sample preparation protocol in order to 
achieve a CD14+ monocyte population of highest purity, key cell surface markers for T cells 
(CD4), dendritic cells (CD123), hematopoietic stem cells (CD34), granulocytes (CD66b; 
CEACAM8 and CD66d; CEACAM3) and platelets (CD41, CD61 and CD62P) were identified in 
the glycoproteomic data set, though in low abundance. These findings could, on the one hand, hint 
at a possible contamination with the above named cell populations. On the other hand, several CD 
markers that were originally thought to be specific cell surface markers, were recently also reported 
to be expressed by (activated) human monocytes. For example, CD4, a putatively T-cell-specific 
surface marker, was also found to be expressed by human monocytes (Zhen et al. 2014). Other 
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classical T-cell surface marker like CD3 and CD8 were not detected in the analyzed 
glycoproteomic data set. Moreover, IL-4 stimulated monocytes were demonstrated to express the 
dendritic cell line-specific CD123 molecule (Borriello et al. 2015) and CD34, a hematopoietic 
stem cell marker, was also found to be expressed on the cell surface of a regulatory monocytes 
subpopulation (D'Aveni et al. 2015). Thus, CD123 and CD34 might be expressed by activated 
monocytes in the current study. Whether the detected expression of CD4, CD123 and CD34 
indicates contamination with other leukocyte cell populations or is rather to interpret as activation 
markers being expressed by stimulated monocytes, can not be evaluated with absolute certainty. 
A low abundant contamination with granulocytes and platelets can not be ruled out due to the 
identification of the cell population specific CD markers (see above). Interestingly, except of 
downregulated expression levels of the platelet marker CD41 in LPS-stimulated monocytes, non 
of them demonstrated altered expression after LPS-, Pam3CSK- and MALP2-stimulation. 
Therefore, it could be assumed that the contaminating cell populations did not or did only slightly 
affect the statistic analysis of glycoproteins annotated in GO as CD antigens. 
A well-described phenomenon in course of endotoxin tolerance is the impaired expression of HLA 
proteins associated with attenuated antigen presenting capacity and T-cell activation (Hynninen et 
al. 2003). Endotoxin tolerance was also shown to be accompanied by decreased cell surface 
expression of MHC II-related proteins CD74 (HLA class II histocompatibility antigen gamma 
chain) and HLA-DRA, as well as reduced expression of the Class II trans-activator (CIITA), a 
transactivator of HLA-DRA gene transcription. In patients, these human monocyte antigens were 
proven to be reliable markers for monocytic immunosuppression, the risk of secondary infections 
and for the prediction of mortality in septic patients (Cazalis et al. 2013, Cajander et al. 2016). 
Flow cytometry-based analysis of HLA-DR protein expression on monocytes was already used to 
identify critically ill patients in the Intensive Care Unit with immunosuppression in the clinical 
setting (Monneret and Venet 2014). In the data obtained in this study, LPS-, Pam3CSK- and 
MALP2-tolerized monocytes displayed significantly decreased expression levels of CD74. 
However, none of the other MHC II-related proteins demonstrated differential expression and 
CIITA, as non-glycosylated protein, was not detected in our glycoproteomic analysis. A possible 
explanation for the lack of differentially expressed HLA-DR antigens in monocytes analyzed in 
this study might be that according to findings of Monneret et al. (2014), HLA-DRA expression is 
only very slightly decreased in tolerant monocytes. Therefore, a possible reduction of HLA-DRA 
expression was not detected in the glycoproteomic data or, since we also detected intracellular 
glycoproteins, the overall amount of HLA-DR antigens is unchanged while cell surface expression 
might be reduced. Another contributing aspect might be that cell-cell interactions or 
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communication via soluble factors with other immune cells are required to induce this specific 
down-regulation of HLA-DRA expression. In our experimental setting, relative pure CD14+ 
monocyte populations were stimulated and other putative key players regulating the HLA-DR 
expression might be absent in this purified population. FACS analysis of HLA-DR did also not 
reveal down-regulated cell surface expression after 24 h (data not shown).  
In accordance with data of Mendes et al. (2011), TLR4 and CD14 expression did not show altered 
expression in LPS-treated human monocytes. Moreover, prior studies observed that tolerance 
induced in macrophages by Gram-positive TLR2 agonists Pam3CSK or MALP2 did not affect 
TLR4 and TLR2  cell surface expression, which is consistent with unaltered expression levels of 
TLR4 and TLR2 in Pam3CSK- and MALP2-stimulated monocytes found in the current study 
(Dobrovolskaia et al. 2003, Sato et al. 2000). However, TLR4 and TLR2 expression on tolerant 
cells are controversially discussed in the literature: Sato et al. (2000) reported reduced TLR4 and 
CD14 expression on LPS-tolerized murine macrophages, while later studies indicated upregulated 
TLR4 cell surface expression on monocytes of septic patients (Calvano et al. 2003, Harter et al. 
2004). Whereas our findings support those of Calvano et al. (2003), who found unaltered 
expression of TLR2 on monocytes of septic patients, the study of Harter et al.(2004) observed 
strongly enhanced cell surface expression of TLR2 on monocytes of septic patients. Again, these 
discrepant findings might be due to the properties of the experimental setting, stimulating purified 
monocytes in the absence of other immune cells, tissues and organs that all act in concert in the 
septic patient.  
Taken together, the data of this study indicate that reduced TLR2, TLR4 and CD14 expression is 
not necessarily required for tolerance induction. Rather, modulation of signaling components in 
the intracellular down-streaming signaling cascades might be major regulatory mechanisms of 
endotoxin tolerance and, especially, cross-tolerance. 
7.2.3 Effects of different TLR ligands 
As mentioned above, detection of Gram-positive microbial compounds by TLR2 and Gram-
negative bacterial cell wall components by TLR4 were both proven to efficiently induce tolerance. 
Although TLRs belong to a family of highly conserved receptors of the innate immunity and share 
common down-streaming signaling pathways, previous reports let suspect that TLR2- and TLR4-
mediated tolerance differ due to differential engagement and affection of MyD88-dependent and 
MyD88-independent intracellular signaling pathways (Sato et al. 2002, Bagchi et al. 2007). 
Several studies indicated impaired expression of IRAK-1 to be a major mechanism of TLR2-
mediated tolerance, but no such contribution to TLR4-induced tolerance was found (Siedlar et al. 
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2004, Li et al. 2006). Altogether, these findings suggest that TLR2- and TLR4-mediated tolerance 
in human monocytes might result in different global protein and also glycoprotein expression 
patterns. In the present study, data hint in another direction.  
In LPS-, Pam3CSK- and MALP2-tolerized monocytes, 135 of the 1176 identified glycoproteins 
were significantly differentially expressed after a 24 hours-stimulation period. Further analysis 
revealed that LPS, Pam3CSK and MALP2 led to nearly identical changes in the monocytic 
glycoproteome, inducing almost similar levels of up- and down-regulation of the same 
glycoproteins. The high similarity of stimuli-induced glycoprotein expression changes in 
monocytes was indicated by equivalent fold changes of the regulated glycoproteins, although 
statistical significance (two sample t-test with FC >2 and adjusted p<0.05 according to Benjamini 
and Hochberg) was not reached for all differentially expressed proteins (see table 21). These 
findings could be confirmed in a linear regression model displaying highly similar pearson 
correlation coefficients (ρ) of 0.949, 0.965 and 0.955, when glycoprotein expression changes of 
LPS- vs. MALP2-, MALP2- vs. Pam3CSK- and Pam3CSK- vs. LPS-stimulated monocytes of all 
three donors were compared, respectively (Fig. 27). 
As expected, cellular component analysis revealed a high resemblance in numbers and localization 
of significantly regulated glycoproteins between the different stimuli. Plasma membrane-resident 
glycoproteins and glycoproteins annotated as “extracellular space” comprised the largest numbers 
of significantly altered glycoproteins upon exposure of monocytes towards LPS, Pam3CSK and 
MALP2. The majority of plasma membrane proteins showed enhanced expression levels, while 
glycoproteins from the extracellular space displayed slightly higher numbers of downregulated 
proteins.  
Altogether, the Gram-negative stimulus LPS and both Gram-positive stimuli Pam3CSK and 
MALP2 induced highly similar alterations in the monocyte glycoproteomes of all three donors 
analyzed. This is contrary to our first hypothesis that different TLR agonists might lead to 
dissimilar changes in the global glycoprotein expression patterns based on different usage of 
down-streaming signaling pathways. Despite the previously described differences in the 
intracellular signaling of tolerant cells, our findings indicate different TLRs to induce highly 
similar changes in the monocyte glycoproteome. 
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7.2.4 Cell surface signature of tolerant monocytes 
Due to the majority of cell surface proteins being glycosylated, mass spectrometry-based analysis 
of the tolerant monocytes glycoproteome offers a unique opportunity to identify global alterations 
of the monocytes surfaceome as well as specific marker proteins of the tolerant state. Tolerance-
specific biomarkers might facilitate the identification of critically ill patients suffering from sepsis-
induced immunosuppression or even might be possible new drug targets to reverse 
immunosuppression in future. Therefore, glycoproteins annotated in GO to be plasma membrane-
associated were analyzed in more detail. 
202 CD antigens and 54 GPCRs were identified among the glycoproteins annotated as plasma 
membrane-associated. Plasma membrane-resident glycoproteins, as mentioned above, comprised 
the highest number of significantly regulated glycoproteins, including 32 CD molecules and 4 
GPCRs with altered expression levels. An enrichment of CD antigens involved in cell adhesion 
processes was found when GO-annotation pathway analysis (DAVID) was carried out analyzing 
regulated CD glycoproteins against all 1176 identified glycoproteins. Other categories were not 
detected to be significantly enriched. 
Interestingly, the majority of the regulated plasma membrane-associated glycoproteins in tolerant 
human monocytes displayed increased expression levels. PD-L1 (CD274), ITGB8 and IL-7R 
(CD127) were among the most highly upregulated cell surface-located glycoproteins. In 
accordance with our findings, previous studies showed that PD-L1 expression is upregulated in 
monocytes by several PAMPs and PD-L1 expression levels on monocytes in septic patients to be 
increased (Sharpe et al. 2007, Francisco et al. 2010, Zhang et al. 2011). Data of PD-L1 in the 
present study confirm efficient activation of monocytes by the chosen concentrations of LPS, 
Pam3CSK and MALP2 and, again, demonstrated an equivalent activation level of the differently 
treated monocytes due to highly similar fold change levels of PD-L1 expression. Additionally, 
PD-L1 expression on monocytes was recently identified to be an independent predictor for 28 day-
mortality in septic patients (Shao et al. 2016). Inhibition of PD-L1 (by antibodies directed against 
PD-L1) resulted in reduced T-cell exhaustion and improved survival rates in a septic mouse model 
(via cecal ligation and puncture (CLP)) and was found to reverse monocytes dysfunction in an ex 
vivo performed blockade of PD-L1 on immune cells from septic patients (Zhang et al. 2010, Chang 
et al. 2014). Remarkably, blockade of ICAM-1, a cell adhesion molecule, which was found to be 
upregulated in our data set as well, was shown to be effective in decreasing PD-L1 expression 
levels in tissues and organs like spleen and thymus of septic mice (Zhao et al. 2014). Therefore, 
ligation of ICAM-1 with specific antibodies might also decrease enhanced expression levels of 
PD-L1 on tolerant human monocytes and, in this way, improve the outcome of septic patients. 
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Another candidate to distinguish tolerant from naϊve monocytes and that, probably, might serve as 
prospective therapeutic target is integrin β8 (ITGB8). Our studies identified, for the first time, 
strongly enhanced expression levels of ITGB8 in PAMP-activated tolerant monocytes. The 
integrin β8 subunit non-covalently binds to an αV subunit to form a heterodimeric complex and 
was recently shown to play a major role in the activation of latent TGF-β 1 and 3 (Mu et al. 2002, 
Travis and Sheppard 2014). TGF-β family members have pleiotropic functions: Especially TGF 
β1 is described to be produced in significant amounts by hematopoietic cells and to control 
inflammation. Effects of this immunological mediator are highly context specific, but it mainly 
acts as an immunosuppressive cytokine by downregulating the differentiation of naϊve T-cells to 
Th1- and Th2-cells on the one hand and promoting the development of suppressive regulatory T-
cells on the other hand (Travis and Sheppard 2014). Mice lacking the integrin β8 subunit exhibited 
multiple phenotypes consistent with loss of TGF-β, e.g. severe multiorgan inflammation, decrease 
of Tregs cells and increase of spontaneously activated CD4+ and CD8+ T-cells (Aluwihare et al. 
2009, Travis and Sheppard 2014). Upregulated numbers of Tregs were found to contribute to 
immunological anergy in the immunosuppressive phase of septic patients (Venet et al. 2009). Due 
to the predominantly inhibitory effects of TGF-β in immune signaling processes, inhibition of the 
TGF-β activator ITGB8 might be a possible new therapeutic target in reversing 
immunosuppression in (post-) septic patients. Other integrin beta subunits like ITGB7 are already 
subjects of extensive investigation within the pharmacological industry, e.g. Etrolizumab, a 
humanized monoclonal antibody that selectively binds the integrin β7 subunit of α4β7- and αEβ7-
heterodimers, was shown to be beneficial in the treatment of inflammatory bowel disease 
(Mitroulis et al. 2015). Moreover, other enzymatic regulators of latent TGF-β activation 
demonstrated also significantly altered expression levels in our data set, e.g. matrix 
metalloprotease 9 (MMP9) and cathepsin D (CTSD) (Travis and Sheppard 2014). Several studies 
found a positive correlation of highly upregulated serum levels of MMP9 and tissue inhibitor of 
matrix metalloproteinases 1 (TIMP-1) and mortality in septic patients (reviewed by Lorente et al. 
2014). Both, MMP9 and TIMP-1, showed enhanced expression levels in our data analysis, 
indicating that activated monocytes might be a source for upregulated serum levels in septic 
patients. 
A cytokine affecting T-cell homeostasis is interleukin 7 (IL-7). IL-7 is produced by antigen-
presenting cells and induces the differentiation of naϊve and memory T-cells to effector T-cells, as 
well as it acts as survival signal protecting lymphocytes from cell death. Recent studies by Grealy 
et al. (2013) showed that IL-7 production in monocytes of septic patients was diminished on 
transcriptional level. Simultaneously, the group of Julie Demaret found elevated plasma levels of 
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soluble IL-7 receptor alpha chain (sCD127) positively correlating with an increased risk of death 
in septic shock patients (Demaret et al. 2014). Interestingly, the present study demonstrates highly 
augmented protein abundance of IL-7 receptor in tolerant human monocytes, a receptor for IL-7 
and thymic stromal lymphopoietin (TSPL). IL-7 and IL-7 receptor are already targets of particular 
pharmacological investigations in cancer and sepsis pathology. First attempts of recombinant 
human (rh)IL-7 substitution led to a restoration of lymphocyte functions, when cells of septic 
patients were treated ex vivo with rhIL-7 (Venet et al. 2012). Similar to the rescue signal in 
lymphocytes, treatment of tolerant monocytes with rhIL-7 might be a novel and promising strategy 
to reverse monocytic tolerance and prevent cell death. Thus, effects of IL-7 receptor activation in 
activated tolerant monocytes should be tested in future. Shindo et al. (2015) suggest a combined 
immuno-therapy with rhIL-7 and anti-PD-L1 because they differ in their effects to reverse sepsis-
induced immunosuppression. Outcome and survival of septic patients might be even more 
improved with ITGB8 as third therapeutic target to down-regulate TGF-β-signaling. 
Although most of the significantly regulated glycoproteins displayed upregulated expression 
levels, there are also some interesting downregulated candidates, which might help to distinguish 
tolerant from naϊve monocytes including collectin 12 (COLEC12) and lysophosphatidic acid 
receptor 6 (LPAR6). Collectin 12 (COLEC12), a C-type lectin and member of the scavenger 
receptor family, showed the greatest decrease in its expression in all three differently tolerized 
monocyte subsets. Whereas most collectins belong to the group of soluble pattern recognition 
receptors, COLEC12 also recognizes invading pathogens as a membrane-bound receptor and 
initiates opsonophagocytosis (Ma et al. 2015). This finding is inconsistent with the described 
enhanced phagocytotic capabilities of tolerant monocytes (del Fresno et al. 2009). Besides 
COLEC12, lysophosphatidic acid receptor 6 (LPAR6) showed the second largest expression 
decrease. LPAR6 is a member of the G protein-coupled receptor (GPCR) family and is stimulated 
upon binding of lysophosphatidic acid (LPA). Moreover, LPAR6-mediated signaling results in the 
upregulation of pentraxin 3 (PTX3), a secreted glycoprotein which is involved in the innate 
immunity through binding to the C1q component and activating the complement cascade (Gustin 
et al. 2008). In accordance with the down regulated expression level of LPAR6 found in tolerant 
monocytes, also PTX3 exhibited significantly reduced expression in our data set. Substantial 
reduction of both, LPAR6 and PTX3 protein levels, might contribute to the diminished 
immunological function of monocytes during the sepsis-induced immunosuppressive phase. 
Of the other 53 identified GPCRs 6 further receptors demonstrated altered expression levels. All 
of them (ACKR3, GPR68, GPR84, EMR1, EMR2 and HRH2) were upregulated. The most 
interesting one might be GPR84, a GPCR that functions as a selectively medium-chain (C7-C12) 
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fatty-acid sensing pro-inflammatory receptor (Suzuki et al. 2013, Yonezawa et al. 2013). Bouchard 
et al. (2007)  observed increased expression of GPR84 on monocytes in mice suffering from 
endotoxemia. Recent reports emphasize its role in enhancing pro-inflammatory responses, e.g. 
LPS-stimulated macrophages from GPR84 knock-out mice were found to show markedly reduced 
expression of several pro-inflammatory cytokines (Nicol et al. 2015). Thus, GPR84 might be an 
interesting drug target to downregulate pro-inflammatory responses in the early course of sepsis 
or to restore pro-inflammatory responses in immunosuppressed sepsis survivors with tolerant 
monocytes.  
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7.2.5 Induction of sialyltransferases and SIGLECs 
Changes in the expression of enzymes involved in protein glycosylation might influence cell-cell 
adhesion and cell signaling, as well as it might have affected the enrichment and, thereby, also 
protein quantification within the LC-MS/MS analysis. Therefore, glycoproteins annotated in GO 
to be involved in protein glycosylation were analyzed in more detail, revealing 3 glycosylation 
enzymes of a total of 75 identified members of this category with significantly altered expression 
levels. Beta-1,3-galactosyltransferase 4 (B3GALT4) and two golgi apparatus-resident 
sialyltransferases, ST3GAL1 and ST3GAL2, showed increased protein abundance. These 
enzymes are described to be specific in the usage of donor and acceptor substrates and, therefore, 
major changes mediated by the altered expression of these 3 enzymes affecting the whole 
glycoproteome seem unlikely. Both, ST3GAL1 and ST3GAL2, catalyze the transfer of sialic acid 
in an α-2,3-linkage to terminal galactose residues on glycoproteins or glycolipids, changing the 
negative charge of proteins (Wu et al. 2016). Sialylated glycoproteins are detected by the family 
of sialic acid (Sia)-binding Ig-like lectins (SIGLECs), which mediate cell-cell interactions and cell 
signaling processes and were also found in our data set to be significantly regulated. SIGLEC 10, 
a CD33-related SIGLEC, bearing an immunoreceptor tyrosine-based inhibition motif (ITIM) motif 
and, thus, is strongly suggested to down-regulate pro-inflammatory signaling pathways (Crocker 
and Redelinghuys 2008), was upregulated after LPS, Pam3CSK and MALP2 treatment. In 
contrast, significantly reduced expression levels were found for SIGLEC1 (sialoadhesin), a sialic 
acid binding lectin specifically restricted to monocytes and macrophages (Munday et al. 2001, 
Hartnell et al. 2001). SIGLEC1 mediates mainly cell adhesion of monocytes and macrophages, 
but until now there is little evidence of SIGLEC1 mediating signaling functions via its cytoplasmic 
domain which lacks signaling motifs (Crocker and Redelinghuys 2008). 
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7.3 Perspectives 
This study identified 135 glycoproteins to be putative tolerance markers in human monocytes, 
which might help to identify septic patients with monocytes in the immunosuppressed cell state. 
Up- or down-regulated expression of 60 of those candidates reached significance in all three (LPS-
, Pam3CSK- and MALP2-) stimulations. Although, pro-inflammatory cytokine production of 24 
h-LPS-, Pam3CSK- and MALP2-pretreated monocytes was significantly down-regulated, 
indicating monocytes to be tolerant, it is not clarified with absolute certainty whether these 
differentially expressed glycoproteins are specific markers of the tolerant state or only activations 
markers of the stimulated monocytes. In order to proof if these glycoproteins are specific markers 
of the tolerant state, NLR-stimulated monocytes should be analyzed for the expression of 
glycoprotein-biomarker candidates. NLR ligands iE-DAP and MDP were shown to induce a slight 
pro-inflammatory response in human monocytes, but failed in the induction of tolerance. Thus, 
significantly regulated glycoproteins after LPS-, Pam3SK- or MALP2-stimulation should show no 
alterations of their expression levels upon exposure towards NLR ligands 1 and 2. Otherwise, those 
glycoproteins are likely to be activation markers of stimulated monocytes unrelated to the used 
stimulus, but no tolerance markers. 
In a next step, glycoprotein biomarkers should be evaluated in vivo: So far, all experiments were 
carried out with purified monocytes from buffy coats of healthy male donors and ex vivo-
stimulations with the above named TLR agonists. Due to the manifoldness of influence factors in 
vivo and the special features of the herein used experimental settings, further studies in patients 
are necessary to validate putative candidates. Moreover, prior studies demonstrated monocyte 
tolerance to be present even 28 days after sepsis onset in the patients (Poehlmann et al. 2009), 
which, with regard to circulating monocytes having a life span of 2-3 days, suggests a cellular 
reprogramming at the level of monocytic progenitor cells or stem cells in the bone marrow. Thus, 
it would be interesting to investigate the glycoproteomes of tolerant human monocytes at later time 
points after sepsis diagnosis, due to the fact that isolated human monocytes undergoing apoptosis 
during such long ex vivo cultivation periods. Verified biomarkers of the tolerant state might then 
help to differentiate between patients suffering from sepsis-induced immunosuppression and 
patients who enter the recovery phase. Improved tools for staging patients according to their 
individual risk could be a step towards a more personalized medicine with timely initiated, 
individual pro- or anti-inflammatory therapies. 
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8. Conclusions 
Aim of this study was to examine and compare changes in the glycoproteomes of purified 
peripheral human CD14+ monocytes that were stimulated with different PRR ligands and analyzed 
in the tolerant state. We hypothesized that the TLR agonists LPS, Pam3CSK, MALP2 and the 
endogenous alarmin S100A12, as well as the two NLR ligands iE-DAP and MDP were able to 
induce pro-inflammatory responses in human monocytes, and, thus, might also be able to induce 
monocyte tolerance to subsequent stimulations with LPS. The data obtained in this study revealed 
that stimulation of human monocytes with the Gram-negative TLR4 ligand LPS or with the Gram-
positive TLR2 agonists, Pam3CSK or MALP2, led to a pro-inflammatory activation of monocytes 
with subsequent hyporesponsiveness towards a further LPS challenge. 
RAGE and TLR4 ligand S100A12 was found to induce a pro-inflammatory activation of human 
monocytes only when it contained measurable amounts of LPS. Purified granulocyte-derived, 
LPS-free S100A12 was not capable of inducing pro-inflammatory effects or monocyte tolerance. 
IE-DAP and MDP which bind to the intracellular located NLR1 and NLR 2 were found to induce 
quantifiable pro-inflammatory responses in human monocytes. However, unaltered induction of 
pro-inflammatory cytokines in iE-DAP- or MDP-pretreated and LPS-restimulated monocytes 
indicated that both NLR ligands failed to induce monocyte tolerance.  
Taken together, LPS, Pam3CSK and MALP2 were proven to be effective in inducing tolerance 
and cross-tolerance in human monocytes, whereas S100A12, iE-DAP and MDP did not. 
We further hypothesized that adjusted concentrations of LPS, Pam3CSK and MALP2 which 
induce similar pro-inflammatory responses in human monocytes, may lead to segregation of 
glycoproteomic signatures according to differential usage of downstream signaling pathways. 
Equivalent cell surface expression of ICAM-1 on stimulated monocytes revealed 50 ng/ml of LPS, 
200 ng/ml Pam3CSK and 10 ng/ml MALP2 to induce similar pro-inflammatory activation levels 
in human monocytes.  
Analysis of global alterations in the glycoproteomes of LPS-, Pam3CSK- or MALP2-activated 
monocytes and statistical evaluation of the recorded data for the discovery of segregating 
signatures to classify tolerant human monocytes and naϊve monocytes, discovered highly similar 
changes in the glycoproteomes induced by all three TLR ligands. Altogether, 135 of 1176 
identified glycoproteins, derived from almost all cellular and subcellular compartments, displayed 
significant alterations in their expression after 24 h of stimulation, the time point when tolerance 
induction was measured. The largest subset of identified and also of regulated glycoproteins was 
annotated in Gene Ontology (GO) as “plasma membrane”-associated. Of 202 identified CD 
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antigens, 35 comprised significant differentially expression levels and KEGG pathway analysis 
revealed an enrichment of CD antigens involved in cell adhesion processes. 54 glycoproteins were 
annotated in GO as glycoproteins with ““G-protein coupled receptor activity”, of which 7 
displayed distinct alterations in their expression. 
Glycoproteomics identified well-known cell surface markers to be upregulated after monocyte 
stimulation like PD-L1 and IL-7R, as well as several, so far, not described glycoprotein 
biomarkers, which were unknown to be differentially expressed by monocytes in the tolerant state 
like ITGB8. 
 
In summary, the tolerant state of human monocytes is associated with significant alterations in the 
monocytic glycoproteome, especially of glycoproteins located on the cell surface. LPS-, 
Pam3CSK- and MALP2-induced changes of the glycoprotein expression pattern revealed highly 
similar glycoprotein expression changes, independent of the ligand used for the first activation, 
targeting TLR2 or TLR4. The identified expression changes of new biomarker candidates for 
monocyte tolerance should now be evaluated in in vivo-models to test their validity to characterize 
tolerant monocytes. 
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